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1. GENERAL INTRODUCTION 
1.1  Tanzania: geographical location and social economical characteristics 
Tanzania is a sub-Sahara African country located in the Great Lakes region (Fig. 
1.1). It is a fairly large country with an area of about 950.000 km2 and a population 
of about 33 million, 70% of them living in rural areas (Bureau of Statistics 
Tanzania, 1992). Economically it is a poor country with an annual Gross Domestic 
Product (GDP) of 290 US$ and a Gini coefficient (a parameter representing the 
distribution of the wealth of a nation amongst the population) of 0.355, indicating 
that the national wealth is fairly distributed amongst the population (Odedokun and 
Round, 2001).  
Figure 1.1: Map of Tanzania and its neighbouring countries 
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Shortly after independence from Britain in 1961, the country embraced a socialistic 
policy whereby the economy was centrally controlled. However, after the fall of the 
Berlin wall a liberal market economy has been introduced. The result has been the 
reversal of the economic slump into an annual economic growth of around 5% as 
the country has attracted direct foreign investments (especially in the mining 
sector). Currently Tanzania is rated as the country attracting the most external 
investment in sub-Saharan Africa. 
1.2 Health care services 
Since gaining independence in 1961, the country has strived to improve the 
provision of social services to its people, especially in health care. This was in 
recognition of the fact that improving the health status of a population in a country 
has a big impact on the reduction of poverty. Some commendable achievements 
have been made in this respect. A survey on the geographical access to health 
care facilities in Tanzania has shown that there are 479 health centres and 3995 
dispensaries throughout the country. Furthermore, it is estimated that about 70% 
of the population in rural areas are within a 5 km and 80% within a 10 km radius of 
a health facility (Ministry of Health Tanzania, 1997). The health status of the 
populations has also improved as indicated by the rise in the life expectancy from 
41 years in 1961 to 52 years in 2001. Correspondingly, the infant mortality rate 
has been reduced from 250 to 164 per 1000 live births.  
An important component for a health care program is ensuring constant availability 
of drugs in the health care facilities. The government has the obligation to ensure 
that effective, safe and good quality drugs are available at these facilities. 
However, the prevailing economic situation has made this task very difficult in 
Tanzania. In developing countries, drugs are known to consume more than 40 to 
60% of the total public and private spending on health, while in the developed 
countries it is limited to about 15 to 20% (WHO, 2000). One of the major reasons 
for these differences is the increased frequency of contracting diseases in the 
developing countries. In Tanzania, pharmaceuticals consume about 40% of the 
health budget (Ministry of Health Tanzania, 1997). Against the background of the 
expanded and widespread health services, the Tanzanian government needed to 
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commit much more financial resources for the acquisition of drugs. But due to the 
prevailing poor economy, these resources were not always forthcoming. 
In order to realise its objective of improving health services as the means of 
reducing poverty, the government had to find ways of ensuring a sustained access 
to drugs and continue with the efforts to expand its capacity in the provision of 
health services to the general public. One of the most rational options was to 
adopt the World Health Organisation’s (WHO) essential drugs concept. 
1.3 The Essential Drugs Concept (EDC) 
The vicious circle of diseases and poverty (diseases leading to a decline in 
economical productivity, hence more poverty and more diseases) is an unfortunate 
situation that exists in most developing countries. The drugs to treat most of the 
diseases prevalent in the developing countries exist. However, most of the 
populations in these countries lack access to such drugs as they are too 
expensive or the populations are underserved by medical facilities.  
In the mid 70’s, the WHO reviewed the major drug problems facing the developing 
countries and proposed the essential drugs concept as a strategic policy that 
would enable developing countries to improve the availability and access to drugs 
by the general public. The most important component of this concept is the 
recognition of the fact that only a few drugs are necessary for the treatment, 
diagnosis and prophylaxis of diseases facing the majority of people in a 
community. By concentrating on few essential drugs the meagre resources 
available in developing countries could be well managed and wastage minimised. 
This policy encouraged the compiling of a list of essential drugs tailored to each 
country health needs. It was recommended that as far as possible the drugs 
included in the list should be generic drugs (drugs which are off patent) as these 
are usually cheaper (about 30% less) and have a proven safety record. 
Furthermore, the essential drugs concept emphasised the importance of 
encouraging the rational use of drugs as a means of minimising wastages due to 
the misuse or excessive use of drugs.  
In 1975, The World Health Assembly (WHA) of the WHO passed resolution WHA 
28.66 that marked the birth of the essential drugs concept. The WHA requested 
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the Director General of the WHO to call upon and assist developing countries to 
implement the outlined policy proposals. According to the WHO, the adoption of 
the concept is a means of bridging the gap between the need of medicines and the 
ability of the population to afford them. Essential drugs have the potential to 
reduce morbidity and mortality from common illnesses for millions of people in the 
developing countries where medicines are unaffordable, unavailable, improperly 
used or of poor quality. The main pillars of the essential drugs concept are: 
established safety and efficacy, proven quality, constant availability, affordability 
and rational use.  
The Tanzanian government through the Ministry of Health has since then 
recognised the importance of the essential drugs concept and has issued 
measures and policies to ensure the implementation of the concept. It is the policy 
of the ministry that all health workers in governmental, private and non-
governmental organisations should strictly adhere to the national essential drugs 
list, while purchasing, labelling, prescribing and dispensing of pharmaceuticals 
should be in generic names as much as possible (Ministry of Health Tanzania, 
1998).  
1.4 Adoption of EDC in Tanzania 
Studies done in Tanzania using the International Network for Rational Drug Use 
(INRUD) indicators have shown that much success has been achieved in the 
promotion of rational drug use (Gilson et al., 1993; Massele and Mwaluko, 1993). 
According to the INRUD, the major indicators for irrational drug use are prescribing 
in brand names, prescribing too many drugs as well as unnecessary use of 
injections and antibiotics. These studies have shown that the average number of 
drugs per prescription is about 1.8 and more than 75% of all drugs are prescribed 
and dispensed as generics. About 80% of all prescribed drugs are from the 
national essential drugs list and less than 40% were injectables. In addition, 
Tanzania has been categorized by the WHO as a country where the essential 
drugs list exists and is used in all aspects of drug management (WHO, 1988). 
While much success has been achieved in this field, not much information is 
available concerning the quality of the essential drugs on the market.  
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1.5 Quality of drugs – a global concern 
The importance of drugs in reducing mortality, increasing the quality of life and 
reducing suffering cannot be overemphasised. However, poor quality drugs are 
potentially dangerous. In addition to the possibility of causing death and increasing 
suffering, poor quality drugs increase treatment costs.  
There is a worldwide concern about the quality of pharmaceuticals sold around the 
world. The WHO has been tracking and documenting the incidences of 
substandard drugs. The records show that problems of substandard and 
counterfeit drugs are on increase as 50% of all reported cases occurred in the 
period 1993 to 1997. Most of these incidences (70%) were reported in developing 
countries. The report identifies the causes of the poor quality of drugs: in about 
50% of all the cases the formulations did not contain any drug, 20% contained the 
wrong active ingredient and 10% the wrong amount of the active ingredient. Only 
in 5% of the reported incidences did the drugs contain the right active ingredient in 
the correct amounts, but were judged substandard by failing other quality tests. 
The antibiotics were the major pharmacological class of drugs with the largest 
incidence (60%) of counterfeiting (WHO, 2000), posing an even greater health risk 
as substandard anti-infective drugs may lead to selection of resistant strains of 
microorganisms, reducing the achievements made so far in combating infectious 
diseases. 
According to the International Federation of Pharmaceutical Manufacturers 
Association (IFPMA) about 7% of all drugs being sold around the world in 1992 
were of poor quality: being counterfeit or substandard. The problem is worldwide 
and occurs both in rich and poor countries. Global drug expenditures were 
estimated at 226 billion US$ in the year 1992 (Pharma daten, 1993). According to 
the IFPMA, the economic impact of the presence of substandard/counterfeit drugs 
in the world is estimated to cost more than 10 billion US$ in trade only. The impact 
is even much more if consideration is given to the increased treatment costs, 
reduced productivity, patient suffering and possible development of resistance by 
susceptible microorganisms. 
Substandard drugs are not found only in developing countries. In developed 
countries where the drug regulations are strictly enforced, some incidences about 
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the presence of substandard drugs on the market have been reported. Regular 
surveillance of the quality and bioequivalency of pharmaceuticals on market in 
Finland has identified amongst different brands of erythromycin tablets, one with a 
very low bioavailability (Venho et al., 1987). This brand had to be withdrawn from 
the market.  
However, there is more prevalence of substandard drugs in the developing 
countries in general as less stringent quality control measures are in place in these 
countries. In a study to evaluate the bioavailability of 3 different brands of 
ampicillin capsules marketed in Nigeria, Ogunbona and Akanni (1985) reported 
that one of the analysed brands was not bio-equivalent to the innovator brand 
(Penbritin®). A study on different ampicillin brands on the Sudanese market had 
previously obtained similar findings (Ali et al., 1981). Sowunmi et al. (1994) 
evaluated the quality of quinine tablets marketed in Nigeria and reported the 
presence of fake quinine tablets.  
Shakoor et al. (1997) evaluated the quality of pharmaceuticals on market in 
Thailand and Nigeria. The potency of 81 and 15 drug formulations from Nigeria 
and Thailand, respectively, was determined. The sampled drugs were antimalaria 
and antibiotic formulations that are the most frequently used in these countries. 
The study revealed that 36% (26) of the samples from Nigeria and 40% (6) from 
Thailand did not comply with the British Pharmacopoeia standards. The content of 
the active ingredient in some of the failed samples was marginally outside the 
official limits. Three of the substandard samples from Nigeria (2 chloroquine and 1 
amoxycillin) and 3 from Thailand (all chloroquine) were fake. Since the authors 
could not detect impurities or degradation products (except from an ampicillin/ 
cloxacillin suspension), they suggested that the major reason for substandard 
drugs in the developing countries was poor manufacturing practices on the part of 
the suppliers.  
Taylor et al. (2001) evaluated the quality of 581 formulations of 27 different drugs 
from 35 urban pharmacies in Nigeria. The assayed potency of 48% of the samples 
did not comply with the pharmacopoeia specifications for drug content. Most of the 
failed samples had a drug content that was marginally below the pharmacopoeia 
limits. 
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Some reports on the presence of substandard drugs on the market have also been 
made from the East African region of which Tanzania forms a part. In Kenya, the 
quality of metronidazole products available on market was evaluated. The assay 
for drug content of all products conformed to pharmacopoeia specifications. 
However two formulations failed in the dissolution test as they released only 
46.8% and 45.8% of drug in 40 minutes (Kibwage et al., 1991) whereas a 
minimum of 80% drug release within 40 min is required. Kibwage et al. (1992) 
reported that about 45% of the drugs sampled on the Kenyan market and 
analysed at the Daru quality control laboratory on a routine basis were of 
substandard quality in terms of the drug content. 
Another study done in Kenya in 1995 evaluated the bioavailability of different 
brands of carbamazepine tablets on market. This was done after complaints from 
clinicians that breakthrough seizures were reported on switching from one brand to 
another. Four different brands were on market at that time. The quality of one 
brand was found to be poor in terms of friability, content uniformity, disintegration 
and dissolution. Upon determination of its bioavailability, this brand was found to 
give lower plasma drug concentrations (Cmax) and a reduction in the extent of drug 
absorption (AUC) compared with the other three (Oluka, 1995). Presumably this 
was responsible for the reported breakthrough seizures. This brand was also the 
cheapest on the market.  
A study was done to evaluate the quality of 9 different brands of chloroquine 
marketed in Dar es Salaam (Tanzania). The drug content and dissolution 
performance of the tablets were determined. All brands complied with the USP 
requirement for drug content; however, one formulation (a sugar-coated brand) 
failed the dissolution test (Abdi et al., 1995).  
The influence of storage at tropical conditions (as is found in many developing 
countries) on the stability and quality of essential drugs has been one of the 
concerns of the WHO. Nazerali and Hogerzeil (1998) conducted a study in 
Zimbabwe to investigate the influence of storage in a tropical climate on the quality 
of 13 essential drugs. Samples of the same batch of a drug were taken from the 
government medical stores and from district hospitals and health centres. The 
content of the active ingredient was assayed and the influence of storage 
conditions on the quality of the drugs evaluated. Only two drugs (ergometrine 
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injection and retinol capsules) showed a significant loss of potency, indicating that 
they were unstable during storage at tropical conditions. The other drugs, including 
those with known instability (acetylsalicylic acid tablets, amoxicillin and ampicillin 
capsules), remained stable during the study period. The authors concluded that 
with few exceptions, essential drugs have a good stability profile during storage in 
tropical climates.  
A pilot study was carried out in Sudan to evaluate the stability of 15 essential 
drugs during transport and storage at tropical climatic conditions. Samples of 
drugs supplied by International Dispensary Association (IDA) to the Nile provinces 
in Sudan were collected and evaluated for potency. The assay results were 
compared with those from the original batch kept by the IDA in Amsterdam (The 
Netherlands). The authors reported that only 3 (ergometrine injection, epinephrine 
injection and retinol capsules) of the 15 drugs analysed had a significant loss in 
potency. The other drugs including those with suspected instability (acetylsalicylic 
acid tablets, ampicillin capsule) did not show a significant loss of potency and were 
considered stable on exposure to tropical climatic conditions during transport and 
storage (Hogerzeil et al., 1991a). The results of the pilot study were confirmed by 
an extensive study where drugs transported to Bangkook (Thailand), Lagos 
(Nigeria) and Kampala (Uganda) from Aarhus (Denmark) showed no significant 
drug degradation for the majority of essential drugs (except for ergometrine 
injection and retinol capsules), despite being exposed to temperatures of up to 
42°C in some regions during the sea voyage (Hogerzeil et al., 1991b).  
As can be summarized from the literature cited, the problem of substandard drugs 
is more pronounced in the developing countries and some factors responsible for 
this can be identified. One is that in these countries there are few functioning drug 
regulatory authorities. It is estimated that only 30% of the developing countries 
have an established and functioning drug regulatory authority (WHO, 2000). In 
addition, most of the regulatory authorities have not established quality control 
laboratories. Even when these are available, most of the time they lack proper 
equipment and resources to perform the work properly and/or to monitor the 
quality of the drugs on market. In some cases they have not instituted good 
laboratory practices, which is required for the reliability of the analytical results. In 
1994, Roy reported on the existence of substandard formulations (37 out of 137) in 
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Bangladesh, some of which had been found to be of acceptable quality by the 
local Drug Regulatory Authorities. Gomez et al. (1998) reported on the differences 
in assay results of antimalaria drugs analysed by the quality control laboratory of 
the Institute of Drug Control in Vietnam. Some of the drugs that had passed the 
quality tests by the Institute failed when independently assessed by a World 
Health Organization accredited laboratory. 
The other factor contributing to the prevalence of substandard drugs in developing 
countries is inadequate financing. In more than 36 developing countries, Tanzania 
being one of them, the average annual per capita expenditure on drugs by the 
population is less than one US dollar. This compares unfavourably to other 
countries in the developed world such as the USA, Germany and Belgium where 
the expenditure is estimated at 110, 98 and 70 US $, respectively (WHO, 1988). 
This low per-capita consumption is a good indicator for the inability of the people 
to afford basic drugs.  
As the purchasing power for pharmaceuticals in these countries is very low, most 
importers and distributors of pharmaceuticals would tend to pay more attention to 
low prices rather than to the quality. They will source their imports from the 
cheapest suppliers and may circumvent regulatory and quality assurance systems. 
The general population will be attracted to lower priced drugs that are available 
even outside pharmacies (Pecoul et al., 1999). 
1.6 Situation in Tanzania 
Tanzania is a net and multisource importer of pharmaceuticals. The country has a 
tropical climate and is classified by the International Conference on Harmonization 
(ICH) as a country having a Class IV tropical climate (Grimm, 1998). If imported 
drug formulations have not been optmised for stability in tropical climates, their 
effectiveness may be compromised on exposure to conditions of high 
humidity/high temperature during transport and storage. 
During the 1980’s the country was enduring an economic slump and had to 
introduce structural adjustment programmes and reforms recommended by the 
International Monetary Fund (IMF). In the health sector, one of the results of 
implementing the reforms was increased participation of the private sector in 
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importation of pharmaceuticals (previously it was a public sector domain), without 
a parallel increase in the capacity of the regulatory authority to institute effective 
quality assurance measures. Tanzania has an established drug regulatory 
authority since 1968. The Pharmacy Board is the authority that has been 
empowered by law to control and regulate the manufacture, import, distribution 
and sale of pharmaceuticals in the country. However, its capacity to control the 
quality of drugs on market has been limited by the lack of facilities. For more than 
30 years of its existence it had no quality control laboratory.  
There is a wide price difference of the formulations containing the same amount of 
active ingredient(s). In some cases the difference in price between an innovator 
brand and a generic equivalent is as high as 1000%. Suppliers of pharmaceuticals 
to a market characterised by such a low purchasing power as in Tanzania would 
go for cheap brands, as low prices would be most favourable to the general 
population. With such a large difference in prices one would be interested to know 
if those brands are pharmaceutically equivalent. In addition, the free substitution of 
one brand for another is practised on the assumption that those dosage forms 
containing the same amount of active ingredient are equivalent. It is a known fact 
that the bioavailability of generically identical drugs might vary (Hendels et al., 
1993; Maddock, 1986). The outcome of such variations may have serious 
therapeutic implications, especially for drugs with a narrow therapeutic index and a 
steep dose response curve. It is reasonable to discourage substitution between 
different brands/generics, unless the necessary measures have been taken to 
show that the products are equally effective in delivering the medicament to the 
systemic circulation.  
The Pharmacy Board established a quality control laboratory in the year 2000 as 
part of its efforts to monitor the quality of drugs on market in the country. This is an 
important achievement. However, for a country as large as Tanzania, a lot of 
resources are required to enable the Board to conduct post-marketing quality 
surveillance of the drugs. A single laboratory in the whole country will have a 
limited effectiveness in evaluating the quality of the imported drugs and monitoring 
the quality of those already on the market. 
In an environment having the inadequacies highlighted above (multi source 
importation, market preference for cheaper brands and lack of quality control 
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facilities) the trade in substandard/counterfeit drugs is likely to flourish and make 
the assurance of quality of drugs on market a challenging problem. Moreover, the 
confidence of health workers and patients in the health system is easly eroded 
when there are reports (even when they are unsubstantiated) of substandard 
drugs in circulation. Prescribers overwhelmed by presence of many brands, some 
of which are perceived to be of poor quality may prefer the use of expensive 
brands as they could associate good quality with high price. This may negatively 
influence the achievements made through the efforts by the government to 
increase access to safe, effective and affordable medicinal drugs to the majority of 
its people. 
Currently there is no information available on the quality of drugs marketed in 
Tanzania. This study is aimed at evaluating the in vitro and in vivo quality 
parameters and the stability of the most commonly used essential drugs on 
market. The results will be useful to the Ministry of Health and especially to the 
Pharmacy Board in developing appropriate intervention strategies to ensure that 
only effective drugs are allowed on the Tanzanian market and to promote the 
public confidence in the quality of the medicinal drugs. This will contribute towards 
the implementation of the Essential Drugs Concept as envisaged in the WHO 
guidelines. 
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2. OBJECTIVES OF THE STUDY 
2.1 Objectives 
Main objective 
The evaluation of the quality of different brands of oral solid dosage forms of 
essential drugs available on the Tanzanian market. 
Specific objectives 
1. Determination of the drug potency.   
2. Determination of the in vitro dissolution as a function of storage time at tropical 
conditions. 
3. Determination of the human bioavailability as a function of storage time at 
tropical conditions of some selected brands.  
2.2 Selection of the drugs 
The drugs evaluated during this study have been chosen on the basis of two 
criteria. The first criterion was the drug’s relevance to public health: included in the 
National Essential Drugs List (NEDL) and commonly used. The other criterion was 
known or suspected quality problems in adverse storage conditions.  
A drug list was obtained from Médecins sans Frontières, an organization of health 
professionals working in many developing countries. The 15 most commonly used 
tablet/capsules by this organization were compared with a list of the ten most 
commonly prescribed drugs at Muhimbili Medical Centre, the biggest University 
Teaching Hospital in Tanzania. Four drugs listed by both organisations and all in 
the National Essential Drugs List (NEDL) of Tanzania were then chosen. The 
drugs are: chloroquine, metronidazole, paracetamol and the sulfamethoxazole/ 
trimethoprim combination. During the course of this study the Ministry of Health 
(Tanzania) withdrew chloroquine as the primary antimalarial drug and replaced it 
with a sulfadoxine/pyrimethamine combination, so it was decided to include this 
combination in the study.  
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Diclofenac sodium, formulated as an enteric-coated tablet, is also in the NEDL of 
Tanzania and was included in the study as a modified release formulation. 
Ciprofloxacin, a life saving drug and also in the NEDL of Tanzania, is included in 
the study for economical reasons. It is among drugs whose current market price 
differential between the innovator brand and the generics is more than 2000%. 
Acetylsalicylic acid tablets and amoxycillin capsules, both being in the NEDL of 
Tanzania, have been included in the study because of their reported instability in a 
tropical climate (high humidity and high temperature). 
2.3 Selection of sampling points 
The study aimed to establish the quality of the drugs at the user level. The drugs 
were sampled in Dar es Salaam from different sources: the Tanzanian Medical 
Stores Department (MSD) and 10 registered pharmaceutical wholesalers.  
The MSD is an autonomous body that imports and distributes drugs to all 
governmental health facilities in the country. The pharmaceutical wholesalers are 
among the major importers and were selected based on the pharmaceuticals’ 
import data from the Pharmacy Board (Tanzania). Both the MSD and the 
wholesalers are multi-source importers of pharmaceuticals. These pharmacies 
distribute their products to both the public and private health facilities in the 
country.  
The drugs were anonymously purchased in their original package as supplied by 
the manufacturers. Furthermore only one package of a particular brand was 
purchased from one wholesaler. Samples from the MSD (2 chloroquine, 2 
ciprofloxacin, 2 paracetamol and 2 metronidazole formulations) were donated for 
the study. 
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3. IN VITRO EVALUATION OF POTENCY AND INFLUENCE OF 
TROPICAL CLIMATIC CONDITIONS ON DISSOLUTION 
3.1 Introduction 
A number of in vitro tests are recommended to evaluate the quality of 
pharmaceutical solid dosage forms. Some tests (such as friability and hardness) 
are considered to be more of in process tests performed by manufacturers to 
check batch to batch uniformity. Other tests (recommended in pharmacopoeia 
monographs) might be useful in predicting the in vivo efficacy of formulations. The 
assay for drug content in a formulation is one of such tests as the efficacy and 
safety of a dosage form depends on the amount of the drug contained in. 
For an oral solid dosage form, the ability to release the drug in the gastrointestinal 
(GI) fluids is an important quality attribute. Even when a formulation contains the 
required amount of drug, the manufacturing process and/or formulation 
components may affect the quality and result in a failure to release the drug into 
solution at the site of absorption in the gastrointestinal tract. The disintegration test 
is recommended in pharmacopoeia (Eur. Ph.; BP; USP) as an in vitro quality 
control test that determines the potential of a solid dosage form to disintegrate in 
the GI fluids. The test measures the time required for the dosage form to 
disintegrate into its primary particles. However, there is a possibility (especially for 
poorly soluble drugs) that a dosage form may disintegrate into primary particles 
and yet fail to dissolve in the GI fluids.  
Dissolution is another in vitro test that determines the ability of the drug to dissolve 
in the GI fluids. The in vitro dissolution test (as recommended by the USP) 
measures the amount of drug dissolved in the dissolution medium (usually 
aqueous solutions with modified pH) after a specified time interval. The test is 
predictive of the absorption potential of a dosage form since when the drug is in 
solution in the GI tract, its absorption is no longer influenced by factors related to 
the drug formulation. 
In this chapter, the quality of selected essential drug formulations available on the 
Tanzania market is evaluated by performing drug assay and in vitro dissolution 
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tests. In addition, the influence of tropical storage conditions on the in vitro 
dissolution of these formulations is investigated.  
3.2 General methods 
Drug assay 
The assay for the active ingredient(s) in the formulations was performed using 
high performance liquid chromatographic (HPLC) methods described in the USP 
24 monographs. For chloroquine tablets an HPLC method cited in literature 
(Pussard et al., 1986) was used instead of the USP 24 recommended method 
which is based on chloroform extraction and UV detection. For metronidazole 
tablets, an HPLC method that had been developed in the Laboratory of Drug 
Analysis (Faculty of Pharmaceutical Sciences, Ghent University, Belgium) for the 
analysis of metronidazole and its degradation products (Baeyens et al., 1998) was 
used. All analyses (HPLC assays as well as dissolution tests) were performed 
using validated techniques and were done at the Laboratory of Pharmaceutical 
Technology (Faculty of Pharmaceutical Sciences, Ghent University, Belgium). The 
assays were repeated three times and the results are presented as the mean of 3 
determinations (± standard deviation). 
In vitro dissolution  
The stability of the in vitro drug dissolution at tropical storage conditions was 
investigated by performing an accelerated stability test under Class IV climatic 
conditions as recommended for Tanzania by the International Convention on 
Harmonization (Grimm, 1998). The samples in their original package were stored 
in a sealed chamber containing a saturated sodium chloride solution (relative 
humidity (RH): 75 ± 5%) and in an oven (Memmert, Namen, Belgium) maintained 
at 40 ± 2°C. The dissolution profile (n = 6) of each formulation was determined 
immediately after purchase (0 months) and after a storage period of 3 and 6 
months at the above-mentioned conditions.  
Evaluation of the dissolution data 
The dissolution profiles were evaluated using the USP 24 tolerance limits for 
dissolution: a minimum percentage of drug dissolved after a specified time interval. 
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Futhermore, the profiles of formulations that met these requirements were further 
evaluated using the similarity factor (f2) as recommended by the FDA for the 
comparison of the dissolution profiles of immediate release dosage forms (FDA, 
Guidance for industry, 1997). In this study, the dissolution profile of the reference 
formulation (innovator brand) obtained before storage at simulated tropical 
conditions was compared with dissolution characteristics of the formulations 
containing the same drug. To evaluate the influence of storage conditons on the in 
vitro drug release, the profiles obtained after 3 and 6 months storage at the test 
conditions were compared with those obtained immediately after purchase (0 
months). 
 The similarity factor was computed using the equation by Moore and Flanner 
(1996) recommended by the FDA (1997). 
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Where Rt and Tt are the percentages of drug dissolved at time t (for t = 1, 2,…..n), 
of the reference and test formulation, respectively. The measurements at each 
time point can be weighed according to its importance in the dissolution curve 
using wt as an optional weight factor. If all points are considered equal wt is 
assigned a value 1.  
As recommended in the FDA SUPAC guidelines, the profile of two batches is 
considered similar and pharmaceutically equivalent when the average difference 
at any sample time point is less than 10% which corresponds to a similarity factor 
(f2) greater or equal to 50. 
Equipment 
The HPLC apparatus consisted of a LaChrom L-7100 isocratic pump, a L-7400 
UV/VIS detector and a L-7000 integrator (Merck, Darmstadt, Germany). A 
Lichrospher® 100RP-C18 endcapped (5 µm) column (Merck, Darmstadt, 
Germany) was used for chromatographic separations. The dissolution tests were 
carried out using a Vankel VK 7010 dissolution apparatus that was linked to a VK 
8000 automatic sampler (Vankel Technology, Cary, NC, USA). The drug 
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concentration of the dissolution samples was measured spectrophotometrically 
using a Lambda 12 UV/VIS spectrophotometer (Perkin Elmer, Norwalk, USA). 
3.3 Amoxicillin formulations 
Four amoxicillin formulations, all of them capsules, were analysed. Three 
formulations were obtained from the Tanzanian market, while the fourth one from 
Eurogenerics (used as a reference) was purchased in a Belgian pharmacy. Table 
3.1 gives the details of the formulations evaluated. 
Table 3.1:  Amoxicillin 250 mg capsule formulations 
Manufacturer Package Batch number 
Price per 1000 
units (US$) 
Eurogenericsa    
(Belgium) 
Blister, 100 capsules 00C04D N/A 
Medochemie 
(Cyprus) 
Blister, 100 capsules P4551 27.0 
Medopharm 
(India) 
Blister, 100 capsules 006 
 
24.5 
Shelys Pharmaceuticals 
(Tanzania) 
Blister, 100 capsules 435 25.0 
aReference formulation containing 500mg amoxicillin per capsule. 
N/A Not available on the Tanzanian market  
3.3.1  Materials 
Amoxicillin trihydrate (Eur. Ph.) was obtained from Sigma Aldrich (Steinheim, 
Germany) and acetonitrile from Biosolve (Valkenswaard, The Netherlands). 
Monobasic potassium phosphate and potassium hydroxide were obtained from Vel 
(Leuven, Belgium).  
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3.3.2  Assay for amoxicillin 
3.3.2.1 Methods 
The amount of amoxicillin in each formulation was determined by the method 
described in the USP 24 monograph for amoxicillin. 
Sample preparation 
The content of 20 capsules was removed as completely as possible. The 
combined contents were properly mixed and an amount equivalent to 200 mg of 
anhydrous amoxicillin was transferred into a 200 ml volumetric flask. A sufficient 
quantity of diluent (0.05M monobasic potassium phosphate pH 5.0) was added, 
the resulting suspension was mixed and sonicated to dissolve the drug. A portion 
of the solution was filtered through a 0.5 µm cellulose acetate filter (Minisart®, 
Sartorius, Goettingen, Germany) and the filtered solution was used as the assay 
preparation.  
Calibration curve 
A calibration curve (peak area vs. concentration) y = 2096.2x (± 46.8) + 186198 (± 
38507) with a coefficient of determination (R2) of 0.9996 ± 0.0004 (n = 5) was 
constructed using standard solutions with amoxicillin concentrations of 400, 600, 
800, 1000 and 1200 mg/l. The unknown concentration of amoxicillin in the assay 
preparation was determined from the calibration curve.  
The precision of the assay method was determined by calculating the relative 
standard deviation (within day and between days) of the peak areas obtained after 
repeated injections (n = 5) of an amoxicillin standard solution (1000 mg/l). 
Mobile phase 
The mobile phase consisted of a mixture of a 0.05M monobasic potassium 
phosphate (pH adjusted to 5.0 with 0.2N KOH) and acetonitrile in a ratio of 
96:4(v/v). Aliquots of the assay preparation and standard solutions (20 µl) were 
injected into the chromatographic system and the peaks were monitored by UV 
absorbance at 272 nm. The analyses were performed within six hours of preparing 
the solutions.  
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3.3.2.2 Results  
The relative standard deviation (RSD) for replicate injections of the standard 
preparation (1000mg/l) was 0.6% and 1.9% for the within day and between day 
analyses, respectively. According to the USP 24, the RSD should be less than 2%. 
The results of the assay (Table 3.2) shows that all formulations complied with the 
USP 24 specifications for amoxicillin content (90 - 120% of the labelled content).  
Table 3.2:  Mean amoxicillin content of different formulations expressed as a 
percentage of the labelled amount 
Manufacturer 
Mean amoxicillin content 
per capsule (mg) 
% of the labelled 
amount per capsule 
Eurogenericsa 495.7 ± 9.4 99.1 
Medochemie 248.5 ± 4.7 99.4 
Medopharm 244.2 ± 4.6 97.7 
Shelys 230.8 ± 4.3 92.3 
aReference formulation containing 500 mg amoxicillin per capsule 
3 3.3  In vitro dissolution  
3.3.3.1 Methods 
Dissolution testing 
Dissolution tests were performed using the USP basket method (Method 1) at a 
rotational speed of 100 rpm for formulations containing 250 mg amoxicillin, and 
using the USP paddle method (Method 2) at a rotational speed of 75 rpm for the 
Eurogeneric formulation which contained 500 mg amoxicillin. The volume of the 
dissolution medium (distilled water) was 900 ml per vessel maintained at a 
temperature of 37 ± 0.5°C. Dissolution samples (5 ml) were taken after 10, 20, 30, 
40, 50 and 60 min. All samples were analysed spectrophotometrically at 272 nm. 
Dissolution samples from the Eurogenerics formulation were diluted twice with 
distilled water before UV analysis.  
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3.3.3.2 Results  
Table 3.3 shows the percentage amoxicillin dissolved within 1 hr of dissolution 
testing and Figure 3.1 the dissolution profiles of the four amoxicillin formulations 
before and after storage at simulated tropical conditions. Before storage all 
formulations had a drug release that complied with the USP 24 dissolution 
requirements, the amount of drug released within 60 min ranging from 94.7 to 
102.9%. 
Table 3.3:  Percentage of drug released after 1 hour of dissolution testing on 
amoxicillin capsules stored at simulated tropical conditions (40°C, 
75% RH). USP 24 requirement: more than 80% is released within 1 
hour 
Storage time 
Manufacturer 
0 months 3 months 6 months 
Eurogenericsa 94.7 94.4 94.2 
Medochemie 102.9 93.4 93.9 
Medopharm 96.3 96.8 94.3 
Shelys 96.0 92.1 91.2 
 aReference formulation  
The dissolution profile of the Eurogenerics formulation obtained before storage at 
simulated tropical conditions (0 months) was compared with those of the other 
three formulations. The f2 factors for the Medochemie, Medopharm and Shelys 
formulations were 50, 54 and 60, respectively, indicating that the drug dissolution 
profiles from these formulations were pharmaceutically similar to that of the 
Eurogenerics capsules.  
Upon storage at the specified conditions for 3 and 6 months, the percent drug 
released within 60 min of dissolution testing from all formulations did not show any 
appreciable change. The percent drug release remained above 90% and all 
formulations met the USP 24 requirements for dissolution. 
The dissolution profile of each formulation obtained after 3 and 6 months of 
storage at simulated tropical conditions was compared with those obtained at 0 
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months for the same formulation. The f2 values for the profiles obtained after 3 
months storage were 63, 58, 64 and 76 for the Eurogenerics, Medochemie, Shelys 
and Medopharm formulations, respectively. The respective values for the profiles 
obtained after 6 months storage were 59, 55, 58 and 59. This shows that the 
dissolution profiles of the four formulations obtained after storage at simulated 
tropical conditions were pharmaceutically equivalent to the ones obtained 
immediately after purchase and that the storage conditions did not influence the in 
vitro dissolution profiles of these formulations.  
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Figure 3.1:  Dissolution profiles of amoxicillin capsule formulations after 0 (♦), 3 (■) 
and 6 (▲) months of storage at simulated tropical conditions (40°C, 75% 
RH) 
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3.4 Acetylsalicylic acid formulations 
Four formulations were evaluated, three were sampled from the Tanzanian 
market, while the Bayer formulation (the innovator brand used as a reference) was 
obtained from a retail pharmacy in Belgium. Table 3.4 gives the detailed 
description of the analysed formulations. 
Table 3.4:  Acetylsalicylic acid (300 mg) tablet formulations 
Manufacturer Package Batch number 
Price per 1000 
units (US$) 
Bayera                     
(Belgium) 
Blister, 100 tablets 98A05 37.5b 
Shelys Pharmaceuticals 
(Tanzania) 
Bulk, 1000 tablets 5497 
 
1.3 
Betahealth 
(Kenya) 
Bulk, 1000 tablets 1700 
 
1.3 
Mansoor Daya  
(Tanzania) 
Bulk, 1000 tablets 214372 
 
1.3 
aReference formulation, containing 500 mg acetylsalicylic acid per tablet 
bMarket price if purchased in Dar es Salaam 
3.4.1  Materials 
Acetylsalicylic acid, 1-heptanesulfonic acid and formic acid were purchased from 
Sigma Aldrich (Steinheim, Germany), while salicylic acid was obtained from 
Ludeco (Brussel, Belgium). Sodium acetate anhydrous and glacial acetic acid 
were purchased from Vel (Leuven, Belgium). Acetonitrile was obtained from 
Biosolve (Valkenswaard, The Netherlands). 
3.4.2  Assay for acetylsalicylic acid and salicylic acid  
3.4.2.1 Methods 
The amount of acetylsalicylic acid and salicylic acid in each formulation was 
determined by the method described in the USP 24 monograph for acetylsalicylic 
acid tablets. 
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Sample preparation 
20 tablets were weighed and finely powdered. An accurately weighed portion of 
the powder, equivalent to about 100 mg of acetylsalicylic acid, was transferred into 
a 20 ml volumetric flask, and 20 ml of diluting solution (a mixture of acetonitrile and 
formic acid in a ratio of 99:1 v/v) was added. The resulting mixture was vigorously 
shaken for 10 min and allowed to equilibrate to room temperature. A portion of the 
mixture was filtered through a 0.5 µm cellulose acetate filter (Minisart®, Sartorius, 
Goettingen, Germany). 1 ml of the clear filtrate was transferred into a 10 ml 
volumetric flask, diluted to volume with the diluting solution and homogenised. This 
assay solution was used to determine the acetylsalycilic acid and salicylic acid 
content.  
Calibration curves 
A calibration curves (peak area vs. concentration) y = 4034.3x (± 55.7) - 186198 (± 
656) with a coefficient of determination (R2) of 0.9997 ± 0.0002 (n = 5) for 
acetylsalicylic acid was constructed using standard solutions at acetylsalicylic acid 
concentrations of 200, 300, 400, 500 and 600 mg/l. Salicylic acid standard 
solutions with concentrations of 0.8, 1.0, 1.2, 1.5 and 2.0 mg/l were made and a 
calibration curve y = 9689.4x (± 695.3) – 2895 (± 115.8), with a coefficient of 
determination (R2) of 0.9996 ± 0.0005 (n = 5) was obtained. The unknown 
concentration of acetylsalicylic acid and salicylic acid in the samples were 
determined from the respective calibration line. 
The precision of the assay method was determined by calculating the relative 
standard deviation (within day and between days) of the peak areas obtained after 
repeated injections (n = 5) of acetylsalicylic acid (500 mg/l) and salicylic acid (1.5 
mg/l) standard solutions. 
Mobile phase 
The mobile phase consisted of a mixture of a 0.35% (w/v) aqueous 
heptanesulfonic acid solution and acetonitrile in a ratio of 85:15 (v/v). Aliquots of 
the assay and standard solutions (50 µl) were injected into the HPLC system and 
the peaks were monitored by UV absorbance at 280 nm. 
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3.4.2.2  Results  
The relative standard deviation (RSD) for replicate injections of the standard 
preparation of acetylsalicylic acid was 0.75% and 1.25% for the within day and 
between days analysis, respectively. The respective values for salicylic acid were 
5.0 and 7.5%. According to the USP 24 specifications the RSD for acetylsalicylic 
acid should be less than 2%.  
The drug content in all formulations ranged from 95.9 to 105.4% (Table 3.5) and 
was within the 90 to 110% range specified in the USP 24. The content of salicylic 
acid in all formulations was below the limit of detection of the analytical method 
(0.3 mg/l) and below the maximum tolerable level of 0.3% specified in the USP 24.  
Table 3.5:  Mean acetylsalicylic acid (ASA) content of the different formulations 
expressed as a percentage of the labelled amount 
Manufacturer 
Mean ASA content 
per tablet (mg) 
% of the labelled 
amount per tablet 
Bayera  494.1 ± 6.1 98.8 
Betahealth  287.8 ± 3.6 95.9 
Mansoor Daya 316.2 ± 3.9 105.4 
Shelys 295.6 ± 3.7 98.5 
aReference formulation, containing 500 mg acetylsalicylic acid per tablet 
3.4.3  In vitro dissolution  
3.4.3.1  Methods 
Dissolution testing 
Dissolution profiles were determined using the USP basket method (Method 1) at 
a rotational speed of 50 rpm. The volume of the dissolution medium (0.05M 
acetate buffer pH 4.5) was 900 ml per vessel maintained at a temperature of 37 ± 
0.5°C. Samples (5 ml) were automatically withdrawn from each dissolution vessel 
after 5, 10, 15, 20, 25 and 30 min. The samples were diluted (2:1) with the 
dissolution medium before being spectrophotometrically analysed at 265 nm. 
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3.4.3.2 Results 
The dissolution profiles obtained for each formulation before and after stability 
testing are shown in Figure 3.2 and the percent drug dissolved in Table 3.6. Only 
one formulation (Bayer) complied with the USP 24 requirements. This formulation 
released 98.1% of the labelled amount, while the others released less than 40% of 
their acetylsalicylic acid content.  
Table 3.6:  Percentage of drug released after 30 minutes of dissolution testing on 
acetylsalicylic acid tablets stored at simulated tropical conditions 
(40°C, 75% RH). USP 24 requirement: more than 80% is released 
within 30 minutes  
Storage time 
Manufacturer 
0 months 3 months 6 months 
Bayera  98.1 94.3 90.2 
Betahealth  33.1 32.2 24.8 
Mansoor Daya  38.3 37.2 36.8 
Shelys  24.7 17.5 12.1 
aReference formulation 
Upon storage at simulated tropical conditions all formulations that failed the 
dissolution test had as expected a drug release that was below the USP 24 
recommended values. The drug release from the Shelys formulation was halved 
(from 24.7 to 12.1%) after 6 months storage, while that from the Betahealth 
formulation decreased by about 10%. It was observed that the tablets from the 
Betahealth, Shelys and Mansoor Daya formulations failed to disintegrate during 
the dissolution test after storage at simulated tropical conditions.  
The dissolution profiles obtained from the Bayer formulation after 3 and 6 months 
of storage at simulated tropical conditions were compared with that obtained at 0 
months. The f2 value obtained after 3 months was 52, while that of the 6 months 
profile was 35. The f2 analysis shows that in the first 3 months of storage the drug 
release profile was pharmaceutically equivalent to that obtained at 0 months. 
However, after 6 months the dissolution pattern of this formulation had changed, 
indicating that the storage conditions affected the in vitro dissolution behaviour. 
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Despite the observed changes in drug release profile, the percent drug dissolved 
remained within the USP 24 tolerance limits and the changes may not be 
pharmaceutically significant.  
The drug content of all formulations was determined after the 6 months storage 
period at simulated tropical conditions. The assay results showed that compared 
with the values obtained immediately after purchase, the acetylsalicylic acid 
content (ranged from 95.5 to 101.3%) remained relatively unchanged and was 
within the USP 24 specifications. The salicylic acid content remained below the 
maximum tolerance limit (0.3%). 
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Figure 3.2:  Dissolution profiles of acetylsalicylic acid formulations after 0 (♦), 3 (■) 
and 6 (▲) months of storage at simulated tropical conditions (40°C, 75% 
RH) 
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3.5 Ciprofloxacin formulations 
Nine formulations, all available on the Tanzanian market were evaluated. Table 
3.7 shows the detailed information of the ciprofloxacin formulations sampled.  
Table 3.7:  Ciprofloxacin (500 mg) film coated tablet formulations 
Manufacturer Package Batch number 
Price per 1000 
units (US$) 
Ajanta Pharmaceuticals 
(India) 
Blister, 100 tablets P44418A 48.0b 
Aurobindo 
(India) 
Blister, 100 tablets E9002 58.0 
Bayera 
(Belgium) 
Blister, 10 tablets 98L16 2000.0 
Cadila Pharmaceuticals  
(India)  
Blister, 100 tablets E902 87.5 
Flamingo Pharmaceuticals  
(India) 
Blister, 100 tablets SL272 60.0 
Freudun Pharmaceuticals 
(India) 
Blister, 100 tablets T9002 58.8 
Medopharm  
(India) 
Blister, 100 tablets 980234 48.0b 
Intas Pharmaceuticals  
(India) 
Blister, 100 tablets 9012 58.0 
S Kant Health Care  
(India) 
Blister, 100 tablets SK 105 58.0 
aReference formulation 
bSample obtained from the Medical Stores Department 
3.5.1 Materials 
Ciprofloxacin hydrochloride (Ph. Eur.) was purchased from Alpha Pharma 
(Zwevegem, Belgium), triethylamine was from Sigma Aldrich (Steinheim, 
Germany), orthophosphoric acid was obtained from Vel (Leuven, Belgium) and 
acetonitrile from Biosolve (Valkenswaard, The Netherlands). 
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3.5.2   Assay for ciprofloxacin  
3.5.2.1 Method 
The amount of ciprofloxacin in each formulation was determined by the method 
described in the USP 24. 
Sample preparation 
5 tablets were put into a 500 ml flask. About 400 ml of distilled water was added 
and the mixture was sonicated for 20 min. The volume was adjusted with distilled 
water, mixed and left to settle for 30 min. An aliquot (50 µl) of this mixture was 
transferred into a 20 ml volumetric flask and diluted to volume with distilled water, 
a portion (10 ml) was filtered through a 0.5 µm cellulose acetate filter (Minisart®, 
Sartorius, Goettingen, Germany) and used as the assay preparation. 
Calibration curve 
A calibration curve (peak area vs. concentrations) y = 195415.5x (± 1563.3) + 
220761.9 (± 1766.1) with a coefficient of determination (R2) of 0.9999 ± 0.0004 (n 
= 5) was constructed using standard solutions at ciprofloxacin hydrochloride 
concentrations of 6.0, 8.0, 10.0, 12.0 and 15.0 mg/l. The unknown concentration of 
ciprofloxacin (calculated on the anhydrous basis and taking into account the 
molecular weights of ciprofloxacin hydrochloride and anhydrous ciprofloxacin) in 
the assay preparation was determined from the calibration curve.  
The precision of the assay method was determined by calculating the relative 
standard deviation (within day and between days) of the peak areas obtained after 
repeated injections (n = 5) of a 12.0 mg/l ciprofloxacin hydrochloride standard 
solution. 
Mobile phase 
The mobile phase was a mixture of a 0.025M phosphoric acid buffer (pH 3.0 with 
triethylamine) and acetonitrile in a ratio of 3:1 (v/v). Aliquots (20 µl) of the assay 
and standard solutions were injected into the HPLC system and the peaks were 
monitored by UV absorbance at 277 nm. 
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3.5.2.2 Results 
The relative standard deviation (RSD) was 0.6% and 0.8% for the within day and 
between days analysis, respectively. According to the USP 24 specification the 
RSD should be less than 1.5%. 
The assayed drug content of each formulation is shown in Table 3.8. All 
formulations passed the assay test as the drug content ranged from 93.2 to 
100.8%. This is within the USP 24 acceptance range: 90 to 110% of the labelled 
content.  
Table 3.8:  Mean ciprofloxacin content of the different formulations expressed as a 
percentage of the labelled amount per tablet 
Manufacturer  
Mean ciprofloxacin content 
per tablet (mg) 
% of the labelled 
amount per tablet 
Ajanta  466.1 ± 3.7 93.2 
Aurobindo  496.3 ± 3.9 99.3 
Bayera 503.9 ± 4.0 100.8 
Cadila 500.7 ± 4.0 100.1 
Flamingo  474.2 ± 3.8 94.8 
Freudun  493.8 ± 3.9 98.8 
Medopharm 474.3 ± 3.8 94.9 
Intas  470.9 ± 3.7 94.2 
S Kant  479.8 ± 3.8 96.0 
aReference formulation 
3.5.3  In vitro dissolution 
3.5.3.1 Methods 
Dissolution testing 
Dissolution tests were performed using the USP paddle method (Method 2) at a 
speed of 50 rpm. The volume of the dissolution medium (distilled water) in each 
vessel was 900 ml, maintained at a temperature of 37.0 ± 0.5°C. Samples (5 ml) 
were withdrawn from each vessel every 5 min (5, 10, 15, 20, 25 and 30 min). The 
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samples were diluted with the dissolution medium (1:50) and the drug 
concentration was spectrophotometrically measured at 276 nm. 
3.5.3.2 Results 
Table 3.9 shows the percent drug released from the formulations. Before storage 
at simulated tropical conditions all formulations met the USP 24 specifications for 
dissolution.  
Table 3.9:  Percentage of drug released after 30 min of dissolution testing on 
ciprofloxacin tablets stored at simulated tropical conditions (40°C, 75% 
RH). USP 24 requirements: more than 80% is released within 30 
minutes 
Storage time 
Manufacturer 
0 months 3 months 6 months 
Ajanta 95.3 94.0 95.0 
Aurobindo 96.8 97.1 96.2 
Bayera 100.5 100.7 99.9 
Cadila 98.4 98.8 98.0 
Flamingo 97.3 95.0 94.9 
Freudun 92.9 93.3 90.2 
Medopharm  96.5 93.8 90.8 
Intas 94.2 93.2 91.7 
S Kant 97.0 97.1 96.3 
 aReference formulation 
The dissolution profile of the Bayer formulation obtained at 0 months was 
compared with the profiles of the other formulations. The calculated f2 values are 
shown in Table 3.10. Only the formulation from Flamingo had an f2 value above 50 
(f2 = 52). The other formulations had f2 values that ranged from 14 to 37. 
Compared with the other formulations, the Bayer and Flamingo tablets had initially 
a higher drug release as more than 90% ciprofloxacin was dissolved within the first 
5 min. The drug release rate from the other formulations during the same interval 
was slower. The Ajanta formulation had the lowest f2 factor (f2 = 14) and also the 
slowest drug release (less than 5%) during the same time interval (Fig.3.3). 
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Table 3.10: The f2 values of the dissolution profiles obtained from the different 
ciprofloxacin formulations before storage at simulated tropical conditions 
using the Bayer formulation as the reference formulation 
 Formulation f2 value 
Ajanta 14 
Aurobindo 24 
Cadila 37 
Flamingo 52 
Freudun 34 
Medopharm  23 
Intas 35 
S Kant 31 
 
After storage at simulated tropical conditions for 6 months, all formulations passed 
the USP 24 dissolution requirements. Calculation of the f2 factors from the 
dissolution data obtained after 3 and 6 months of storage showed that, with the 
exception of the Cadila formulation, the profiles were similar to those obtained 
before the storage. The f2 values of the profiles from the Cadila formulation 
obtained after 3 and 6 months storage were 45 and 38, respectively, indicating 
that the drug release pattern was different and was influenced by the storage 
conditions.  
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Figure 3.3:  Dissolution profiles of ciprofloxacin formulations after 0 (♦), 3 (■) and 6 
(▲) months of storage at simulated tropical conditions (40°C, 75% RH) 
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3.6  Sulphamethoxazole / trimethoprim formulations 
Five sulphamethoxazole (400 mg) / trimethoprim (80 mg) formulations were 
analysed. All formulations are available on the Tanzanian market under the 
generic name cotrimoxazole. The innovator brand from Roche was obtained from 
a retail pharmacy in Ghent (Belgium), while the others were obtained in Tanzania. 
Table 3.11 gives the detailed information of the sampled formulations. 
Table 3.11:  Sulphamethoxazole (400 mg) / trimethoprim (80 mg) tablet formulations 
 
Manufacturer Package  Batch number 
Price per 1000 
units (US$) 
ACE laboratories 
(India) 
Blister,100 tablets TE446 10.0 
Shalina laboratories  
(India) 
Blister,100 tablets SL272 9.5 
S Kant Health care 
(India) 
Blister,100 tablets SK 503 10.0 
Rochea 
(Belgium) 
Blister, 20 tablets B143 98DO6 65.0 
TPI  
(Tanzania) 
Bulk, 1000 tablets NE 15 8.75 
aReference formulation 
3.6.1   Materials 
Sulfamethoxazole and trimethoprim (Ph. Eur.) were obtained from Alpha Pharma 
(Zwevegem, Belgium). Hydrochloric acid and glacial acetic acid were purchased 
from Merck (Darmstadt, Germany). Triethylamine was obtained from Sigma 
Aldrich (Steinheim, Germany) and acetonitrile was from Biosolve (Valkenswaard, 
The Netherlands). 
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3.6.2  Assay for sulfamethoxazole and trimethoprim 
3.6.2.1  Methods 
The content of sulfamethoxazole and trimethoprim in each formulation was 
determined by the method described in the USP 24. 
Sample preparation 
20 tablets were weighed and finely powdered. An accurately weighed portion of 
the powder, equivalent to 160 mg of sulfamethoxazole, was transferred into a 100 
ml volumetric flask and about 50 ml of the mobile phase was added. The mixture 
was sonicated for 5 min, allowed to equilibrate to room temperature, then adjusted 
to volume with the mobile phase. The resulting mixture was filtered through a 0.5 
µm cellulose acetate filter (Minisart®, Sartorius, Goettingen, Germany). 5 ml of the 
clear filtrate was diluted 10 times with the mobile phase to obtain the assay 
solution. 
Calibration curves 
A calibration curve (peak area vs. concentrations) y = 13135x (± 26.3) + 32372 (± 
2366) with a coefficient of determination (R2) of 0.9995 ± 0.0003 (n = 5) was 
constructed using standard solutions with sulfamethoxazole concentrations of 40, 
80, 120, 160 and 180 mg/l. Similarly, a calibration curve y = 7156.3x (± 100.2) + 
2247.8 (± 29.5) with a coefficient of determination (R2) of 0.9997 ± 0.0006 (n = 5) 
was obtained for trimethoprim using standard solutions with concentrations of 16, 
20, 24, 32 and 36 mg/l. The unknown concentration of sulfamethoxazole and 
trimethoprim in the assay solution was determined from the respective calibration 
curve.  
The precision of the assay method was determined by calculating the relative 
standard deviation (within day and between days) of the peak areas obtained after 
repeated injections (n = 5) of sulfamethoxazole (160 mg/l) and trimethoprim (32 
mg/l) standard solutions.  
The resolution factor (R) between sulfamethoxazole and trimethoprim was 
determined from the peaks obtained from the sulfamethoxazole and trimethoprim 
standard solutions. Based on the retention times and the baseline widths of the 
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peaks R was calculated as  
     R = 2(t1 – t2)/(W1 + W2) 
with t1 and W1 being the retention time and baseline width, respectively, of the 
sulfamethoxazole peak and t2 and W2, the respective values for the trimethoprim 
peak.  
Mobile phase 
The mobile phase consisted of a water, acetonitrile and triethlylamine mixture in a 
650:250:1 (v/v) ratio. The pH was adjusted to 5.9 with diluted acetic acid (0.1N). 
Aliquots (20 µl) of the assay and standard solutions were injected into the HPLC 
system and the peaks monitored by UV absorbance at 254 nm. 
3.6.2.2 Results  
The relative standard deviation (RSD) for replicate injections of the 
sulfamethoxazole standard preparation was 0.2% and 0.4% for the within day and 
between day analysis, respectively. The respective values for trimethoprim were 
0.1% and 1.4%. According to the USP 24, the RSD should be not more than 2.0%. 
The resolution factor R between the sulfamethoxazole and trimethoprim peaks 
was 6.5. 
The mean sulfamethoxazole and trimethoprim contents of each formulation 
expressed as a percentage of the labelled amount are shown in Table 3.12. All 
formulations passed the assay requirements specified in the USP 24 for both 
drugs (93 to 107% for sulfamethoxazole and trimethoprim). The drug content in 
the formulations ranged from 96.2 to 103.0% and from 96.6 to 101.0% for 
sulfamethoxazole and trimethoprim, respectively.  
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Table 3.12: Mean sulfamethoxazole and trimethoprim content of the different 
formulations expressed as percentage of the labelled amount 
Manufacturer 
Mean drug content 
per tablet (mg) 
% of the labelled 
amount per tablet 
Sulfamethoxazole   
ACE Laboratories 397.6 ± 1.6 99.4 
Shalina Laboratories  392.8 ± 1.5 98.2 
S Kant Health care 408.4 ± 1.4 102.1 
Rochea 412.0 ± 1.6 103.0 
TPI  385.0 ± 1.5 96.2 
Trimethoprim 
  
ACE Laboratories 80.1 ± 1.0 100.1 
Shalina Labolatories  78.3 ± 1.0 97.9 
S Kant Health care 79.8 ± 1.1 99.8 
Rochea 80.8 ± 1.1 101.0 
TPI  77.3 ± 1.2 96.6 
aReference formulation 
3.6.3  In vitro dissolution  
3.6.3.1 Methods 
Dissolution testing 
The in vitro dissolution profiles were determined using the USP paddle method 
(Method 2) at 75 rpm. The volume of the dissolution medium (0.1N HCl) in each 
vessel was 900 ml maintained at 37 ± 0.5°C during the entire duration of the test. 
Samples (5 ml) were withdrawn at 10 min intervals (10, 20, 30, 40, 50 and 60 min) 
and diluted 5 times with the mobile phase before HPLC analysis. The 
concentration of trimethoprim and sulfamethoxazole in the samples were analysed 
by UV after chromatographic separation by HPLC as described in the assay 
procedure (section 3.6.2). 
3.6.3.2 Results 
Table 3.13 shows the percent drug released after 1 hr dissolution testing on the 
tablets from the different manufacuters. Before being subjected to the accelerated 
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stability test conditions, two out of five formulations failed the USP 24 drug release 
specifications: the sulfamethoxazole release from the ACE and Shalina 
formulations being 63.3 and 69.2%, respectively. It was observed that tablets from 
these formulations did not completely disintegrate during the dissolution test. 
Table 3.13:  Percentage of sulfamethoxazole and trimethoprim released after 1 hr of 
dissolution testing on sulfamethoxazole/trimethoprim tablets stored at 
simulated tropical conditions (40°C, 75% RH). USP 24 requirements: 
more than 70% of both sulfamethoxazole and trimethoprim is released 
within 1 hr  
Storage time 
Manufacturer 
0 months 3 months 6 months 
Sulfamethoxazole    
ACE 63.3 60.9 55.2 
Shalina 69.2 64.5 63.6 
S Kant 79.4 76.6 71.1 
Rochea 100.3 98.8 98.1 
TPI 100.4 93.5 88.6 
Trimethoprim    
ACE 82.9 78.7 76.0 
Shalina 94.9 88.2 79.8 
S Kant 96.3 95.2 94.2 
Rochea 98.4 97.6 97.3 
TPI 97.8 95.5 90.5 
aReference formulation 
The f2 values were calculated for the formulations that satisfied the USP 24 
requirements for dissolution, taking the Roche profile as a reference. The f2 values 
for the TPI formulation were 76 and 72 for sulfamethoxazole and trimethoprim, 
respectively. The respective values for the S Kant formulation were 26 and 44. 
The Roche and TPI formulation had released more than 90% of sulfamethoxazole 
during the first 10 min, while the S Kant formulation released only 70% 
sulfamethoxazole during the same time interval (Fig. 3.4). Although the S Kant 
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formulation released 96.3% trimethoprim within 1 hr, it had a slower drug release 
rate during the first 10 min. 
Upon storage at simulated tropical conditions the sulfamethoxazole release from 
the Roche and S Kant formulations remained stable and met the USP 24 
dissolution criteria. The f2 factors for the S Kant dissolution profiles after 3 and 6 
months storage at simulated tropical conditions were 69 and 63, respectively. The 
respective values for the Roche formulation were 78 and 75. The TPI formulation 
showed a decrease in the percent sulfamethoxazole released during dissolution 
testing after storage at simulated tropical conditions. This was reflected in the f2 
values being 40 and 35 for the 3 and 6 months profiles, respectively. Although the 
sulfamethoxazole release from the TPI tablets remained within the USP 24 limits, 
the dissolution profiles obtained before and after storage were not equivalent and 
the in vitro drug release profile was not stable during storage at simulated tropical 
conditions (Fig. 3.4). 
Similar to sulfamethoxazole, the percent trimethoprim released from the TPI 
formulation during 1 hr dissolution testing decreased after storage at simulated 
tropical conditions. The f2 values for the 3 and 6 months profiles were 39 and 32, 
respectively, and this shows that the dissolution profiles obtained before and after 
the stability test were not equivalent (Fig 3.5). Similar observations were made for 
the ACE formulation (f2 values of 44 and 37, respectively). The dissolution profile 
obtained after 3 months storage of the Shalina formulation was similar to that 
obtained before storage (f2 = 65), but after 6 months storage the drug release 
profile had changed (f2 = 48). The percent trimethoprim released from the Roche 
and S Kant formulations remained stable during 6 months of storage at simulated 
tropical conditions. The f2 values obtained for the Roche and S Kant profiles after 
6 months were 71 and 69, respectively, indicating that the in vitro drug release 
from these formulations was not influenced by storage at simulated tropical 
conditions. 
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Figure 3.4:  Dissolution profiles of sulfamethoxazole from sulfamethoxazole/ 
trimethoprim (cotrimoxazole) formulations after 0 (♦), 3 (■) and 6 (▲) 
months of storage at simulated tropical conditions (40°C, 75% RH) 
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Figure 3.5:  Dissolution profiles of trimethoprim from sulfamethoxazole/trimethoprim 
(cotrimoxazole) formulations after 0 (♦), 3 (■) and 6 (▲) months of 
storage at simulated tropical conditions (40°C, 75 % RH) 
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3.7 Chloroquine formulations 
Seven formulations were analysed: 6 formulations contained chloroquine 
phosphate and were available on the Tanzanian market, while the reference 
formulation (purchased in a Belgian pharmacy) contained chloroquine sulphate. 
Table 3.14 gives the detailed information of the samples. 
Table 3.14:  Chloroquine phosphate (250 mg) tablet formulations  
Manufacturer Package Batch number 
Price per 1000 
units (US$) 
ACE laboratories 
(India) 
Bulk, 1000 tablets T70120 8.5 
Mepro Pharmaceuticals b 
(India) 
Bulk, 1000 tablets 9048 
 
8.5 
Rhône Poulenc Rorera 
(Belgium) 
Bulk, 100 tablets 96J17 N/A 
Shanghai Simplex 
(China) 
Bulk, 1000 tablets F610080 8.3 
Shelys Pharmaceuticals  
(Tanzania) 
Bulk, 1000 tablets 573 
 
6.4c 
TPI 
(Tanzania) 
Bulk, 1000 tablets LK 72 8.3 
Taiyuan Yangling Shanxi  
(China) 
Bulk, 1000 tablets 971001 8.8 
aReference sample, contained chloroquine sulphate equivalent to 100 mg chloroquine base per 
tablet 
bChloroquine phosphate sugar coated tablets  
cSample obtained from the Medical Stores Department 
N/A Not available on the Tanzanian market 
3.7.1  Materials 
Chloroquine phosphate (Ph. Eur.) was obtained from Alpha Pharma (Zwevegem, 
Belgium), potassium dihydrogen phosphate from Merck (Darmstadt, Germany) 
and acetonitrile from Biosolve (Valkenswaard, The Netherlands). Orthophosphoric 
acid was obtained from Vel (Leuven, Belgium). 
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3.7.2  Assay for chloroquine  
3.7.2.1 Methods 
The amount of chloroquine in each formulation was determined by the method 
described by Pussard et al. (1986). 
Sample preparation 
20 tablets were weighed and finely powdered. An accurately weighed portion of 
the powder, equivalent to 100 mg chloroquine phosphate was transferred into a 
100 ml volumetric flask and about 50 ml of distilled water was added. The mixture 
was sonicated for 20 min after which it was adjusted to volume with the mobile 
phase. The suspension was allowed to settle for 1 hr, after which 10 ml of the 
clear supernatant was transferred into a 100 ml volumetric flask and diluted to 
volume with the mobile phase. The solution was filtered through a 0.5 µm cellulose 
acetate filter (Minisart®, Sartorius, Goettingen, Germany) and used as the assay 
solution. 
Calibration curve 
A calibration curve (peak area vs. concentrations) y = 56384x (± 1691.5) – 2975 (± 
89.3) with a coefficient of determination (R2) of 0.998 (± 0.0005) was constructed 
using standard solutions with chloroquine phosphate concentrations of 60, 80, 
100, 120 and 140 mg/l. The unknown concentration of chloroquine phosphate in 
the assay solution was determined from the calibration curve.  
The precision of the assay method was determined by calculating the relative 
standard deviation (within day and between days) of the peak areas obtained after 
repeated injections (n = 6) of a chloroquine phosphate standard solution (100 
mg/l).  
Mobile phase 
The mobile phase was a mixture of a 0.2M monobasic sodium phosphate buffer 
(pH 3.0 with phosphoric acid) and acetonitrile in a ratio of 10:3 (v/v). Aliquots (50 
µl) of the assay and standard solutions were injected into the HPLC system and 
the peaks monitored by UV at 340 nm. 
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3.7.2.2 Results 
The relative standard deviation (RSD) for replicate injections of the standard 
preparation was 2.4% and 3.1% for the within day and between day analysis, 
respectively. The assay values for chloroquine sulphate obtained from the Rhône 
Poulenc Rorer formulation were converted to an equivalent amount of chloroquine 
phosphate. The assayed chloroquine phosphate content of each formulation is 
shown in Table 3.15. The assay results show that all formulations contained 
chloroquine in an amount that was within the range specified by the USP 24, being 
93.0 to 107.0% of the labelled amount.  
Table 3.15:  Mean chloroquine phosphate content of the different formulations expressed 
as a percentage of labelled amount 
Manufacturer 
Mean chloroquine phosphate 
content per tablet (mg) 
% of the labelled 
amount per tablet 
ACE Laboratories 242.5 ± 7.6 97.0 
Mepro Pharmaceuticals 247.1 ± 7.5 98.8 
Rhône Poulenc Rorera 167.1 ± 5.2b 103.8 
Shanghai Simplex 249.7 ± 7.7 99.9 
Shelys Pharmaceuticals 249.2 ± 7.6 99.7 
TPI 246.6 ± 7.7 98.6 
Taiyuan Yangling Shanxi  242.9 ± 7.5 97.2 
aReference formulation, contained 100 mg chloroquine base per tablet 
bconverted into an equivalent amount of chloroquine phosphate 
3.7.3  In vitro dissolution 
3.7.3.1 Methods 
Dissolution testing 
Dissolution profiles were determined using the USP paddle method (Method 2) at 
100 rpm. The volume of dissolution medium (distilled water) in each vessel was 
900 ml, maintained at 37 ± 0.5°C. At different time intervals (10, 20, 30, 40 and 45 
min), 5 ml samples were withdrawn from the vessels, diluted (1:10) with the 
dissolution medium and the absorbances measured at 343 nm. 
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3.7.3.2 Results  
Table 3.16 shows the percentage drug released after 45 minutes of dissolution 
testing on all formulations. Before storage at simulated tropical conditions, all 
formulations complied with the USP 24 requirements for drug release: the 
percentage drug dissolved ranged from 90.8 to 98.5%.  
Table 3.16:  Percentage of chloroquine phosphate released after 45 min of 
dissolution testing on chloroquine tablets stored at simulated tropical 
conditions (40°C, 75% RH). USP 24 requirement: more than 75% of 
chloroquine phosphate is released within 45 min 
Storage time 
Manufacturer 
0 months 3 months 6 months 
ACE 90.8 89.9 89.5 
Mepro 95.3 92.5 85.1 
Rhône Polenc Rorera 96.0 83.4 50.3 
Shanghai Simplex 97.3 97.6 96.3 
Shelys  95.2 94.7 88.8 
TPI  94.1 54.9 42.2 
Taiyuan Yangling Shanxi 98.5 98.0 96.2 
aReference formulation 
The dissolution profile of Rhône Poulenc Rorer was compared with the profiles 
from the other formulations. The f2 values obtained show that only the Shelys 
profile was similar to that of Rhône Poulenc Rorer (f2 = 57). Both formulations had 
a slower drug release in the first 10 min (67 and 76%, respectively) compared with 
the TPI (f2 = 49) and Shanghai Simplex (f2 = 42) formulations (82 and 90% drug 
released, respectively). The other three formulations had a much slower drug 
release (less than 35%) in the same interval and their f2 values were 35, 41 and 43 
for the Mepro, ACE and Taiyuan Yangling Shanxi formulations, respectively (Fig. 
3.6). 
Upon storage at the test conditions it was observed that the percentage drug release 
from the TPI formulation decreased to 42.2% after 6 months of storage. The Rhône 
Poulenc Rorer formulation also had a decrease in drug release from 96.0% to 83.4 
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and 50.3% after 3 and 6 months, respectively (Fig. 3.6). The percentage drug 
released from the other formulations remained within the USP 24 recommended 
values. However, only the Taiyuan Yangling Shanxi and the Shangai Simplex 
formulations had dissolution profiles that were stable upon exposure to the test 
conditions as the f2 values at 6 months were 70 and 59, respectively (Fig. 3.6).  
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Figure 3.6:  Dissolution profiles of chloroquine formulations after 0 (♦), 3 (■) and 6 
(▲) months of storage at simulated tropical conditions (40°C, 75% RH) 
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3.8 Enteric coated diclofenac sodium formulations 
Four enteric coated formulations available on the Tanzanian market were 
analysed. Table 3.17 gives the detailed information of the sampled formulations. 
Table 3.17:  Diclofenac sodium (50 mg) enteric coated tablet formulations 
Manufacturer Package Batch number 
Price per 1000 
units (US$) 
Camden  
(Malyasia) 
Blister, 100 tablets 00523 10.0 
Intas Pharmaceuticals 
(India) 
Blister, 100 tablets A005 12.0 
Novartisa 
(Belgium) 
Blister, 20 tablets 00D03BT 125.0 
Remedica  
(Cyprus) 
Blister, 100 tablets 13915 40.5 
aReference formulation 
3.8.1 Materials 
Diclofenac sodium (Ph. Eur.) was obtained from Alpha Pharma (Zwevegem, 
Belgium), while methanol was purchased from Biosolve (Valkenswaard, The 
Netherlands). Ortho-phosphoric acid, monobasic sodium phosphate, tribasic 
sodium phosphate, hydrochloric acid and sodium hydroxide were obtained from 
Vel (Leuven, Belgium).  
3.8.2 Assay for diclofenac sodium 
3.8.2.1 Methods 
The amount of sodium diclofenac in each formulation was determined by HPLC 
using the method described in the USP 24. 
Sample preparation 
20 tablets were transferred into a 1000 ml volumetric flask and about 800 ml of 
diluent (methanol:water, 7:3 v/v) was added and the mixture was sonicated for 20 
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min to allow the tablets to disintegrate. After all tablets had disintegrated, the 
mixture was stirred for 5 min and the volume adjusted with the diluent. A portion 
(15 ml) of the resulting mixture was filtered through a 0.5 µm cellulose acetate filter 
(Minisart®, Sartorius, Goettingen, Germany). 7.5 ml of the filtrate was diluted to 10 
ml and used as the assay solution. 
Calibration curve 
A calibration curve (peak area vs. concentration) y = 21603.6x (± 118.2) + 342034 
(± 1894) with a coefficient of determination of 0.9998 (± 0.0003) (n = 5) was 
constructed using standard solutions with diclofenac sodium concentrations of 
250, 500, 750, 1000 and 1250 mg/l. The unknown concentration of diclofenac 
sodium in the assay solution was determined from the calibration curve.  
The precision of the assay method was determined by calculating the relative 
standard deviation (within day and between days) of the peak areas obtained after 
repeated injections (n = 5) of a diclofenac sodium standard solution (750 mg/l). 
Mobile phase 
The mobile phase consisted of a mixture of methanol and a phosphate buffer in a 
ratio 7:3 (v:v). The buffer was a mixture of equal volumes of 0.01M phosphoric 
acid and 0.01M monobasic sodium phosphate adjusted to pH 2.5 with phosphoric 
acid. 20 µl aliquots of the assay and standard solutions were injected into the 
HPLC system and the peaks were monitored by UV absorbances at 276 nm.  
3.8.2.2 Results  
The relative standard deviation (RSD) for replicate injections of the standard 
preparation was 0.3% and 0.6% for the within day and between day analysis, 
respectively. According to the USP 24 the RSD should be less than 2%. The mean 
sodium diclofenac content of each formulation expressed as a percentage of the 
labelled amount is shown in Table 3.18. 
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Table 3.18:  Mean diclofenac sodium content of the different formulations expressed 
as a percentage of the labelled amount 
Manufacturer  
Mean diclofenac sodium 
content per tablet (mg) 
% of the labelled 
amount per tablet 
Camden  48.9 ± 0.3 97.8 
Intas Pharmaceuticals 49.9 ± 0.3 99.7 
Novartisa 49.6 ± 0.2 99.2 
Remedica 50.2 ± 0.2 100.4 
aReference formulation 
All formulations meet the USP 24 requirements for drug content. The drug content 
in the formulations ranged from 97.8 to 100.4%, which is within the specified range 
of 90 - 110%. 
3.8.3  In vitro dissolution  
3.8.3.1 Methods 
Dissolution testing 
Acid stage 
Dissolution profiles were determined using the USP paddle method (Method 2) at 
a rotational speed of 50 rpm. The dissolution vessels were filled with 900 ml of 
0.1N HCl, maintained at 37 ± 0.5°C. After 2 hr of the test, the tablets were 
transferred into another vessel which contained 900 ml phosphate buffer (pH 6.8) 
also maintained at 37 ± 0.5°C. To the 0.1N HCl remaining in the vessel 20 ml of a 
5.0N NaOH solution was added, stirred for 5 min and a 5 ml sample withdrawn for 
spectrophotometrical analysis at 276 nm. 
Buffer stage 
The tablets from the acid stage were tested in the phosphate buffer media for 50 
min using the USP paddle method (Method 2) at a speed of 50 rpm. Samples (5 
ml) were automatically withdrawn after 10, 20, 30, 40, 45 and 50 min. The samples 
were diluted (1:1) and spectrophotometrically analysed at 276 nm.  
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3.8.3.2 Results  
Table 3.19 shows the percent drug released from the formulations before and after 
storage at simulated tropical conditions. Immediately after purchase, all 
formulations met the USP 24 specifications for dissolution (not less than 75% of 
the labelled amount should be dissolved within 45 min and no drug release during 
the acid stage). The in vitro drug release ranged from 87.3 to 100.1% of the 
labelled amount and the enteric coat of all formulations remained intact during the 
acid stage test.  
Table 3.19:  Percentage of drug released after 45 min of dissolution testing (in buffer 
medium pH 6.8) on enteric coated diclofenac sodium tablets stored at 
simulated tropical conditions (40°C, 75% RH). USP 24 requirement: 
more than 75% is released within 45 min 
Storage time 
Manufacturer 
0 months 3 months 6 months 
Camden 87.3 12.1 10.4 
Intas 94.7 51.4 41.9 
Novartisa  100.1 99.8 100.2 
Remedica 99.3 98.2 98.6 
aReference formulation 
Fig. 3.7 shows the dissolution profiles obtained before and after storage at 
simulated tropical conditions. The dissolution profile of the Novartis formulation 
(the reference) was compared with the profiles of the other formulations. The f2 
values for the Camden, Intas, and Remedica formulations were 23, 34 and 46, 
respectively, indicating that despite meeting the USP 24 drug release 
requirements, their dissolution profiles were not pharmaceutically equivalent to 
that of the Novartis formulation. This formulation had a higher drug release during 
the initial 10 min in the phosphate buffer compared with the Camden and Intas 
formulations. Although the drug release of the Remedica and Novartis 
formulations were similar during the first 10 min, after 20 min the percentage drug 
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released from Novartis formulation was 100%, while that of Remedica was only 
about 70%.  
After exposure to simulated tropical conditions the dissolution characteristics of the 
formulations from Intas and Camden changed dramatically. After 3 and 6 months 
of storage, it was visually observed that the enteric coat from the Intas formulation 
disintegrated during the acid stage testing. However, the release of diclofenac 
sodium in this medium remained relatively low (1.7% after 3 months and 3.2% 
after 6 months) due to the low solubility of diclofenac sodium in acidic media. The 
drug release during the buffer stage from the Camden and Intas formulations 
decreased dramatically after storage at simulated tropical conditions. After 6 
months storage, the formulation from Camden released 10.4% of the drug, while 
that from Intas released 41.9% of the labelled drug content (Fig. 3.7). Although the 
in vitro drug release of these two formulations decreased dramatically, the drug 
content in both formulations was still within the USP 24 specifications as assays 
performed after 6 months storage showed that the drug content was 98 and 97% 
for the Camden and Intas formulations, respectively. The respective values for the 
Novartis and Remedica formulations were 99.9 and 100.0%.  
The dissolution profiles from the Novartis and Remedica obtained after 3 and 6 
months were compared with those obtained before stability testing. The f2 values 
for the Novartis formulation were 57 and 46 for the profiles obtained after 3 and 6 
months, respectively. The respective values for the Remedica formulation were 44 
and 38. The dissolution profiles of the Novartis formulation obtained after 6 months 
of storage at the test conditions showed a decrease in the drug release during the 
first 10 min. Before exposure to the storage conditions, the drug released in this 
time interval was more than 20%, wheras it was only 5% after 6 months. For the 
Remedica formulation, the drug release in the first 10 min was 5%, but after the 
storage it increased to 28%, indicating that the enteric coat disintegrated more 
rapidly (in the phosphate buffer) upon exposure to conditons of high temperature 
and high humidity. However, these detailed differences between the profiles of the 
two formulations as explained by f2 analysis probably have no pharmaceutical 
significance. 
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Figure 3.7:  Dissolution profiles of diclofenac sodium formulations after 0 (♦), 3 (■) 
and 6 (▲) months at simulated tropical conditions (40°C, 75% RH) 
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3.9 Metronidazole formulations 
A total of 11 metronidazole formulations from 10 manufacturers were evaluated. 
10 of these formulations were available on the Tanzanian market, the reference 
formulation was purchased in a retail pharmacy in Ghent (Belgium). Table 3.20 
gives the detailed information of the samples. 
Table 3.20:  Metronidazole (200 mg) tablet formulations 
Manufacturer Package Batch number 
Price per 1000 
units (US$) 
ACE Laboratories  
(India) 
Bulk, 1000 tablets TE565 4.4 
Flamingo Pharmaceuticals 
(India) 
Bulk, 1000 tablets 3956 4.5 
Intas Pharmaceuticals  
(India) 
Blister, 100 tablets 3792 
 
6.0 
Medopharm  
(India) 
Bulk, 1000 tablets M0019 
 
4.4 
Pharmamedb 
(Malta) 
Bulk, 100 tablets 1865 0107 3.0c 
Rhône Poulenc Rorera 
(Belgium) 
Blister, 20 tablets 97A28 
 
45.0 
Shelys Pharmaceuticalsb 
(Tanzania) 
Bulk, 1000 tablets 415 3.0c 
S Kant Health Care  
(India) 
Blister, 100 tablets SK 101 6.3 
TPI  
(Tanzania) 
Bulk, 1000 tablets LG 27 4.3 
TPI  
(Tanzania) 
Bulk, 1000 tablets ND 34 4. 3 
Vinpa Exports  
(India) 
Bulk, 1000 tablets 2E107 
 
4.5 
aReference formulation, contained 500 mg of metronidazole per tablet 
bContained 250 mg of metronidazole per tablet 
cSample obtained from the Medical Stores Department 
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3.9.1   Materials 
Metronidazole and sulfamethoxazole (Ph. Eur.) were obtained from Alpha Pharma 
(Zwevegem, Belgium). Orthophosphoric acid and hydrochloric acid were obtained 
from Vel (Leuven, Belgium), sodium dodecyl sulphate (SDS) from Fluka Chemie 
(Buchs, Switzerland) and acetonitrile from Biosolve (Valkenswaard, The 
Netherlands).  
3.9.2  Assay for metronidazole  
3.9.2.1 Methods 
The amount of metronidazole in each formulation was determined by the method 
described by Baeyens et al. (1998). 
Sample preparation 
20 tablets were weighed and finely powdered. An accurately weighed portion of 
the powder, equivalent to 160 mg metronidazole, was transferred into a 100 ml 
volumetric flask and the mobile phase was added to volume. The mixture was 
sonicated for 15 min and the suspension left to settle for 1 hr. From the clear 
supernatant, 10 ml was transferred into a 100 ml flask and 10 ml of the internal 
standard solution (1400 mg/l sulfamethoxazole) was added. The volume was 
adjusted with the mobile phase to obtain the assay solution. 
Calibration curve 
A calibration curve defined by the equation (metronidazole/sulfamethoxazole peak 
area ratio vs. concentration) y = 0.0195x (± 0.0004) – 0.0515 (± 0.0001) with a 
coefficient of determination (R2) of 0.9998 (± 0.0001) (n = 5) was made. The peak 
area ratios were determined from standard solutions with metronidazole 
concentrations of 80, 120, 140, 160 and 180 mg/ml spiked with sulfamethoxazole 
(to obtain a concentration 140 mg/l). The unknown concentration of metronidazole 
in the assay solution was determined from the calibration curve.  
The precision of the assay method was determined by calculating the relative 
standard deviation (within day and between days) of the peak areas obtained after 
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repeated injections (n = 5) of a standard solution with 160 mg/l metronidazole and 
140 mg/l sulfamethoxazole. 
The resolution factor (R) between metronidazole and sulfamethoxazole was 
determined from the peaks obtained from the standard solutions. Based on the 
retention times and baseline widths R was calculated as  
      R = 2(t1 – t2)/(W1 + W2) 
with t1 and W1 being the retention time and baseline width, respectively, of the 
sulfamethoxazole peak, while t2 and W2 are the respective values for the 
metronidazole peak. 
Mobile phase 
492 µl of ortho-phosphoric acid (85%) was transferred into a 2 l flask and 1.4 l of 
distilled water was added. 3.46 g of sodium dodecyl sulphate and 200 ml of 
acetonitrile were added and mixed. The pH of the solution was adjusted to 3.5 with 
0.2M sodium hydroxide, carefully added to avoid precipitation of the sodium salt. 
The volume was adjusted with distilled water and the solution was homogenized. 
The buffer was mixed with acetonitrile at a ratio of 3:2 (v/v) to obtain the mobile 
phase. 20 µl of the assay preparation and a standard solutions were separately 
injected into the HPLC system and the peaks were monitored by UV absorbance 
at 278 nm. 
3.9.2.2 Results  
The relative standard deviation (RSD) for replicate injections of the standard 
preparations was 0.17% and 0.62% for the within day and between day analysis, 
respectively. The resolution between the metronidazole and the internal standard 
(sulfamethoxazole) peak was 6.4.  
The metronidazole content of each product expressed as a percentage of the 
labelled amount is shown in Table 3.21. The content of metronidazole in the 
formulations ranged from 92.7 to 99.7%. This is within the 90 - 110% range 
specified in the USP 24. 
In vitro evaluation 
60
Table 3.21:  Mean metronidazole content of the different formulations expressed as a 
percentage of the labelled amount 
Manufacturer 
Mean metronidazole content 
(mg) per tablet 
% of the labelled 
content per tablet 
ACE 185.4 ± 1.2 92.7 
Flamingo  198.6 ± 1.2 99.3 
Intas  195.0 ± 1.3 97.5 
Medopharm 199.4 ± 1.1 99.7 
Shelys b 247.9 ± 1.5 99.2 
S Kant  196.2 ± 1.1 98.1 
Pharmamedb 245.8 ± 1.6 98.3 
RhônePoulenc Rorera 497.8 ± 3.1 99.6 
TPI (batch LG 27) 187.9 ± 1.3 94.0 
TPI (batch ND 34) 193.5 ± 1.1 96.8 
Vinpa 190.8 ± 1.2 95.4 
aReference formulation, contained 500 mg metronidazole per tablet. 
bContained 250 mg metronidazole per tablet. 
3.9.3  In vitro dissolution  
3.9.3.1 Methods 
Dissolution testing 
Dissolution tests were performed using the basket method (USP 1 method) at a 
rotational speed of 100 rpm. The volume of the dissolution medium (0.1N HCl) in 
each vessel was 900 ml, maintained at 37 ± 0.5°C. 5 ml samples were withdrawn 
after 10, 20, 30, 40, 50 and 60 min, diluted (1:20) with the dissolution medium 
before being spectrophotometrically analysed at 278 nm.  
3.9.3.2 Results 
The percentage drug released from the formulations before and after storage at 
the stability test conditions are presented in Table 3.22. Before being stored at 
simulated tropical conditions, all formulations met the USP 24 requirements for 
dissolution. 
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Table 3.22:  Percentage of metronidazole released after 1 hr of dissolution testing on 
metronidazole tablets stored at simulated tropical conditions (40°C, 75% 
RH). USP 24 requirement: more than 80% is released within 1hr 
Storage time Manufacturer 
0 months 3 months 6 months 
ACE 97.3 94.1 93.7 
Flamingo 100.0 96.5 93.9 
Intas 97.8 97.6 93.9 
Medopharm  100.9 100.3 99.8 
Pharmamed 98.3 98.1 98.0 
Rhône Poulenc Rorera  97.5 97.2 96.1 
Shelys 97.2 97.0 94.3 
S Kant 95.7 94.7 93.7 
TPI (batch LG 27) 86.5 64.7 52.6 
TPI (batch ND 34) 97.1 52.6 52.7 
Vinpa 95.2 94.1 93.7 
 aReference formulation 
The dissolution profile of the Rhône Poulenc Rorer formulation before exposure to 
simulated tropical conditions was compared with those from the other formulations 
for similarity. The f2 factors (Table 3.23) indicate that although all formulations met 
the USP 24 specifications for drug release, the dissolution profiles of all but the 
TPI formulation (batch ND 34) were not similar to that of the Rhône Poulenc Rorer 
tablets (f2 < 50). The TPI and the Rhône Poulenc Rorer formulations had a slower 
drug release during the first 10 min compared with the others. While the other 
formulations had released more than 90% drug within 10 min, these two 
formulations had released only 75% (Fig. 3.8). 
Upon storage at simulated tropical conditions, the percentage drug released after 
60 min of dissolution test from all formulations (except TPI) remained fairly 
constant during the entire storage period at the test conditions. The drug release 
from these formulations ranged from 93.7 to 99.8% and remained within the USP 
24 recommended values for dissolution.  
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Table 3.23: The f2 values of the dissolution profiles obtained from the different 
metronidazole formulations before storage at simulated tropical 
conditions, using the Rhône Polenc Rorer formulation as a reference 
Formulation f2 value 
ACE 37 
Flamingo 37 
Intas 35 
Medopharm  34 
Pharmamed 35 
Shelys 38 
S Kant 37 
TPI (batch LG 27) 37 
TPI (batch ND 34) 87 
Vinpa 42 
 
The in vitro drug release of both TPI batches was considerably reduced after 
storage at simulated tropical conditions. After 3 months the drug release 
decreased from 86.5 and 97.1% to 64.7 and 52.6% for batch LG 27 and ND 34, 
respectively. The tablets of both batches failed to disintegrate during the 
dissolution test. Assays performed on the tablets from both batches after the 6 
months storage period revealed that the metronidazole content (96.2% batch ND 
34; 93.5% batch LG 27) remained within USP 24 recommended range. 
The f2 factors computed for each formulation (except for TPI) using the dissolution 
data obtained at 0 months as a reference show that the dissolution profiles of all 
formulations did not change (f2>50) during storage at simulated tropical conditions. 
The Medopharm formulation (Fig. 3.8) had the highest f2 factor (f2 = 85).  
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Figure 3.8:  Dissolution profiles of metronidazole tablets after 0 (♦), 3 (■) and 6 (▲) 
months at simulated tropical conditions (40°C, 75% RH) 
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3.10 Paracetamol formulations 
A total of 9 paracetamol formulations were sampled, 8 of them from the Tanzanian 
market. Table 3.24 gives the detailed information of the sampled formulations. 
Table 3.24: Paracetamol (500 mg) tablet formulations 
Manufacturer  Package Batch number
Price per 1000 
units (US$) 
Alferez 
(India) 
Bulk, 1000 tablets CTC –378 3.0 
Granules  
(India) 
Blister, 100 tablets 084 5.0 
Interchem Pharma 
(Tanzania) 
Bulk, 1000 tablets 951203 3.0 
Jansen-Cilaga 
(Belgium) 
Blister, 100 tablets 99G05B110 N/A 
Medopharm  
(India) 
Bulk, 1000 tablets M6018 2.5b 
Medopharm 
(India) 
Bulk, 1000 tablets M0173 3.2 
Panacea Biotec 
(India) 
Blister, 100 tablets 101569 5.0 
TPI  
(Tanzania) 
Bulk, 1000 tablets LK 72 2.5b 
TPI 
(Tanzania) 
Bulk, 1000 tablets NH 231 3.0 
aReference sample  
bSample obtained from the Medical Stores Department 
N/A Not available on the Tanzanian market 
3.10.1  Materials 
Paracetamol (Ph. Eur.) was supplied by Ludeco (Brussel, Belgium), methanol was 
obtained from Biosolve (Valkenswaard, The Netherlands), while potassium 
dihydrogen phosphate and sodium hydroxide were from Vel (Leuven, Belgium). 
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3.10.2  Assay for paracetamol  
3.10.2.1 Methods 
The amount of paracetamol in each formulation was determined by the method 
described in the USP 24. 
Sample preparation 
20 tablets were weighed and finely powdered. An accurately weighed portion of 
the powder, equivalent to 100 mg of paracetamol, was transferred into a 100 ml 
volumetric flask and about 50 ml of the mobile phase was added. The mixture was 
sonicated for 5 min, then the volume was adjusted with the mobile phase and 
homogenised. The suspension was filtered through a 0.5 µm cellulose acetate 
filter (Minisart®, Sartorius, Goettingen, Germany). 1 ml of the filtrate was 
transferred into a 100 ml volumetric flask, diluted to volume with the mobile phase 
and homogenised to make up the assay solution.  
Calibration curve 
A calibration curve (peak area vs. concentration) y = 108338.4x (± 1697.6) – 
9746.7 (± 1043.1) with a coefficient of determination (R2) of 0.9997 (± 0.0002) (n = 
5) was constructed using standard solutions with paracetamol concentrations of 3, 
6, 10, 15 and 20 mg/l. The unknown concentration of paracetamol in the assay 
solution was determined from the calibration curve.  
The precision of the assay method was determined by calculating the relative 
standard deviation (within day and between days) of the peak areas obtained after 
repeated injections (n = 5) of a 10 mg/l paracetamol standard solution. 
Mobile phase 
The mobile phase consisted of a mixture of methanol and water in a ratio of 25:75 
(v/v). 20 µl aliquots of the assay and standard solutions were injected into the 
HPLC system and the peaks monitored by UV absorbance at 243 nm. 
3.10.2.2 Results  
The relative standard deviation (RSD) for replicate injections of the standard 
preparation was 0.2% and 1.2% for the within day and between day analysis, 
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respectively. According to the USP 24 the RSD should be less than 2%. 
The assayed paracetamol content of each formulation is shown in Table 3.25. All 
were in compliance with the USP 24 specifications (90-110% of the labelled 
amount). The amount of paracetamol found in the formulations ranged from 92.9 
to 99.5%. 
Table 3.25:  Mean paracetamol content of the different formulations expressed as 
percentage of the labelled amount 
Manufacturer  
Mean paracetamol content 
per tablet (mg) 
% of the labelled 
amount per tablet 
Alferez 486.7 ± 5.8 97.3 
Granules 484.1 ± 5.8 96.8 
Interchem Pharma 489.2 ± 5.9 97.8 
Jansen-Cilaga 497.3 ± 5.9 99.5 
Medopharm (batch M6018) 486.9 ± 5.8 97.4 
Medopharm (batch M0173) 483.5 ± 5.8 96.7 
Panacea Biotec 481.6 ± 5.8 96.3 
TPI (batch LK 72) 464.6 ± 5.6  92.9 
TPI (batch NH 231) 479.9 ± 5.7 96.0 
  aReference sample  
3.10.3  In vitro dissolution 
3.10.3.1 Methods 
Dissolution testing 
Dissolution tests were conducted using the USP paddle method (Method 2) at a 
rotational speed of 50 rpm. The volume of the dissolution medium (0.2M 
phosphate buffer pH 5.8) in each vessel was 900 ml, maintained at a temperature 
37 ± 0.5°C. Dissolution samples (5 ml) were automatically withdrawn after 5, 10, 
15, 20, 25 and 30 min and diluted with the dissolution medium (1:40) before 
measuring their absorbances at 243 nm.  
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3.10.3.2 Results  
The percentage drug released from the formulations is shown in Table 3.26. 
Before the stability test at simulated tropical conditions, only two formulations 
failed the USP 24 requirements for dissolution. The formulation from Interchem 
failed the dissolution test marginally as it released 78.1% of the labelled claim. The 
Medopharm formulation batch M6018 (sampled in 1998) released only 20% of 
labelled amount of paracetamol (the tablets failed to disintegrate). On the contrary, 
another batch from the same manufacturer (sampled in 2000) had a 100% drug 
release (Fig. 3.9).  
Table 3.26:  Percentage of paracetamol released after 30 min of dissolution testing 
on paracetamol tablets stored at simulated tropical conditions (40°C, 
75% RH). USP 24 requirement: more than 80% is released within 30 
min 
Storage time 
Manufacturer 
0 months 3 months 6 months 
Alferez 92.0 56.3 50.0 
Granules  100.7 92.9 88.3 
Interchem 78.1 78.3 76.8 
Jansen Cilaga 94.3 94.3 94.5 
Medopharm (batch M6018) 20.0 19.2 18.0 
Medopharm (batch M0173) 101.2 100.8 97.8 
Panacea Biotec 101.6 100.1 99.9 
TPI (batch LK 72) 88.8 21.5 20.0 
TPI (batch NH 231) 100.1 20.8 16.2 
    aReference sample 
The dissolution profiles of the 6 formulations that complied with the USP 24 
specifications were compared with that from Jansen-Cilag (the reference 
formulation). All f2 factors were less than 50 (Table 3.27), indicating that there 
were differences between the profiles. The reference formulation had released 
more than 90% drug within 5 min, while the others had a lower drug release (46 - 
70%) within this interval.  
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Table 3.27: The f2 values for the dissolution profiles obtained from the different 
paracetamol formulations before storage at simulated tropical conditions, 
using the Jansen Cilag formulation as a reference 
Formulation f2 value 
Alferez 41 
Granules  35 
Medopharm (batch M0173) 44 
Panacea Biotec 44 
TPI (batch LK72) 40 
TPI (batch NH231) 41 
 
Upon storage at simulated tropical conditions, the drug release of two formulations 
decreased dramatically. The drug release from the Alferez formulation decreased 
to 56.3% after 3 months of storage, then to 50.0% after 6 months. Similar 
observations were made for both batches of the TPI formulation. After 3 months, 
the drug release of this formulation had already decreased to about 20% (Fig. 3.9). 
It was observed that the tablets of both batches failed to disintegrate during the 
dissolution test.  
The drug content of the formulations that failed the in vitro dissolution after storage 
at simulated tropical conditions was evaluated. The assay results showed that 
there was no appreciable change in paracetamol content in these formulations 
during the 6 month test duration. This indicates that the decreased drug release 
occurred as a result of factors other than chemical instability.  
The percentage drug released from the other four formulations remained within the 
USP 24 tolerance limits for dissolution during the 6 months storage period at 
simulated tropical conditions. The f2 values of the dissolution profiles obtained 
after 6 months (compared with that obtained before stability testing) were 82, 78, 
61 and 50 for the Jansen-Cilag, Panacea Biotec, Medopharm and Granules 
formulations, respectively, indicating that the storage conditions did not infuence 
the in vitro drug release profiles of these formulations.  
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Figure 3.9:   Dissolution profiles of paracetamol formulations after 0 (♦), 3 (■) and 6 
(▲) months of storage at simulated tropical conditions (40°C, 75% RH)  
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Figure 3.9 (continued) 
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3.11  Sulfadoxine/pyrimethamine formulations 
Four formulations were evaluated, all of them available on the Tanzanian market. 
The detailed information of the sampled formulations is shown in Table 3.28. 
Table 3.28:  Sulfadoxine (500 mg) / pyrimethamine (25 mg) tablet formulations 
Manufacturer  Package Batch number 
Price per 1000 
units (US$) 
Ellys Chemical Industries 
(Kenya) 
Blister, 100 tablets OE84 125 
Flamingo Pharmaceuticals 
(India) 
Blister, 100 tablets 5560 130 
Rochea                             
(Switzerland)   
Blister, 250 tablets B3015 500 
Shelys Pharmaceuticals 
(Tanzania) 
Blister, 100 tablets 068 120 
aReference sample 
3.11.1  Materials 
Sulfadoxine (USP) was obtained from Indis (Aartselaar, Belgium), while 
pyrimethamine (USP) and phenacetin were from Sigma Aldrich (Steinheim, 
Germany). Acetonitrile was obtained from Biosolve (Valkenswaard, The 
Netherlands), glacial acetic acid from Merck (Darmstadt, Germany) and perchloric 
acid from UCB (Brussel, Belgium). Potassium dihydrogen phosphate and sodium 
hydroxide were obtained from Vel (Leuven, Belgium). 
3.11.2  Assay for sulfadoxine and pyrimethamine  
3.11.2.1 Methods 
The amount of sulfadoxine and pyrimethamine in each formulation was 
determined using the method described in the USP 24. 
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Sample preparation. 
10 tablets were weighed and finely powdered. An accurately weighed portion of 
the powder, equivalent to 550 mg sulfadoxine and 27.5 mg pyrimethamine was 
transferred into a 100 ml volumetric flask and 35 ml of acetonitrile were added. 
The mixture was sonicated for 25 min, adjusted to volume with the mobile phase 
and then homogenised. The resulting mixture was filtered through a 0.5 µm 
cellulose acetate filter (Minisart®, Sartorius, Goettingen, Germany). 10 ml of the 
filtrate were transferred into a 100 ml volumetric flask and diluted to volume with 
the mobile phase. From this solution, 5 ml was transferred into a 10 ml volumetric 
flask, 1 ml of phenacetin solution (120.0 mg/l) was added and the volume was 
adjusted with the mobile phase to make the assay solution.  
Calibration curves 
For the sulfadoxine assay, a calibration curve y = 0.0409x (± 0.0006) + 0.3499 (± 
0.0052) with a coefficient of determination (R2) of 0.9993 (± 0.0004) (n = 5) was 
constructed using the peak area ratio (sulfadoxine/phenacetin) vs. concentration 
obtained from standard solutions with sulfadoxine concentrations of 50, 100. 150, 
275 and 350 mg/l. The concentration of phenacetin in each standard solution was 
12 mg/l. Similarly a calibration curve y = 0.04400x (± 0.0007) – 0.00613 (± 0.0001) 
with a R2 of 0.9998 (± 0.0007) (n = 5) was obtained for pyrimethamine using 
standard solutions with concentrations of 6, 8, 12.5, 16 and 25 mg/l. The unknown 
concentrations of sulfadoxine and pyrimethamine in the assay solution were 
determined from the respective calibration line.  
The precision of the assay method was determined by calculating the relative 
standard deviation (within day and between days) of the peak areas obtained after 
repeated injections (n = 6) of a standard solution having concentration of 275 mg/l 
sulfadoxine, 12.5 mg/l pyrimethamine and 12 mg/l phenacetin. 
The resolution factor (R) between sulfadoxine and phenacetin and between 
pyrimethamine and phenacetin was determined from the peaks obtained from the 
standard solutions. Based on the retention times and baseline widths R was 
calculated as:  
     R = 2(t1 – t2)/(W1 + W2) 
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with t1 and W1 being the retention time and baseline width, respectively, of the 
phenacetin peak, while t2 and W2 are the respective values of the sulfadoxine or 
pyrimethamine peak.  
Mobile phase 
The mobile phase was a mixture of a dilute acetic acid solution (1:100), acetonitrile 
and perchloric acid (70%) in the following propotions: 800:200:8 (v/v). Samples (20 
µl) were injected into the HPLC system and the peaks were monitored by UV 
absorbance at 254 nm. 
3.11 2.2  Results  
The relative standard deviation (RSD) for replicate injections was 0.26% and 
0.73% for the within day and 0.86% and 1.44% for the between day analysis for 
sulfadoxine and pyrimethamine, respectively. According to the USP 24 the RSD 
should be below 2.5%. The resolution factor R between sulfadoxine and 
phenacetin and between pyrimethamine and phenacetin was 2.2 and 2.0, 
respectively. According to the USP 24, R should be not less than 1 for both drugs.  
The sulfadoxine and pyrimethamine contents of each formulation, expressed as a 
percentage of the stated amount, are shown in Table 3.29. All formulations passed 
the assay requirements specified in the USP 24 (90 –110% of the labelled content 
for both sulfadoxine and pyrimethamine). The assayed sulfadoxine in the 
formulations ranged from 95.5 to 101.1% and that of pyrimethamine from 99.2 to 
101.6%. 
3.11.3  In vitro dissolution  
3.11.3.1 Methods 
Dissolution testing 
Dissolution tests were performed using the USP paddle method (Method 2) at a 
rotational speed of 75 rpm. The dissolution vessels were filled with 900 ml of 
dissolution medium (phosphate buffer pH 6.8), maintained at 37 ± 0.5°C. Samples 
(5 ml) were withdrawn at regular intervals (5, 10, 15, 20, 25 and 30 min). The 
samples were diluted (1:1) with the mobile phase before being analyzed by HPLC 
as is described in the assay (section 3.11.2). 
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Table 3.29:  Mean sulfadoxine and pyrimethamine content of the different 
formulations expressed as a percentage of the labelled amount 
Manufacturer  
Mean drug content 
per tablet (mg) 
% of the labelled 
amount per tablet 
Sulfadoxine   
Ellys  490.3 ± 4.2 98.1 
Flamingo  477.5 ± 4.1 95.5 
Rochea 498.6 ± 4.3 99.7 
Shelys  505.5 ± 4.6 101.1 
Pyrimethamine   
Ellys  25.4 ± 0.4 101.6 
Flamingo  24.8 ± 0.4 99.2 
Rochea 25.2 ± 0.4 100.8 
Shelys  25.0 ± 0.4 100.0 
aReference sample 
3.11.3.2 Results 
The percent drug sulfadoxine and pyrimethamine released before and after 
storage are shown in Table 3.30 and the dissolution profiles in Fig. 3.10 and Fig. 
3.11.  
Before storage at simulated tropical conditions, only two of the four formulations 
complied with the USP 24 requirements for drug release. The formulation from 
Ellys released 100.2% sulfadoxine and 71.3% pyrimethamine, while that from 
Roche was 97.8 and 66.4% for sulfadoxine and pyrimethamine, respectively.  
The dissolution profiles obtained from the Ellys formulation before storage at 
simulated tropical conditions (0 months) were compared with those of the Roche 
formulation. The f2 values (calculated using the Roche formulation data as the 
reference) were 53 and 51 for sulfadoxine and pyrimethamine, respectively, 
showing that the two formulations had pharmaceutically equivalent drug release 
profiles.  
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Table 3.30:  Percentage of sulfadoxine and pyrimethamine released after 30 minutes 
of dissolution testing on sulfadoxine/pyrimethamine tablets stored at 
simulated tropical conditions (40°C, 75% RH). USP 24 requirements: 
more than 60% of both sulfadoxine and pyrimethamine is released within 
30 min  
Storage time 
Manufacturer 
0 months 3 months 6 months 
Sulfadoxine    
Ellys 100.2 96.1 84.2 
Flamingo 53.3 51.7 51.3 
Rochea 97.8 92.0 89.3 
Shelys 60.9 41.6 30.0 
Pyrimethamine    
Ellys 71.3 72.0 60.8 
Flamingo 17.4 17.2 15.6 
Rochea 66.4 63.2 60.4 
Shelys 26.5 20.0 13.6 
aReference formulation 
Upon storage at simulated tropical conditions, the release of both sulfadoxine and 
pyrimethamine from the Roche and Ellys formulations remained within the USP 24 
recommended values for in vitro drug release. The Ellys formulation however, 
showed a marked decrease in vitro release of both drugs during storage at 
simulated tropical conditions. The sulfadoxine release decreased to 96.1 and 
84.2% after 3 and 6 months storage, respectively. The respective values for 
pyrimethamine during the same intervals were 72.0% and 60.8%.  
The dissolution profiles obtained for both sulfadoxine and pyrimethamine before 
and after stability test from the Roche and Ellys formulations were compared for 
similarity. For the Roche formulation the f2 value of the 6 months profiles were 53 
and 50, for sulfadoxine and pyrimethamine, respectively. The respective values for 
the Ellys formulation were 37 and 48. The in vitro drug dissolution from the Roche 
formulation was not influenced by storage at simulated tropical conditions (Fig 
3.10 and 3.11). The f2 values for sulfadoxine and pyrimethamine dissolution 
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profiles from the Ellys formulation after 3 months were 53 and 79, respectively. 
This shows that the drug release profile after 3 months storage was similar to the 
one immediately after purchase. However, after 6 months of storage at the test 
conditions, the drug release profiles were not similar to the ones obtained before 
the storage. Although this formulation had acceptable drug release characteristics 
before the stability test, the f2 analysis of the profiles indicates that the dissolution 
pattern was influenced by storage at simulated tropical conditions.  
In addition to the failure to meet the USP 24 dissolution specifications immediately 
after purchase, the drug release from the Shelys formulation also decreased 
during storage at simulated tropical conditions. The sulfadoxine release from this 
formulation decreased to 41.6% and 30.0%, after 3 and 6 months, respectively. 
The respective pyrimethamine release was 20.0% and 13.6%. The drug release 
from the Flamingo formulation did not decrease appreciably during the accelerated 
stability test and the in vitro drug dissolution remained well below the USP 24 
specifications.  
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Figure 3.10:  Dissolution profiles of sulfadoxine from sulfadoxine/pyrimethamine 
tablets after 0 (♦), 3 (■) and 6 (▲) months of storage of storage at 
simulated tropical conditions (40°C, 75%RH) 
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Figure 3.11: Dissolution profiles of pyrimethamine from sulfadoxine/pyrimethamine 
tablets after 0 (♦), 3 (■) and 6 (▲) months of storage at simulated 
tropical conditions (40°C, 75% RH) 
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3.12  Discussion 
During the acquisition of the samples it was evident that there are large price 
differences between the innovator brands and their generic equivalents. The 
availability of low priced generics on the market may be considered as a welcome 
development resulting from the implementation of the Essential Drugs Concept. It 
is imperative that measures are put in place to control and monitor the quality of 
the drugs on the market. As has been observed by Pecol et al. (1999) the quality 
of drugs becomes less certain especially for poor populations who are attracted to 
lower priced drugs in an unregulated environment. In this case it is important that 
the drug regulatory authority in Tanzania put in place the necessary controls to 
ensure that the drugs on market are consistently of good quality.  
The assay results on the content of the active substance showed that this 
parameter was within the specifications recommended by the USP 24 for all 
formulations. The findings are similar to those obtained by Abdi et al. (1995) on the 
quality of chloroquine tablets on market in Tanzania, where all samples from 10 
different manufacturers passed the assay test. However, Kibwage et al. (1992) 
reported that about 45% of drugs sampled on the Kenyan market and analysed at 
the Daru quality control laboratory on a routine basis were of substandard quality 
in terms of the content of the active ingredient. Shakoor et al. (1997) reported on 
the presence of both fake and substandard drugs on Thai and Nigerian markets 
where 32% of 89 samples failed the assay determination. These differences in 
findings cannot be explained on the basis of the existence of an effective drug 
control and monitoring system in Tanzania. On the contrary such a system was 
not in place during the period when the samples were taken. For example, it was 
only until July 2000 when the Pharmacy Board of Tanzania established the only 
drug control laboratory in the country and the drug registration exercise has taken 
place recently. As has been noted by Shakoor et al. (1997) in many reports 
concerning the quality of drugs in developing countries the terms counterfeit and 
substandard drugs have been used interchangeably. Counterfeiting is a criminal 
activity driven by the motive for quick profits. Consequently, counterfeit drugs 
exists on market sporadically thus the absence of counterfeit drugs amongst the 
analysed formulations could possibly be due the sampling window or sample size. 
On the other hand, the presence of cheap generic brands on market may have 
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been deterrent to introducing counterfeit drugs, as it makes counterfeiting less 
profitable. A systematic quality assurance system is required as a further deterrent 
to the introduction of counterfeit / substandard drugs into the country. 
Several studies have been reported in the literature on the stability of essential 
drugs under real storage conditions in the tropics (Hogerzeil et al., 1991; Ballereau 
et al., 1997; Nazerali and Hogerzeil, 1998). All these studies have dwelt on the 
chemical stability of the drug. It is known that under conditions of high temperature 
and humidity the drug may undergo polymorphic or crystal changes that may 
decrease its inherent solubility. In addition, excipient - excipient and/or excipient - 
drug interactions may occur under the influence of high temperature and high 
relative humidity conditions, reducing the dissolution rate of a formulation 
containing a chemically stable drug (Saville, 2001). In the present study dramatic 
changes in the dissolution behaviour of some formulations have been observed. 
The drug formulations (paracetamol, acetlysalicylic acid, diclofenac sodium, 
metronidazole, sulfadoxine/pyrimethamine and chloroquine) that failed the stability 
test had a more than 40% reduction in the amount of drug released after 3 and 6 
months of stability testing. It was not possible to identify the cause of the failure in 
dissolution of the formulations, as the exact composition of the formulations was 
not available. It is known that the interactions that may occur for a drug formulation 
stored at high temperature and humidity conditions are complex and formulation 
dependent (Murthy and Ghebre-Sellassie, 1993). The formulations may have for 
example contained disintegrants such as maize starch, which can loose its 
capacity to swell on ageing or on exposure to high humidity/temperature (Pandit et 
al., 1997).  
For the formulations that failed the dissolution test, no firm conclusion may be 
drawn on their bioavailability. Murthy and Gherbe-Sellasie (1993) have reported on 
cases of experimental drug formulations with a largerly reduced in vitro drug 
release on ageing, but with a similar bioavailability profiles to fresh formulations. 
Similar cases have been reported for aged nitrofurantoin capsules (Vila-Jato et al., 
1987). On the other hand other authors have reported cases where nitrofurantoin 
tablet formulations exposed to stress conditions had a reduced in vitro drug 
release and also a significant reduction in their rate of absorption (Gouda et al., 
1987). The failure to meet the USP dissolution specifications may be taken as an 
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indication of a potential bioavailability problem. Further in vivo work needs to be 
done to determine the effect of the changed dissolution characteristics on the 
bioavailability of the failed formulations. 
Due considerations should be given to the formulation and manufacturing process 
to ensure a reproducible and stable in vitro and in vivo drug availability. The in 
vitro performance of a solid dosage form depends on the use of ingredients with 
predetermined properties as well as on controlled and validated manufacturing 
procedures. These are achieved if the manufacturer adheres to the Good 
Manufacturing Practices (GMP) principles as is advocated by the WHO. In this 
study it has been observed that different batches of the same drug from the same 
manufacturer had different in vitro drug dissolution characterisitics (eg. 
paracetamol from Medopharm). Furthermore, samples of different drugs from the 
same manufacturer were found to have a different in vitro dissolution stability (eg. 
amoxcicillin and metronidazole from Shelys had a satisfactory drug release, but 
acetylsalicylic acid and sulfadoxine/pyrimethamine tablets were not stable). It may 
be considered that the manufacturer of these formulations did not use appropriate 
ingredients in the formulation and/or applied an inappropriate manufacturing 
process and that the products were not manufactured in accordance to the WHO 
GMP guidelines for the manufacture of pharmaceuticals. 
The dissolution tests were able to discriminate poor quality formulations amongst 
the samples that had passed the assay tests. 16% (9/57) of the analysed 
formulations failed the initial dissolution test: 3 acetylsalicylic acid, 2 
sulfadoxine/pyrimethamine, 2 paracetamol and 2 sulfamethoxazole/trimethoprim 
formulations. From the 48 samples that passed the initial dissolution test, 19% 
(9/48) of them (3 paracetamol, 2 chloroquine, 2 enteric coated diclofenac sodium 
and 2 metronidazole formulations) failed the dissolution test after being subjected 
to a stability test at simulated tropical conditions  
As regards the regulatory aspects, the WHO recommends an accelerated stability 
test under zone IV climatic conditions to be performed on all drugs intended for the 
global market (Matthews, 1999). A stability test is recommended as a quality 
control tool that may be used to verify if a formulation and the manufacturing 
process do not affect the efficacy and safety of the product under the distribution 
and storage conditions. The failure of some formulations to satisfy dissolution 
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requirements after being subjected to a stability test (at simulated tropical 
conditions) infers that the drug formulations are unsuitable for marketing in 
countries with tropical climatic conditions such as Tanzania. Regular monitoring of 
the quality and stability in tropical conditions of the drugs on market by the 
regulatory authority of Tanzania (The Pharmacy Board) should be encouraged as 
means of preventing the access to the market of drugs with inferior quality.  
3.13  Conclusion 
The in vitro evaluation of 54 formulations of 9 essential drugs available on the 
Tanzanian market has shown that all of them meet the USP 24 potency 
specifications. However, the initial in vitro dissolution characteristics as well as the 
dissolution behaviour after storage at simulated tropical conditions of 18 of these 
formulations were not satisfactory. The evaluation of the bioavailability of these 
formulations is recommended to shed light on the effect of poor dissolution on their 
bioavailability.  
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4. EVALUATION OF DISSOLUTION PROFILES: INTER 
LABORATORY COMPARISON OF DISSOLUTION DATA  
4.1 Introduction 
The potential for variation between results of an analytical test performed in 
different laboratories is well known. Analyses performed in developing countries 
are especially prone to this problem as in many of these countries quality control 
laboratories are not equipped with the appropriate equipment and training of 
personnel to man the laboratories is not routinely done and good laboratory 
practices (GLP) are not in place. In such laboratories the analytical results are 
usually treated with reservations. Gomes et al. (1998) has reported on the 
differences in assay results of antimalaria drugs analyzed by the Institute of Drug 
Quality Control of Vietnam and those from a WHO accredited laboratory. The 
results from the Institute showed a failure of 3.2% of all sampled drugs. Ten 
percent of the samples originally analyzed at the Institute were reanalyzed in a 
WHO accredited laboratory where it was found that 70% of them failed to meet 
specifications for drug content. Roy (1994) has also reported on the existence of 
substandard drugs in Bangladesh that had been affirmed to be of satisfactory 
quality by the local drug authority. 
In the execution of this research project (a sandwich program), in vitro dissolution 
tests on the same batches of ciprofloxacin and metronidazole tablet formulations 
were performed in two laboratories. The tests were done at the Laboratory of 
Pharmaceutical Technology, Ghent University (Ghent - Belgium) and at the 
laboratory of Tanzania Pharmaceutical Industries (Arusha - Tanzania).  
4.2 Comparison of dissolution data 
Various methods have been described to compare dissolution data. The United 
States Pharmacopoeia (USP 24) recommended method for the evaluation of the 
dissolution data involves a single point determination of the percentage drug 
dissolved at a predefined time. The FDA guidance for industry on dissolution 
testing has three categories of dissolution test specifications: (1) single point 
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specification, (2) two point specification and (3) dissolution profile comparison 
(FDA Guidance for industry, 1997). The point (single and 2 point) estimate is 
suitable for high solubility – high permeability drugs, but may not be adequate for 
drugs with low solubility. For poorly soluble drugs, the dissolution curves of two 
batches can differ significantly before reaching the same value at the predefined 
time point and this can result in different plasma concentration – time profiles. 
In the literature, other methods have been described to compare dissolution 
profiles. They may be classified into model independent and model dependent 
methods. In the model independent methods, the data are analysed in their native 
form without transformation. Analysis of variance (ANOVA) may be applied on the 
dissolution data in the native form to compare the level and shape of dissolution 
profiles (Mauger et al., 1986). Similarities and differences between profiles can be 
determined using the fit factors: f1, difference factor and f2, similarity factor (Moore 
and Flanner, 1996). In the model dependent methods, the dissolution data are 
fitted into a mathematical model such as the Weibull distribution (Langenbucher, 
1972) and the model parameters are employed for pairwise statistical comparison 
of the dissolution data.  
The fit factors compare the two mean curves and do not consider the within curves 
variability. However, they are simple to apply and interpret. The ANOVA based 
and model dependent methods are more complicated, but describe better the 
relationship between the percent dissolved and time variables. The ANOVA 
methods provide detailed information on the level and shape of the dissolution 
profile, which is useful in formulation development. In comparison to the fit factors, 
the ANOVA and model dependent methods are considered to be more 
discriminative.  
Principal Component Analysis (PCA) is an important visualization tool for 
multivariate data (Vandeginste et al., 1998). PCA can reduce a large number of 
original variables to a few principal components (PCs) that still contain the most 
important information. PCA has been shown to be a useful method for visualizing 
differences within a set and between sets of dissolution profiles (Adams et al., 
2001). PCA can also be used to compare dissolution data where measurements 
have been made at different sample time points (Adams et al., 2002). 
In this chapter the inter-laboratory dissolution data is compared using the FDA 
similarity factor and Principal Component Analysis (PCA).  
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4.2.1  Similarity factor 
The FDA recommends the use of the similarity factor (f2), which is calculated using 
the equation proposed by Moore and Flanner (1996) 
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with Rt and Tt the average percentage dissolved at time t (for t = 1, 2, ..., n) for the 
reference and the test batch, respectively, and wt the optional weight factor (mostly 
wt = 1). Two sets are considered equivalent when the f2 factor is between 50 and 
100. A value of 100 is obtained when both batches are identical. The lower limit of 
50 was determined empirically by permitting a 10 % average difference at any 
sample time point. The FDA considers the dissolution profiles of two batches to be 
equivalent when the f2 factor is greater or equal to 50 and allows the use of such in 
vitro data to ensure the product quality in case of scale-up and post approval 
changes (SUPAC) like manufacturing site changes, increase or decrease of batch 
size and changes in excipients (FDA Guidance for Industry, 1995, 1997).  
4.2.2  Principal component analysis 
Principal Component Analysis (PCA) is a technique that allows exploring 
multivariate data. For example the percent drug dissolved at 3 different time points 
(3 variables: 15, 30 and 45 min) for a set of tablets may be compared by plotting 
the values (percent drug released) in a three dimensional space of their original 
variables (time points) as shown in Fig. 4.1. The illustration has been limited to 
three variables to be able to visualize PCA in a 3D-plot, but the PCA technique is 
not limited to 3 variables. 
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Figure 4.1: Percent dissolved at the different time points plotted in 3 original 
variables 
 
 
 
 
 
 
 
 
The second step in PCA is usually column centering. The central point (0,0,0) of 
the 3 axes is moved to the centre of the cloud of measurements (Fig. 4.2). After 
column centring, a line is drawn through the centre of the data points (the centre of 
the 3 axes) in the direction of the largest variance of the data points. This line is 
the first Principal Component (PC1). The direction is found by rotating the PC 
around the central point until a direction is found where the sum of the orthogonal 
distances of the data points to the PC is the smallest. The direction of the PC may 
point in either way since only the magnitude of variation is put into consideration 
(Fig. 4.3). 
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Figure 4.2: Column centring of the data points 
 
 
 
After the construction of PC1, a second PC is constructed through the centre 
orthogonal to PC1 and in the direction of the largest variance around PC1. As 
many PCs as the original variables can thus be constructed, but PC1 displays 
more information (variance) contained in the original variables than PC2 and the 
other subsequent PCs (PC1>PC2>PC3…). Usually the first few PCs displays most 
of the information contained in the original variables and the other PCs explain 
only small random variations in the data. 
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Figure 4.3:  The column centred measurements plotted in the 3 original variables 
together with the first PC  
 
 
 
 
 
 
The data measurements plotted in the 3 original variables can now be represented 
in a new axes system of a few latent variables or PCs as is shown in Fig 4.4. 
The distance from the origin of the PC space to the perpendicular projection of an 
object on a PC is called the score of the object on that particular PC. In Fig. 4.4 
the score of the tablet X1 is t11 on PC1 and t12 on PC2.  
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Figure 4.4: The dissolution measurements represented in the PC1/PC2 space with 
the scores of the tablet Xi on PC1 and PC2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathematically the score of an object on a PC is a linear combination of the 
original variables. The score of tiq of tablet i on PCq may be expressed as:  
tiq      =      ∑
=
p
j 1
vjq (xij -xj)                                                 (1) 
Where vjq is the loading of tablet i at sample time j on PCq, xij is the percent drug 
dissolved from tablet i measured at time j andxj is the mean drug dissolved at 
time point j. 
In a matrix notation equation 1 can be expressed as:  
T(mxa) = Xc(mxp)V(pxa)                                             (2) 
with Xc being the column centred matrix (X -X), V the loading matrix, m the 
number of tablets tested, p the number of sample time points and a the number of 
PCs.  
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To compute the scores of matrix T and loadings matrix V starting from the column 
centred data matrix Xc the Singular Value Decomposition (SVD) algorithim is used:  
Xc(mxp) = X -X = U(mxa)S(axa)VT(axp) = T(mxa)VT(axp)            (3) 
Equation 3 may be illustrated schematically in a diagram as in Fig. 4.5. 
Figure 4.5: Schematic illustration of singular value decomposition (SVD) 
 
 
 
 
 
 
with m the number of objects (here: the number of tablets measured in the batch), 
p the number of original variables (here: the number of time points) and a the 
number of principal components (PCs), with a = m − 1 if m ≤ p or a = p if m > p. U 
is the unweighed (normalised) and T the weighed (unnormalised) score matrix. V 
is the loading matrix containing the loadings of the original variables on the 
different PCs and S is a diagonal matrix with the singular values λj (for j = 1, 2, … 
a) on the main diagonal. Since a21 ... λ≥≥λ≥λ , the first PCs contain the most 
relevant information, while the remaining PCs contain only noise.  
For analysis of dissolution data the scores of the reference batch are used to 
construct the PC space and those of the test batch can be projected on the same 
PC1/PC2 space as shown in Fig. 4.6. 
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Figure 4.6:  An example of a PCA scores plot obtained after PCA analysis of 
dissolution data of the reference batch (○) and a test batch () 
 
 
 
 
 
 
 
 
 
Although PCA is a very useful technique to analyse dissolution data, it does not 
provide statistical criteria to decide if the dissolution behaviour of different batches 
is similar. This drawback has been overcome by combining PCA with the 
resampling with replacement (or bootstrap) method to construct confidence limits, 
which form the criteria for the decision on similarity.  
4.2.2.1 Bootstrap technique in combination with PCA 
The technique of sampling with replacement or bootstrapping is used to simulate 
the distribution of the mean in the PC space and to construct a 95 % confidence 
limit for complete data matrices (Efron and Tibshirani, 1986). 
The bootstrap method randomly reassigns the observations and recomputes the 
estimate mean. When this is repeated many times it gives an estimate of the 
population mean. Performing bootstrapping is similar to repeating the experiment 
many times over. The experimenter does with a computer what she/he would have 
done if circumstances would allow. 
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In matrix notation bootstrapping may be illustrated as follows: starting from matrix 
X (m×p) containing the original data, a new matrix X1 (m × p) is generated by 
drawing with replacement m rows from the orginal matrix X. Repeating the 
procedure n times (usually 1000) n matrices (X1, X2 ……., Xn) are constructed all with 
size (m x p) (Fig. 4.7).  
After calculation of the vector of column means for each matrix, a (n x p) matrix is 
formed. PCA is then performed on the (n x p) matrix so obtained.  
Figure 4.7:  Schematic illustration of resampling and replacement or bootstrapping 
 
 
 
 
 
 
 
 
 
 
 
 
 
When combined with PCA analysis the scores of the bootstrapped values 
projected on a PC space will appear closely together because their mean values 
are similar (Fig. 4.8). A 95% confidence interval may be constructed by removing 
the 5% outliers. Practically this is achieved by measuring the distances towards 
the center of the cluster, and constructing a circle from the center as to include 
95% of the values (Fig. 4.9). Similarity between the dissolution data (at 95% 
confidence interval) of a test and the reference formulation may be compared by 
performing BOOT(PCA) of the two sets and projecting the data on a PCA plot (Fig. 
4.10). When there is a complete overlap between the scores of the test batch and 
the reference batch similarity (at 95% confidence interval) is assumed. 
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Figure. 4.8:  Normalised PCA scores plot after BOOT/PCA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Construction of a 95% confidence interval limit by plotting a circle around 
the BOOT/PCA scores to exclude 5% of the data 
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Figure 4.10:  Normalised scores plot for the reference (0) and test (0) formulation 
showing a partial overlap of the scores of the reference and test 
formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.2.2 PCA and missing data 
When many data have to be measured, the possibility arises that some values are 
missing. In this case, case deletion and imputation methods are frequently used to 
obtain a "complete" data set without missing values. In case deletion, all subjects 
(here: tablets) with missing values are omitted. It is clear that this approach is 
inefficient when only a limited number of subjects (typically 6 or 12 tablets) are 
measured since a substantial part of the information is discarded. Imputation 
methods imply that the missing data are filled in with plausible values. The easiest 
way is to replace the missing value(s) by the mean for that variable. However, by 
doing so the correlation between the data is not respected. Another possibility is 
the expectation-maximization (EM) algorithm. The expectation-maximization 
approach has been shown to be an efficient tool to deal with missing data. 
Furthermore, it can easily be combined with PCA (EM(PCA)) (Nelson et al., 1996; 
Grung and Manne, 1998).  
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The EM procedure can be summarized as follows: 
1. Replace the missing elements in data matrix X with their initial estimates, for 
instance, the mean values for the corresponding variable. 
2. Perform PCA of the completed data set. 
3. Predict the missing value(s) using a limited number of significant principal 
components (PC’s). This results in a matrix of the predicted values Xˆ . 
4. Replace the missing elements in the original matrix X with their predicted 
values from Xˆ  (the observed values of X remain unchanged). 
5. Repeat steps 2 to 4 till convergence.  
The result is the original data matrix X in which the missing elements are replaced 
by the predicted values from the EM(PCA) algorithm. It is important to emphasize 
that the values for the missing data are optimized in order to be analyzed further 
by PCA.  
As regards to dissolution testing, a special case of missing data is encountered 
when the data sets to be compared are measured at different time points. The 
missing values (time points) for each data set are replaced by the predicted values 
obtained by the EM(PCA) algorithm after which PCA is performed on the 
recomposed, originally incomplete data set. The procedure is schematically 
illustrated in Fig. 4.11. EM can only be successfully applied if the sets of data have 
at least one common sample time point.  
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Figure 4.11: Schematic illustration of EM/PCA procedure on two sets of dissolution 
data measured at different sample time points 
 
 
In the case of missing values in one of the dissolution sets, two approaches are 
possible for bootstrapping: 
EM/BOOT/PCA: the missing values in matrix Xmiss (m × p) are first replaced by 
their values estimated by EM(PCA) to yield a matrix X (m × p). Next, n 
bootstrap matrices (X1, X2,…, Xn) are formed, all with size (m × p). After 
computation of the n column mean vectors with size (1 × p), an (n × p) matrix 
is formed followed by PCA. 
BOOT/EM/PCA: starting from matrix Xmiss (m × p) with missing values, first n 
bootstrap matrices, also with missing values, are formed. Each of the n 
bootstrap matrices is then completed using EM (PCA). After construction of 
the (n × p) matrix of column means, PCA is performed. The results obtained 
after BOOT/EM/PCA are similar to those from EM/BOOT/PCA, but the former 
method is much slower to perform. 
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4.3  Materials and methods 
4.3.1  Laboratories 
The dissolution tests of the same batches of ciprofloxacin and metronidazole 
tablets were performed at the quality control laboratory of the Tanzania 
Pharmaceutical Industries (TPI) (Arusha, Tanzania) and at the Laboratory of 
Pharmaceutical Technology, Ghent University (Ghent, Belgium) by the same 
analyst. 
4.3.2  Drug samples  
Eight ciprofloxacin and seven metronidazole generic tablet formulations available 
on the Tanzanian market were purchased from pharmacies in Tanzania. The 
innovator brand for metronidazole (Rhône Poulenc Rhorer) was obtained from a 
pharmacy in Belgium. The samples were allocated a code shown in Table 4.1. 
Table 4.1: Manufacturers of and the code allocated to the samples  
Metronidazole tablets  Ciprofloxacin tablets 
Manufacturer Code  Manufacturer Code 
ACE Laboratories A  Aurobindo 1 
Flamingo Pharmaceuticals F  Cadila Pharmaceuticals 2 
Intas Pharmaceuticals I  Egyptian Pharmaceuticals 3 
Medopharm M  Flamingo Pharmaceuticals 4 
Shelys Pharmaceuticals S  Freudun Pharmaceuticals 5 
S Kant Health Care SK  Gracure  6 
TPI T  Intas Pharmaceuticals 7 
Rhône Poulenc Rhorer R  S Kant Health Care 8 
 
4.3.3  Equipment  
In Belgium the dissolution apparatus was a VK 7010 system linked to a VK 8000 
automatic sampler (Vankel Technology, Cary, USA). The UV analysis of the 
samples was performed using a Lambda 12 UV/VIS spectrophotometer (Perkin 
Elmer, Norwalk, USA). 
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In Tanzania the dissolution apparatus was an Erweka DT06 (Erweka Darmstadt, 
Germany). The analysis of the samples was performed using a 551 UV/VIS 
spectrophotometer (Perkin Elmer, Norwalk, USA). 
4.3.4 Materials 
Belgium 
Metronidazole was supplied by Alpha Pharma (Zwevegem, Belgium), ciprofloxacin 
hydrochloride by Bayer (Leverkusen, Germany) and hydrochloric acid was 
obtained from Vel (Leuven, Belgium).  
Tanzania 
Metronidazole was supplied by Sigma (Steinheim, Germany), while ciprofloxacin 
hydrochloride was obtained from Pentex Miles (Kankakee, USA). Hydrochloric 
acid was obtained from BDH Chemicals (Poole, England). 
4.3.5 Dissolution method  
For the metronidazole formulations the USP Method 1 at 100 rpm was used. The 
dissolution medium in each vessel was 900 ml of 0.1N HCl maintained at 37 ± 
0.5°C. Aliquots (5 ml) of the dissolution media were withdrawn after 10, 20, 30, 40, 
50 and 60 min. The samples were withdrawn automatically using sampling probes 
and manually using a 5 ml syringe for the tests conducted in Belgium and 
Tanzania, respectively. In both laboratories the dissolution samples were analysed 
by UV at 278 nm. 
For the ciprofloxacin formulations the USP Method 2 at 50 rpm was used. The 
dissolution medium in each vessel was 900 ml distilled water maintained at 37 ± 
0.5°C. Aliquots (5 ml) of the dissolution media were withdrawn manually (using a 5 
ml syringe) after 5, 15, 30 and 45 min for the dissolution tests performed in 
Tanzania. In Belgium, the samples were automatically withdrawn after 5, 10, 15, 
20, 25 and 30 min using sampling probes. The dissolution samples were analysed 
by UV at 276 nm. 
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Software 
All programs used for PCA analysis were written in MATLAB (Version 4.0, the 
MathWorks, Natick, MA, USA). 
4.4  Results and discussion 
4.4.1  Metronidazole formulations 
4.4.1.1 Dissolution profiles 
Fig. 4.12 shows the dissolution profiles of metronidazole. All formulations satisfy 
the USP 24 tolerance limits for dissolution as they released more than 85% of the 
labelled drug within 1 hr. 
The dissolution profiles show that most of the formulations had a fast drug release 
as within 10 minutes more than 80% of the drug had been released (Fig. 4.12). 
However, for both sets of data there is one formulation having an initial slower 
release rate: the Intas formulation (code I) for the data obtained in Tanzania, while 
for data obtained in Belgium it was the TPI formulation (code T).  
Figure 4.12: Dissolution profiles of metronidazole formulations analysed in Belgium 
and Tanzania  
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4.4.1.2 Comparison by similarity factor f2 
The similarity factor was calculated for each formulation by arbitrarily taking the 
data from Belgium as a reference. Similarity factor analysis (Table 4.2) showed 
that only two formulations had a value less than 50: the Intas and TPI formulations 
having f2 factors of 35 and 41, respectively. As described previously these 
formulations had initially a slower dissolution rate: the Intas batch for samples 
analysed in Tanzania and the TPI batch for those analysed in Belgium (Fig. 4.12). 
Table 4.2:  The f2 values for the metronidazole dissolution profiles  
Formulation f2 value 
ACE 64 
Flamingo 51 
Intas 34 
Medopharm 57 
Shelys 69 
S Kant 68 
TPI 41 
Rhône Poulenc Rhorer 63 
 
4.4.1.3 Comparison by BOOT/PCA 
The data from Intas and TPI formulations were analysed by the BOOT/PCA 
technique. The results show that there is no overlap between the data measured 
in the two laboratories (Fig. 4.13 and 4.14). There is a difference on the scores 
mainly along PC1 (size), indicating that there are significant inter-laboratory 
differences on percent drug release of both formulations. As an example, the 
BOOT/ PCA of the dissolution data for the Shelys formulation (which had an f2 
value greater than 50) is shown, the overlap of the scores indicating that there was 
similarity between the data obtained in the two laboratories (Fig. 4.15). 
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Figure 4.13: PCA/BOOT normalized scores plot of the dissolution data obtained in 
Belgium and Tanzania for the Intas formulation (o Belgium,  Tanzania) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14:  PCA/BOOT normalized scores plot of the dissolution data obtained in 
Belgium and Tanzania for the TPI formulation. (o Belgium,  Tanzania) 
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Figure 4.15:  PCA/BOOT normalized scores plot of the dissolution data obtained in 
Belgium and Tanzania for the Shelys formulation. (o Belgium,  
Tanzania) 
 
 
 
The BOOT/PCA technique was also used to compare the data of the eight 
formulations obtained in the two laboratories. This was done by projecting in a 
single BOOT/PCA scores plot the data of all 8 formulations from one laboratory. 
With the exception of the Intas formulation, the scores of the other formulations 
from the data obtained in Tanzania are closely together along PC1 (Fig. 4.17). 
However, the scores for the data obtained in Belgium are relatively spread (Fig. 
4.16). This indicates that there are differences on the PC1 and PC2 scores 
(percent dissolved and shape of the dissolution profile) for these formulations. 
However the differences illustrated by this method are probably an 
overinterpretation and not pharmaceutically significant.  
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Figure 4.16:  PCA normalized scores plot of the dissolution data obtained in Belgium 
after BOOT/PCA of the data from the metronidazole formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17:  PCA normalized scores plot of the dissolution data obtained in Tanzania 
after BOOT/PCA of the data from the metronidazole formulations 
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4.4.2  Ciprofloxacin formulations 
4.4.2.1 Dissolution profiles 
The dissolution profiles show variations between formulations on the percent drug 
release from 0 to 15 min for both the inter- and intra-laboratory dissolution data 
(Fig. 4.18). 
Figure 4.18: Dissolution profiles of ciprofloxacin formulations analysed in Belgium 
and Tanzania 
 
 
4.4.2.2 Comparison by similarity f2 factor 
For the ciprofloxacin formulations the percentage drug dissolved were measured 
at different sample time points. There are two possibilities to compare the data. 
The first possibility is to compare the values between laboratories using the data 
measured in Belgium taken as a reference. However, EM/BOOT/PCA must be 
performed on each set of data to generate the missing data points as shown in the 
example in Table 4.3. 
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Table 4.3:  An example of missing data generated after EM/PCA using 5 PC’s on 
the Aurobindo dissolution data. The replaced values are shown in bold  
Time (min) 
Laboratory 
5 10 15 20 25 30 45 
Belgium        
tablet 1 36.0 77.3 89.0 94.0 98.9 100.0 99.4 
tablet 2 15.5 72.7 86.7 92.0 98.8 98.5 99.4 
tablet 3 2.5 72.7 84.6 95.2 96.2 95.4 94.2 
tablet 4 1.28 40.4 76.5 84.9 93.7 96.5 96.9 
tablet 5 8.0 68.2 83.7 92.2 96.7 95.9 96.5 
tablet 6 3.4 68.1 82.9 90.2 92.5 94.7 95.2 
Tanzania        
tablet 1 2.6 28.6 68.8 74.1 81.2 89.9 95.2 
tablet 2 2.2 33.7 77.0 81.9 90.9 100.1 98.7 
tablet 3 1.6 40.7 74.1 81.3 88.9 92.8 95.7 
tablet 4 30.0 49.7 76.5 79.9 87.5 92.6 98.1 
tablet 5 11.9 40.0 74.8 80.5 87.3 94.1 96.6 
tablet 6 22.4 48.9 77.8 85.2 88.8 94.8 95.4 
 
After performing EM(PCA) to generate the missing data, the f2 factor for each of 
the eight sets of measurements is calculated taking the measurements made in 
Belgium as a reference. The f2 values obtained are shown in Table 4.4. 
Table 4.4:  The f2 values of ciprofloxacin formulations computed after EM/PCA of 
the ciprofloxacin data 
Formulation f2 value 
Aurobindo 46 
Cadila 53 
Egyptian 68 
Flamingo 71 
Freudun 54 
Gracure 70 
Intas 55 
S Kant 65 
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The f2 analysis shows that the dissolution profiles of seven of the eight 
formulations measured in Belgium and Tanzania are pharmaceutically similar (f2 ≥ 
50). 
The second possibility is to compare the eight formulations with each other using 
data obtained in the same laboratory. Since the data of all eight formulations in 
each laboratory are measured at the same sampling times EM is not necessary. 
There are 28 possible combinations to compare the eight brands in pairs: 1-2, 1-3, 
1-4, 1-5, 1-6, 1-7, 1-8, 2-3, 2-4,.... Using the data obtained in Tanzania only 8 of 
the 28 f2 factors are above the limit of 50. Using the data obtained in Belgium 9 of 
the 28 f2 factors are above 50. Of the combinations with an f2 factor above 50, only 
five pairs (1-3, 5-6, 5-7, 6-7 and 4-6) are common between both laboratories 
although their f2 values were not identical (Table 4.5).  
Table 4.5:  Pair-wise comparison of the ciprofloxacin formulations using f2 factors 
computed from the original dissolution data and from data after EM/PCA: 
combinations with f2 factors ≥ 50  
Belgium Tanzania 
Pair f2 value Pair f2 value 
1-3 55 1-3 73 
1-8 58 2-5 60 
2-7 53 3-8 53 
2-8 55 4-6 68 
3-8 50 4-7 64 
4-6 55 5-6 52 
5-6 55 5-7 61 
5-7 70 6-7 68 
6-7 53 4-5 50* 
4-7 51*   
* f2 –factor was above 50 only after EM/PCA 
The pairwise comparison is also done by calculating f2 after EM(PCA) to test the 
influence of EM(PCA) algorithim. The results (Table 4.5) show that 9 and 10 of the 
28 combinations have f2 values ≥ 50 for the data measured in Tanzania and 
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Belgium, respectively: the same formulations as without EM(PCA) plus one 
additional combination. This demonstrates that the influence of EM(PCA) on the 
results is minimal as the number of combinations with f2 values ≥ 50 increased 
marginally. 
Pairwise comparison of the formulations shows that the dissolution profiles vary 
widely even for the data obtained from the same laboratory. This is not surprising 
as the dissolution profiles (Fig. 4.16) show differences in drug release during the 
initial 15 minutes. However, the pharmaceutical relevance of these differences will 
probably be negligible. 
4.4.2.3 Comparison by BOOT/PCA 
From the f2 analysis of the inter-laboratory dissolution data, the profiles of the 
Aurobindo formulation (code 1) were not equivalent. The inter-laboratory data from 
this formulation were also compared using the BOOT/PCA technique. Since the 
data obtained in Tanzania and in Belgium were measured at different sample time 
points, the EM(PCA) algorithm was applied to generate the missing data before 
BOOT/PCA was done. The results of EM/BOOT/PCA for the Aurobindo 
formulation are shown in Fig. 4.19.  
Figure 4.19: The PCA /BOOT normalised scores plot for the Aurobindo formulation 
after EM/BOOT/PCA of dissolution data obtained in (+) Belgium and (o) 
Tanzania 
 
 
Inter-laboratory comparison of dissolution data 
109
There is no overlap of the scores obtained from the two laboratories. The 
differences on PC1 scores indicate that there is a significant difference between 
the percent drug dissolved from this formulation for the data obtained in the two 
laboratories. 
The EM/BOOT/PCA technique was also used to compare the data of the eight 
formulations by projecting in a single PC1/PC2 scores plot the dissolution data of 
the formulations measured in one laboratory. To check the influence of the 
EM(PCA) algorithm on the observed results, the BOOT/PCA was also used to 
compare the eight brands using the original dissolution data measured in Tanzania 
and in Belgium, respectively (Fig. 4.20 and 4.21).  
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Figure 4.20: The normalized scores plot after EM/BOOT/PCA of the dissolution data 
obtained in Belgium and Tanzania for the ciprofloxacin formulations 
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Figure 4.21: BOOT/PCA normalized scores plot of the dissolution data obtained 
in Belgium and Tanzania for the ciprofloxacin formulations  
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The EM/BOOT/PCA scores plot obtained shows differences in the dissolution data 
of the batches measured in both laboratories: the dissolution profiles differ in the 
percent drug release (PC1) as well as in the shape (PC2).  
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Comparing the data from the two laboratories, it is evident that the EM/BOOT/PCA 
method is more discriminative compared with the f2 analysis. Using f2 analysis 
seven out of the eight formulations are considered pharmaceutically similar (f2 > 
50); but with EM/BOOT/PCA more variations are observed. 
For the Tanzanian data, the paired combination with f2 factor above 50 (Table 4.5) 
are projected close to each other in the EM/BOOT/PCA plot (pairs 1-3, 4-6, 4-7, 5-
7 and 6-7 had the highest f2 values). The other combinations (2-5, 3-8 and 5-6) are 
somewhat further apart in the EM/BOOT/PCA, plot but have similar scores on 
PC1.  
The EM/BOOT/PCA plot for the tablets analysed in Belgium showed similar 
results: the pairs 1-8, 2-7, 2-8, 3-8 and 5-7 are situated close to each other and all 
had a similarity factor greater than 50. The other combinations considered 
pharmaceutically equivalent (1-3, 4-6 and 6-7) were also closer together and have 
similar scores on PC1. 
Comparing the EM/BOOT/PCA and BOOT/PCA plots (Fig 4.20 and 4.21) for the 
data set from each country showed that EM had little influence on the scores 
obtained for the formulations. The formulations are projected in almost the same 
areas of the PC1/PC2 plot. Similar results were also observed when computing f2 
factors from data obtained after performing the EM(PCA) algorithm. 
The evaluation of the dissolution data using different methods has yielded different 
results. Using the USP 24 guidelines for dissolution tests all sets of data obtained 
from the two laboratories meet the tolerance limits for dissolution. On this basis, 
the dissolution data measurements performed in Belgium and Tanzania are 
considered equivalent. 
Evaluation of the dissolution data using the f2 factor (that takes into consideration 
all sampling points) showed that it is more discriminating than the USP 24 method. 
On the basis of f2 analysis there are some differences between the data measured 
in the two countries: 6 out of the 8 metronidazole and 7 out of 8 ciprofloxacin 
formulations were considered pharmaceutically equivalent. This may be 
considered as a minor variation.  
The BOOT/PCA comparison demonstrated that it was a good method that could 
visualize the statistical differences between sets of dissolution data. The 
BOOT/PCA method is more discriminative than the f2 factor as more variations 
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between dissolution data of the different formulations are observed. There are 
more differences between the measurements performed in the two laboratories for 
the two drugs. Although there were statistical differences between the inter-
laboratory dissolution data it is most likely that these differences are not 
pharmaceutically important.  
4.5 Conclusion 
The evaluation by f2 factor and PCA/BOOT of the dissolution data obtained at both 
labolatories has revealed inter-laboratory differences between dissolution profiles 
of the same batch of a formulation. The extent of the differences between inter-
laboratory data was however small. Although these differences were statistically 
significant, it could not be concluded if they were pharmaceutically significant. The 
in vivo significance of the differences between the dissolution profiles based on the 
f2 analysis needs to be investigated.  
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5. INFLUENCE OF DISSOLUTION RATE ON THE 
BIOAVAILABILITY OF TWO ACETYLSALICYLIC ACID 
TABLET FORMULATIONS 
5.1 Introduction 
Acetylsalicylic acid (ASA) is widely used for the analgesic, anti-inflammatory and 
antipyretic actions of the drug itself and of its metabolite salicylic acid. In addition, 
as it inhibits platelet aggregation (action solely attributed to ASA), low doses of 
ASA are recommended as a prophylaxis therapy in reducing the risk of ischemic 
heart attacks, myocardial infarction and thrombolytic arterial diseases. The drug is 
included in the national essential drug list of Tanzania for its analgesic, anti-
inflammatory and antipyretic effects.  
The in vitro dissolution of immediate release ASA formulations (three generic and 
one innovator brand) on market in Tanzania has been investigated in chapter 3. 
The in vitro drug release from the formulations was determined immediately after 
purchase and after 3 and 6 months of storage under simulated tropical conditions 
(40°C, 75% RH) by performing dissolution tests as recommended in the USP 24. 
All formulations obtained from the Tanzanian market failed the dissolution test.  
The aim of the study is to determine whether the different in vitro dissolution 
characteristics of the acetylsalicylic acid formulations significantly influence their 
bioavailability.  
Since the strength of most ASA-formulations on market in Tanzania is 300 mg and 
the innovator brand from Bayer (previously analysed in Chapter 3) is of 500 mg 
strength, an immediate release formulation containing 300 mg ASA and having 
market authorisation in Belgium (Dispril 300) was chosen as a reference 
formulation for the in vivo study. 
5.2 In vitro evaluation 
Acetylsalicylic acid tablets from Reckit & Coleman (Belgium) (Dispril® 300, batch 
01D10) and from Shelys Pharmaceutical Industries (Tanzania) (batch 068) were 
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evaluated. The Shelys formulation had the lowest drug dissolution amongst the 
formulations sampled from the Tanzanian market. The dissolution properties of the 
samples were evaluated before the bioavailability study. 
Dissolution test 
The in vitro drug release of the tablet formulations was determined by performing a 
dissolution test as described in the USP 24 and detailed in chapter 3.  
Equipment 
A dissolution tester VK 7010 linked to an automatic sampler VK 8000 (VanKel 
Technology, Cary, USA) was used for the dissolution tests. A Lambda 12 UV/VIS 
spectrophotometer (Perkin Elmer, Norwalk, USA) was used to determine the drug 
concentrations of the samples. 
5.3 In vivo evaluation 
Clinical protocol 
Ten female volunteers participated in the study after giving informed consent. The 
age of the volunteers ranged from 20 to 34 years (mean: 25 yrs), their weight from 
45 to 74 kg (mean: 61 kg) and their body mass index from 18.1 to 26.2 kg/m2 
(mean: 21.6 kg/m2). The volunteers were healthy as proven by medical history, 
physical examination, electrocardiogram and lab tests (haematological and urine). 
Volunteers with suspected history of alcoholism, barbiturate abuse, allergic 
bronchospasms, bleeding disorders and allergy to ASA or non-steroidal analgesic 
agents were excluded from the study. Pregnant or lactating females or females 
with childbearing potential without adequate contraception were also excluded 
from the study. The Ethics Committee of Ghent University Hospital approved the 
clinical protocol.   
Prior and concomitant therapy  
During the entire trial, subjects were required not to use any medication other than 
the trial medication. The exceptions to this rule were paracetamol and oral 
contraceptives. Subjects were allowed to use paracetamol up to 3 days before 
drug administration in each period. The use of paracetamol could be allowed by 
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the clinical investigator (no more than 3 x 500 mg per day and no more than 3 g 
per week) for the treatment of headache or other pain. Oral contraceptives (OAC) 
were allowed. In case paracetamol or OAC were used, the dose and dosage 
regimen were recorded on the Concomitant Therapy Form that formed a part of 
the Case Report Form (CRF).  
Procedure 
The subjects fasted for at least 10 hrs before drug administration. Drinking of 
water was allowed up to 2 hrs before drug administration. The subjects were 
required not to consume grapefruit, grapefruit juice or beverages containing 
alcohol or quinine 24 hrs before and 24 hrs after drug dosing per period. The 
subjects were required to take the whole tablet together with 200 ml of water. 
From 2 hrs after dosing, intake of water was allowed. A standard breakfast and 
lunch were given 3 and 6 hrs post dosing, respectively. The standard breakfast 
consisted of four slices of bread, one slice of ham, one slice of cheese, butter, jelly 
and two cups of decaffeinated coffee or tea with, if desired, milk and/or sugar. The 
subjects remained in the testing facility for 15 hrs after receiving the dose.  
Randomisation 
The study was an open randomized 2-period cross-over design. The washout time 
between periods was 3 days. In each period subjects were given a single dose of 
300 mg acetylsalicylic acid as an immediate release tablet. Subjects entering the 
study were allocated a number from 1 to 10. The randomisation scheme shown in 
Table 5.1 was used to assign the subjects to either of the two treatments:  
9 A1: (Dispril® from Reckitt & Coleman) 
9 A2: (acetylsalicylic acid tablets from Shelys Pharmaceutical Industries). 
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Table 5.1: Randomisation scheme 
Subject Period 1 Period 2 
1 A1 A2 
2 A2 A1 
3 A1 A2 
4 A2 A1 
5 A1 A2 
6 A2 A1 
7 A1 A2 
8 A2 A1 
9 A1 A2 
10 A2 A1 
 
Blood Sampling 
Venous blood samples of 5 ml (to obtain about 2 ml of plasma) were taken from an 
antecubital vein within one hour before and 0.17 (10 min), 0.33 (20 min), 0.5 (30 
min), 0.67 (40 min), 0.83 (50 min), 1, 1.33 (1 hr 20 min), 1.67 (1 hr 40 min), 2, 2.5, 
3, 4, 6, 8, 11, 15 and 24 hrs after drug administration. Blood samples were 
collected in ice-chilled tubes (heparinized) and centrifuged for 10 minutes at 1500g 
and 4°C within 20 min of collection. While awaiting centrifugation the samples 
were kept in an icebox. Plasma was immediately aspirated into plastic tubes 
previously labelled with the investigator’s name, trial number, CRF ID, subject 
initials, date and sampling time, sealed by means of polyethylene stoppers and 
stored at –20 °C for a maximum of 24 hr and then at -80°C until analysis.  
5.3.1  Plasma drug analysis 
A validated bioanalytical method for the simultaneous determination of 
acetylsalicylic acid (ASA) and salicylic acid (SA) in a limited volume of human 
plasma using ESI(-)-LC-MS/MS was developed by the Laboratory of Bioanalysis 
(Faculty of Pharmaceutical Sciences, Ghent University) (Bouche et al., 2003).  
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5.3.1.1 Materials  
Reagents and solutions 
ASA, SA and the internal standard (IS) 3-methyl-SA were obtained from Sigma-
Aldrich (Bornem, Belgium). All solvents(water, acetonitrile, methanol) were of 
HPLC-grade and purchased from Merck (Darmstadt, Germany). The other used 
products were of analytical grade and include ammonia (UCB, Leuven, Belgium), 
formic acid (FA, Fluka Chemie, Buchs Switzerland), acetic acid (AA, Sigma-
Aldrich, Bornem, Belgium), sulphuric acid, sodium sulphate (both Merck, 
Darmstadt, Germany) and sodium tungstate (UCB, Leuven, Belgium).  
Stock and calibration solutions of ASA were prepared in acetonitrile, 
complemented with FA (2%) and dried on sodium sulphate for at least 48 h. As 
such, ASA solutions remained stable for at least one month, with respect to 
decomposition of ASA to SA. Stock and calibration solutions of ASA and the IS 
were prepared in acetonitrile. All solutions were stored at –20°C in brown glass 
recipients and used no longer than one month. The stock concentration of ASA 
and SA was 1.25 mg/ml, while that of the IS-solution was 1.0 mg/ml.  
5.3.1.2 Methods 
Apparatus 
The analytical set-up consisted of a 2695 Alliance LC chromatographic system 
(Waters, Manchester, UK) linked to a triple quadrupole MS instrument (Quattro 
Ultima, Waters-Micromass MS Technologies, Manchester, UK). The MS interface 
was used in the electrospray negative ion mode (ESI (-)).  
Sample pre-treatment  
Samples were allowed to thaw at room temperature. As soon as the liquefied state 
was reached (i.e. no longer than 20 min), 250 µl of crude plasma was sampled 
and immediately acidified with 10µl of sulphuric acid (residual pH 1). After addition 
of the IS-solution (20 µl, concentration 0.1 mg/ml) and 40 µl of acetonitrile (similar 
to the calibration standards) ultra-fast sample clean-up was achieved by protein 
precipitation with 50 µl of a 10% sodium tungstate solution. Samples were then 
shaken vigorously for 15 seconds and centrifuged at 6000 rpm for 10 min 
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(Biofuge, Heraeus Instruments, Germany). Subsequently, the obtained clear 
supernatant was transferred into autosampler vials.  
Chromatographic conditions 
Chromatographic separation between ASA and SA was achieved by injecting 15 µl 
of the clear supernatant on a Waters XTerra MS C8 column (3.5 µm particle size, 
150x2.1 mm). In order to protect the analytical column, a guard column was 
coupled to the analytical column (Hypersil BDS, 3.5 µm particle size, 20x2.1 mm, 
Alltech, Deerfield, IL). The guard column was replaced after approximately 150 
injections.  
Total run time was 15 min. The mobile phase consisted of a gradient of water: 
acetonitrile  in a ratio 9:1 (A) and acetonitrile : water in ratio 9:1 (B). Both eluents 
were complemented with 0.02% acetic acid, which resulted in a pH of 3.1. Detailed 
LC-gradient conditions are given in Table 5.2. 
Table 5.2: Overview of the LC-gradient conditions 
Time 
(min) 
A% B% 
Flow rate 
(ml/min) 
0.0 80 20 0.3 
1.9 80 20 0.3 
2.0 80 20 0.2 
3.0 80 20 0.2 
3.5 30 70 0.2 
4.5 30 70 0.2 
5.5 80 20 0.2 
15.0 80 20 0.2 
 
Due to the chemical instability of ASA (basic hydrolysis of the ester-function), it is 
of prime importance that sample preparation and chromatographic separation are 
achieved under acidic conditions. Nevertheless, as ASA and SA are both acidic 
compounds, they need to be analysed in the ESI negative ion mode. Therefore 
post-column decomposition of ASA to SA was applied inside the LC-tubing leading 
the column eluent to the mass spectrometer. To that end, a 0.5 M ammonia 
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solution was added to the column eluent, via a T-piece immediately behind the 
analytical column and using an auxiliary pump (LC3-XP pump, Pye Unicam, 
Cambridge, UK; pumping rate 50 µl/min). As a result, 250 µl/min of eluent with a 
pH of 10 entered the ESI interface.  
During the first minutes of the analytical run (0-2 min), the eluent mixture was 
directed to a waste bin by means of a divert valve, and this due to the highly acidic 
nature of the injected supernatant, containing sulphuric acid. Afterwards, the valve 
was automatically switched, thus guiding the eluent mixture to the mass 
spectrometer for ionisation and detection. 
The high column flow at the beginning of the analytical run (0.3 ml/min) favoured 
the wash-out of residual sulphuric acid and salts from the analytical column, 
thereby decreasing MS interface deterioration as well as ionisation suppression of 
the target components. 
LC/MS-conditions 
Both compounds were analysed on a triple quadrupole mass spectrometer 
(Quattro Ultima, Waters Micromass MS-technologies, Manchester, UK) in the ESI 
negative ion mode, by application of multiple reaction monitoring (MRM).  An 
overview of the optimised and applied ESI(-) MS/MS conditions for the 
investigated compounds is given in Table 5.3.  
Table 5.3: Overview of the applied ESI(-) MS/MS conditions.  
Precussor ion 
Compound 
ion m/z 
Product ion 
(m/z) 
Cone voltage 
(V) 
Collision 
energy (eV) 
ASA [M-H]- 137.0 93.1 30 18 
  179.0 137.0   
      
SA [M-H]- 137.0 93.1 53* 18 
  137.0 65.1   
      
IS (3-MeSA) [M-H]- 151.0 107.0 30 16 
  151.0 95.0   
* Detuned to extend the dynamic range of the MS-detector 
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Quantification was performed based on peak area ratios (ASA/IS and SA/IS), 
using reconstructed mass fragmentograms. For quantification purposes the 
following transitions were monitored: m/z 137.0 to 93.1 for ASA and SA and 151.0 
to 107.0 for the internal standard. The other product ions, mentioned in Table 5.3, 
were monitored as qualifier ions. 
As explained above, ASA enters the mass spectrometric detector after basic 
decomposition to SA. Logically, the same ion transition, as in the case of SA, is 
monitored. However, the genuine precursor ion of ASA (m/z 179) was also 
followed as some sort of identity confirmation for ASA: a small residual peak was 
always present at the retention time of ASA. This peak represents a very small 
amount of ASA not being decomposed to SA. Validation results however, clearly 
shows that this residual amount of ASA does not compromise accurate and 
reproducible quantification of ASA, thereby indicating that the decomposition of 
ASA to SA is reproducible.  By application of the described LC-MS/MS conditions, 
the retention times were 4.7 min, 6.4 min and 10.6 min for ASA, SA and the IS, 
respectively. 
5.3.1.3 Pharmacokinetic and statistical analysis 
The peak plasma concentration (Cmax) and the time to reach the peak plasma 
concentration (tmax) were obtained from the individual plasma concentration vs. 
time profiles. The area under the plasma concentration/time curve to 24 hrs post 
dosing (AUC0-24hrs) was calculated by linear trapezoidal summation. The terminal 
elimination rate constant (λz) was determined by log-linear regression of the 
terminal points of the plasma concentration/time curve and the half-life time (t0.5) 
was defined as 0.693/λz.  
A computer program MW/Pharm software package (v.3.01, Mediware 1987-1991, 
Utrecht, The Netherlands) was used for the pharmacokinetic analysis. 
Statistical analysis of the pharmacokinetic data was performed using a two-way 
ANOVA. The data were tested for normal distribution with the Kolmogorov-
Smirnov test. The homogeneity of variances was tested with the Levene’s test. To 
further compare the effects of the different treatments a multiple comparison 
among pairs of means was performed using the Scheffe test with p < 0.05 as 
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significance level. For all statistical analysis the program SPSS version 10.0 was 
used.  
5.4  Results 
5.4.1  In vitro drug release 
The percent drug released within 30 min from the Dispril®-tablets and the Shelys 
formulation is 100% and 27%, respectively (Fig. 5.1). Dispril® showed a very fast 
dissolution rate, having released its entire drug content within the first 5 min. 
Within this interval the release from the Shelys formulation was only 2.4%.  
Figure 5.1: Dissolution profiles of Dispril® tablets (♦) and acetylsalicylic acid tablets 
of Shelys (■). USP 24 requirement: more than 80% released within 30 
min 
 
 
0
20
40
60
80
100
0 5 10 15 20 25 30
Time (min)
%
 R
el
ea
se
d
ASA availability: in vitro/in vivo comparison 
123
5.4.2  Bioavailability 
As ASA is extensively metabolised in the gut and in plasma into salicylic acid (SA) 
the bio-analytical method used was optimised to measure the plasma 
concentration of both molecules. The individual plasma concentration/time profiles 
of the 10 subjects for both drugs (ASA and SA) are shown in Figures 5.2 and 5.3, 
while the individual pharmacokinetic parameters obtained from the plasma 
concentration/time profiles are shown in Tables 5.4 and 5.5.  
For both formulations, plasma concentrations above the limit of quantitation (LOQ) 
were already observed in all subjects after 10 min. In case of Dispril® the individual 
plasma concentrations in the first 10 min ranged from 1.1 to 4.3 mg/l (median 2.1 
mg/l) and 2.2 to 9.2 mg/l (median 3.7 mg/l) for ASA and SA, respectively. The 
corresponding values for the Shelys formulation were 0.1 to 1.8 mg/l (median 0.6 
mg/l) and 0.1 to 4.9 mg/l (median 1.8 mg/l). In all subjects and for both 
formulations, the plasma concentration of acetylsalicylic acid was below the limit of 
detection (LOD) after 4 hrs, while the plasma concentration of salicylic acid 
remained above LOQ up to 15 hrs.  
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Figure 5.2: Individual salicylic acid plasma concentration/time profiles (n=10) 
following administration of a single dose of 300 mg acetylsalicylic acid: 
Dispril® (A1); Shelys formulation (A2) 
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Figure 5.3:  Individual acetylsalicylic acid plasma concentration/time profiles (n=10) 
following administration of a single dose of 300 mg acetylsalicylic acid: 
Dispril® (A1); Shelys formulation (A2) 
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Table 5.4:  Individual AUC0-24hr and Cmax for acetylsalicylic acid and salicylic acid 
following administration of a single dose of 300 mg acetylsalicylic acid 
Formulation and drug 
Dispril® Shelys Subject 
ASA SA ASA SA 
 AUC0-24hr (µg.hr/ml) 
1 2.48 - 119.53 2.69 109.40 
2 2.98 167.80 3.53 145.30 
3 3.27 81.54 2.11 71.83 
4 0.96 45.72 2.07 73.20 
5 2.64 121.71 3.08 108.00 
6 2.61 172.76 2.42 90.66 
7 3.12 73.18 2.27 62.45 
8 2.29 58.51 1.66 63.25 
9 2.37 100.89 2.53 69.33 
10 2.03 121.15 2.24 112.58 
Mean 2.48 106.28 2.46 93.30 
SD 0.66 42.85 0.54 26.43 
 Cmax (µg/ml) 
1 2.6 23.4 3.0 21.3 
2 5.7 32.6 2.7 28.3 
3 5.3 25.2 1.5 15.4 
4 1.5 11.6 2.2 16.0 
5 3.6 22.4 2.5 13.7 
6 3.0 32.1 1.6 15.5 
7 4.3 19.0 1.6 12.7 
8 4.4 14.6 0.9 11.7 
9 4.3 16.8 3.5 17.0 
10 2.7 21.8 3.2 16.5 
Mean 3.7 21.9 2.3 16.8 
SD 1.3 6.9 0.8 4.8 
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Table 5.5: Individual tmax values (hr) for acetylsalicylic acid and salicylic acid 
following administration of a single 300 mg dose of acetylsalicylic acid 
tmax (hr) 
ASA SA Subject 
Dispril® Shelys Dispril® Shelys 
1 0.5 0.3 0.5 1.7 
2 0.3 0.5 0.5 1.7 
3 0.3 0.1 0.8 1.3 
4 0.3 0.6 0.6 1.7 
5 0.3 0.3 1.0 0.8 
6 0.5 0.9 1.3 3.0 
7 0.5 1.0 0.8 3.0 
8 0.3 0.8 0.7 2.5 
9 0.2 0.3 0.7 1.6 
10 0.3 0.6 1.0 1.6 
Mean 0.4 0.6 0.8 1.9 
Range 0.2 – 0.5 0.2 – 1.0 0.5 – 1.3 0.8 – 3.0 
 
Figure 5.4 shows the mean plasma concentration/time profiles for ASA and SA, 
and Table 5.6 the mean (arithmetic) pharmacokinetic parameters and the 
statistical evaluation.  
The mean Cmax obtained for the Shelys formulation was lower for both ASA and 
SA; their respective values being 39 and 23% lower than those obtained from 
Dispril®. Similarly, this formulation yielded a higher tmax for both drugs. In case of 
salicylic acid, the mean tmax of the Shelys formulation is about twice as high. 
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Figure 5.4: Mean (n=10) acetylsalicylic acid (A) and salicylic acid (B) plasma 
concentration/time profiles following administration of a single dose of 
300 mg acetylsalicylic acid: Dispril® (); Shelys formulation (). 
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Table 5.6: Mean (n=10)(arithmetic) pharmacokinetic parameters (± SD) for ASA and 
SA following oral administration of a single dose of 300 mg acetylsalicylic 
acid. 
Formulation 
Parameter 
Dispril®  Shelys 
Acetylsalicylic acid 
AUC0-24hr (µg.hr/ml) 2.48 ± 0.66 2.46 ± 0.54 
Cmax (µg/ml) 3.7 ± 1.3** 2.3 ± 0.8* 
Cmax/AUC0-24hr (hr) 1.51 ± 0.31** 0.92 ± 0.31* 
tmax (hr) 0.4 ± 0.1** 0.6 ± 0.3* 
t0.5 (hr) 0.3 ± 0.1 0.5 ± 0.1 
Salicylic acid 
AUC0-24h (µg.hr/ml) 106.28 ± 42.85 93.30 ± 26.43 
Cmax (µg/ml ) 21.9 ± 6.9 16.8± 4.8 
Cmax/AUC0-24hr (hr-1) 0.22 ± 0.05 0.18 ± 0.03 
Tmax (hr) 0.8 ±0.3** 1.9 ± 0.7* 
t0.5 (hr) 2.3 ± 0.6 2.0± 0.4 
* Significantly different from **, the corresponding value of the other formulation 
(p< 0.05, Scheffe test). 
Statistical analysis of the pharmacokinetic data shows that the two formulations 
yielded similar AUC0-24h values for both ASA and SA, indicating that the extent of 
absorption of the two drugs from both formulations was similar. The absorption 
rate parameters (Cmax, tmax, and Cmax/AUC0-24h) obtained from Dispril® (for both 
ASA and SA) were higher compared with those of the Shelys formulation. In the 
case of ASA, the difference between the corresponding parameters of the two 
formulations was significant (p < 0.05), indicating that ASA from the Dispril® is 
absorbed faster compared with the Shelys formulation.  
However, while there was no significant difference between Cmax of SA measured 
for both formulations, Dispril® achieved its Cmax faster as the tmax of this formulation 
was significantly shorter than that of Shelys.  
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5.5  Discussion 
Most pharmacokinetic data reported in literature are from studies where the 
administered dose is at least 500 mg of acetylsalicylic acid. Since the elimination 
kinetics of this drug are dose-dependent it is not possible to compare the literature 
values in a linear model. AUC and Cmax values of 7.1 mg.h/l and 5.5 mg/l, and of 
179.7 mg.h/l and 33.4 mg/l for ASA and SA, respectively, have been reported after 
administration of a single 500 mg dose acetylsalicylic acid (Siegmund et al., 1998). 
The values obtained in this study are in a similar range.   
This study aimed at investigating whether the very low in vitro drug release 
obtained from the Shelys formulation would result into a poor bioavailability (hence 
efficacy) of this formulation. The extent of absorption for both formulations was 
similar (for both SA and ASA) indicating that with respect to this primary 
pharmacokinetic parameter, the two formulations have a similar in vivo behaviour. 
Since the inhibition of the platelet aggregation (which is solely attributed to 
acetylsalicylic acid) is irreversible and dose dependent (Burch et al., 1978; 
Patrignani et al., 1982), there will probably be no difference in this activity between 
both formulations as their AUC‘s of ASA were similar. 
The rate of absorption from the Shelys formulation (as evidenced by tmax and 
Cmax/AUC of both ASA and SA) was significantly lower compared with that of 
Dispril®, an observation consistent with the in vitro drug release from both ASA 
formulations. Nevertheless, the two formulations yielded a maximum salicylic acid 
plasma concentration (Cmax) in excess of 90.0 mg/l, which is well above the 
minimal level (20 mg/l) required for effective analgesic action of salicylic acid 
(Dollery, 1999). Thus the efficacy of both formulations to relieve pain will probably 
be similar although Dispril®, having a shorter tmax, could have a faster onset of 
action.  
The results show that although there was a large difference in the in vitro drug 
release between both formulations, the observed difference in Cmax between the 
formulations (for both ASA and SA) was not of the same magnitude. Similar 
observations have been reported in the literature for nitrofurantoin tablets (Gouda 
et al., 1987); where tablet formulations having very low in vitro drug release 
exhibited only a moderate reduction in Cmax, while the AUC was unaffected. These 
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observations highlight the limited predictive power of the in vitro dissolution tests 
about the in vivo drug availability and calls for a cautious approach when 
predicting in vivo efficacy from in vitro data.  
5.6  Conclusion 
The pharmacokinetic data showed that despite the large difference in in vitro drug 
release, the two formulations had similar bioavailability profiles with regard to the 
extent of drug absorption. However, the rate of absorption from the Shelys 
formulation was significantly lower compared to that of Dispril®. Although the 
Shelys formulation had a moderately lower Cmax, its influence on the clinical 
efficacy will probably be insignificant as Cmax is in excess of the minimum plasma 
concentration required for analgesia.  
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6. INFLUENCE OF TROPICAL CLIMATIC CONDITIONS ON 
BIOAVAILABILITY OF ENTERIC COATED DICLOFENAC 
SODIUM TABLET FORMULATIONS 
6.1 Introduction 
The stability of the in vitro dissolution of diclofenac sodium from four enteric-
coated tablet formulations marketed in Tanzania has been previously described in 
Chapter 3. The in vitro drug release and drug content from the formulations was 
determined before and after storage for 6 months at simulated tropical conditions 
(75% RH, 40°C). Immediately after purchase, the in vitro drug release of all 
formulations was above the USP 24 tolerance limits for drug release. Upon 
storage at simulated tropical conditions the drug release of the innovator brand 
(Voltaren® 50 mg) from Novartis and of the formulation from Remedica remained 
stable for the entire test duration. However, the drug release of the Intas and the 
Camden formulations decreased dramatically: the formulation from Camden 
released only 10% of the drug after 45 min of dissolution testing in phosphate 
buffer (pH 6.8). The diclofenac content in all formulations remained stable during 
the 6 months period. 
The objective of this work is to investigate whether the observed trends of the in 
vitro drug release after exposure to simulated tropical conditions are reflected in 
vivo. The formulations with the best and worst stability of the in vitro drug release, 
Voltaren® 50 (Novartis) and Diclo® 50 (Camden), respectively, were investigated. 
6.2 In vitro evaluation 
Study plan 
Samples from Novartis (Voltaren® 50, batch 00D03BT) and Camden (Diclo® 50, 
batch 000523) were purchased in Belgium and Tanzania, respectively. Part of the 
tablets was stored at ambient conditions for 3 months, whereas the remaining part 
was stored for 3 months at the stability test conditions (40°C and 75% RH). After 3 
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months the samples were evaluated for their in vitro drug release and in vivo drug 
availability. 
Dissolution tests 
USP 2 method 
The in vitro drug release of the tablet formulations was determined by performing a 
dissolution test in an acid medium (0.1N HCl) for 2.0 hr, thereafter the tablets were 
transferred into a phosphate buffer (pH 6.8) and tested for 50 min. The volume of 
the dissolution media was 900 ml and was maintained at 37 ± 0.5°C. The 
rotational speed of the paddles was 50 rpm. A 5 ml sample was taken after 2 hr 
testing in the acid medium. During the buffer stage, samples (5 ml) were taken at 
10, 20, 30, 40, 45 and 50 min.  
USP 3 method 
The diclofenac tablets from the Camden formulation stored at simulated tropical 
conditions were tested for their dissolution characteristics using reciprocating 
cylinders (USP 3 apparatus). The test was first performed in acid medium (0.1N 
HCl) for 2.0 hr, thereafter the tablets were transferred into a phosphate buffer (pH 
6.8) and tested for 50 min. The volume of the dissolution media in both cases was 
250 ml and was maintained at 37 ± 0.5°C. The apparatus was operated at 21 dips 
per min. A 2 ml sample was taken after 2 hr testing in acid medium. During the 
buffer stage, samples (2 ml) were taken at 10, 20, 30, 40, 45 and 50 min.  
Disintegration test. 
The tablets from Camden stored at simulated tropical conditions were tested for 
their disintegration properties as described in the European Pharmacopoeia for 
enteric coated tablets: a 2 hr test was conducted in 1000 ml 0.1N HCl, thereafter 
the acid solution was replaced with a phosphate buffer pH 6.8 and the test was 
continued for a further 1 hr. Both solutions were maintained at 37 ± 0.2°C and the 
apparatus was operated at 30 cycles per min. 
Equipment 
A dissolution tester VK 7010 linked to an automatic sampler VK 8000 (VanKel 
Technology, Cary, USA) was used for the USP method 2 test. A VK Bio Dis 
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reciprocating cylinder tester linked to an automatic sampler VK 8000 (VanKel 
Technology, Cary, USA) was used for the USP 3 method test. 
The Pharma Test PTZ E apparatus (Pharma Test, Hainburg, Germany) was used 
for the disintegration test.  
6.3 In vivo evaluation 
Clinical protocol 
Twelve volunteers (8 males) participated in the study after giving an informed 
consent. The age of the volunteers ranged from 19 to 38 years (mean 24 yrs). 
Their weight ranged from 59 to 88 kg (mean 65 kg) and their body mass index 
from 19.8 to 27.1 kg/m2 (mean 22.4 kg/m2). The volunteers were healthy as proven 
by medical history, physical examination, electrocardiogram, and lab tests 
(haematological and urine). Volunteers with suspected history of alcoholism, 
barbiturate abuse and allergy to diclofenac, aspirin and/or nonsteroidal analgesic 
agents were excluded from the study. Pregnant, lactating females or females with 
childbearing potential without adequate contraception were also excluded from the 
study. The Ethics Committee of Ghent University Hospital approved the clinical 
protocol. 
Prior and concomitant therapy  
During the entire trial, subjects were required not to use any medication other than 
the trial medication. The exceptions to this rule were paracetamol and oral 
contraceptives. Subjects were allowed to use paracetamol up to 3 days before 
drug administration in each period. The use of paracetamol could be allowed by 
the clinical investigator (no more than 3 x 500 mg per day and no more than 3 g 
per week) for the treatment of headache or other pain. Oral contraceptives (OAC) 
were allowed. In case paracetamol or OAC were used, the dose and dosage 
regimen were recorded on the Concomitant Therapy Form which formed a part of 
the Case Report Form (CRF).  
Procedure 
The subjects fasted for at least 10 hr before drug administration. Drinking of water 
was allowed up to 2 hr before drug administration. The subjects were required not 
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to consume grapefruit, grapefruit juice or beverages containing alcohol or quinine 
between 24 hr before and 16 hr after drug dosing per period. The subjects were 
required to take the whole tablet together with 200 ml of water. From two hr after 
dosing, intake of water was allowed. A standard breakfast was given 3 hr post 
dosing and lunch 6 hr post dosing. The standard breakfast consisted of four slices 
of bread, one slice of ham, one slice of cheese, butter jelly and two cups of 
decaffeinated coffee or tea with, if desired, milk and/or sugar. The subjects 
remained in the testing facility for 16 hr after receiving the dose.  
Randomisation 
The study was an open randomized 4-period cross-over design. The washout time 
between periods was 3 days. In each period subjects were given a single dose of 
50 mg diclofenac sodium as an enteric coated tablet. 
Subjects entering the study were allocated a number from 1 to 12. The 
randomisation scheme shown in Table 6.1 was used to assign the subjects to 
either of the four treatments:  
9 D1 (Diclo® 50 stored for 3 months at ambient conditions) 
9 D2 (Diclo® 50 stored for 3 months at simulated tropical conditions) 
9 D3 (Voltaren® 50 stored for 3 months at ambient conditions) 
9 D4 (Voltaren ® 50 stored for 3 months at simulated tropical conditions) 
  
Table 6.1:  Randomisation scheme  
Subject Period 1 Period 2 Period 3 Period 4 
1 D1 D2 D3 D4 
2 D2 D3 D4 D1 
3 D3 D4 D1 D2 
4 D4 D1 D2 D3 
5 D2 D3 D4 D1 
6 D3 D4 D1 D2 
7 D4 D1 D2 D3 
8 D1 D2 D3 D4 
9 D3 D4 D1 D2 
10 D4 D1 D2 D3 
11 D1 D2 D3 D4 
12 D2 D3 D4 D1 
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Blood Sampling 
Venous blood samples of 5 ml (to obtain 2 ml of plasma) were taken from an 
antecubital vein within one hr before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 and 
16 hr after the drug administration. Blood samples were collected in heparinized 
tubes and centrifuged for 10 min at 1500g within 2 hr after collection. Separated 
plasma was aspirated with a disposable pipette and transferred in plastic tubes. 
The tubes were sealed by means of polyethylene stoppers, and labelled with the 
investigator’s name, trial number, CRF identity, subject initials, date and time of 
sampling. Samples were stored at -20°C until assayed. 
6.3.1 Plasma drug analysis 
Plasma diclofenac concentrations were measured by a reversed-phase HPLC with 
UV detection according to the method described by Giagoudakis and Markantonis 
(1998).  
6.3.1.1 Materials  
All solvents were of HPLC grade and all reagents were of analytical grade. 
Diclofenac sodium was supplied by Alpha Pharma (Zwevegem, Belgium) 
flurbiprofen was obtained from Sigma Aldrich (Steinheim, Germany). Sodium 
acetate anhydrous, acetic acid, orthophosphoric acid and n-hexane were obtained 
from Vel (Leuven, Belgium). Acetonitrile, methanol and isopropyl alcohol were 
obtained from Biosolve (Valkenswaard, The Netherlands). 
6.3.1.2 Methods 
Standard solutions 
Stock solutions containing 160 mg/l diclofenac sodium and 50 mg/l of flurbiprofen 
(internal standard) (Fig 6.1) were prepared in methanol. These were diluted in 
methanol (1:100) to make solutions of 1.6 µg/ml and 0.5 µg/ml diclofenac sodium 
and flurbiprofen, respectively. From the diclofenac sodium solution, working 
solutions of 16, 40, 80, 400, 800, 1200, and 1600 ng/ml were made by appropriate 
dilutions in methanol. The working solution for the internal standard was 500 
ng/ml. 
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Figure 6.1:  Structural formula of diclofenac sodium (A) and flurbiprofen (B) 
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Extraction procedure 
To 500 µl of a plasma sample with unknown drug concentration or to 500 µl blank 
plasma, 250 µl of the internal standard solution (flurbiprofen) was added and the 
mixture was vortexed for 30 s. Subsequently, 1 ml of 2.5M orthophosphoric acid 
was added followed by 1 min vortexing. Extraction was achieved by adding 3 ml of 
an n-hexane/isopropyl alcohol mixture (80:20 v/v), followed by 2 min vortex mixing. 
The mixture was centrifuged for 10 min at 3000 rpm. Using a Pasteur pipette, the 
upper organic layer was transferred to a 10 ml disposable tube and evaporated to 
dryness at 37°C under a gentle stream of dry nitrogen. The residue was 
reconstituted in 200 µl mobile phase and a 25 µl aliquot was injected into the loop.  
Chromatographic conditions 
The mobile phase consisted of a mixture of 0.1M sodium acetate (pH adjusted to 
6.5 with 10% acetic acid) and acetonitrile (70/30, v/v) and was pumped at a flow 
rate of 1 ml/min through the column. Plasma concentrations were monitored by UV 
absorbance at 280 nm. 
The HPLC equipment (Lachorm, Merck, Darmstadt, Germany) comprised of a L 
7100 isocratic pump, an integrator L 7000 and a UV-detector (Spectra system UV 
2000, Spectra Physics, Darmstadt, Germany). Chromatographic separation was 
achieved using a column LiChrospher RP-18® (5 µm) and guard column 
LiChrospher 100 RP-18® (5 µm). 
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6.3.1.3  Validation of the analytical method 
The method used to determine the diclofenac sodium plasma concentration was 
validated as recommended by Shah et al. (1992) and revised in the FDA Guidance 
for industry (2001). 
6.3.1.4 Pharmacokinetic and statistical analysis 
The peak plasma concentration (Cmax), the time to reach the peak plasma 
concentration (tmax) and the time to the onset of absorption (lag time) were 
obtained from the individual plasma concentration vs. time profiles. The area 
under the plasma concentration-time curve to 16 hr post dosing (AUC0-16hr) was 
calculated by linear trapezoidal summation. Terminal elimination rate constant  (λz) 
was determined by log-linear regression of the terminal points of the plasma 
concentration-time curve and the half-life time (t0.5) was defined as 0.693/λz.  
The MW/Pharm software package (v.3.01, Mediware 1987-1991, Utrecht, The 
Netherlands) was used for the pharmacokinetic analysis. 
Statistical analysis of the pharmacokinetic data was performed using a two-way 
ANOVA. The data were tested for normal distribution with the Kolmogorov-
Smirnov test. The homogeneity of variances was tested with the Levene’s test. To 
further compare the effects of the different treatments a multiple comparison 
among pairs of means was performed using the Scheffe test with p < 0.05 as 
significance level. For all statistical analysis the program SPSS version 10.0 was 
used.  
6.4   Results 
6.4.1  Validation of the bioanalytical method 
6.4.1.1. Linearity 
The calibration range (20-2000 ng/ml) was chosen on the basis of expected 
plasma concentrations after single dose administration of a 50 mg enteric 
diclofenac sodium tablet (Giagoudas and Markantonis, 1998; Shimamoto et al., 
2000; Terhaag et al., 2000). Seven calibration standards (20, 50,100, 500, 1000, 
1500 and 2000 ng/ml) were made by spiking 500 µl blank plasma with 250 µl of 
the appropriate diclofenac sodium working solution and 250 µl of internal standard 
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working solution. A blank sample was included in the calibration curve to ensure 
that no interfering components were co-eluted with the drug and the internal 
standard or introduced during preparation of the standards. The mean calibration 
curve (n = 9) of the diclofenac concentration versus the ratio of peak areas of 
diclofenac sodium and the internal standard was calculated.  
The calibration curve obtained showed that the analytical method is linear over the 
entire concentration range: Y = 0.0040x (± 0.0002) + 0.0062 (± 0. 0025) with a 
coefficint of determination (R2) of 0.9990 (± 0.00008). 
6.4.1.2 Limits of detection and quantitation 
The limit of detection is defined as the minimum detectable level of the analyte 
under the assay conditions. It has been defined as the concentration of the analyte 
that produces a response equivalent to the blank signal plus three times the 
standard deviation of the blank. The blank signal is defined as the mean of the Y 
intercept of the calibration curves. From regression analysis of the calibration 
curves, the limit of detection (LOD) of this method was determined at 2 ng/ml. 
The limit of quantitation (LOQ) is defined as the minimum concentration of the 
analyte in the matrix that can be determined with an acceptable precision, 
accuracy and variability. The precision, accuracy and variability were determined 
using a minimum of five samples to calculate the coefficient of variation and 
accuracy. The lowest concentration in the calibration curve is usually taken as the 
limit of quantitation (LOQ) provided it can be reliably quantitated with an 
acceptable accuracy (FDA guidance: RSD less than 20% and accuracy between 
80 and 120%). For this analytical method the lowest concentration that was 
determined with an acceptable precision and accuracy is 20 ng/ml. The RSD 
obtained for this concentration was 11.5% with an accuracy of 91.3%. 
6.4.1.3 Selectivity 
The extraction and chromatographic procedures were capable of separating the 
plasma constituents from the drug and the internal standard. At a flow rate of 1 
ml/min retention times of about 6.5 min for flurbiprofen and about 9.0 min for 
diclofenac were recorded. There were no interfering peaks at these retention times 
as evidenced by the representative chromatograms of blank plasma and of plasma 
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(spiked with the internal standard) obtained from a volunteer 2.5 hr after 
administration of a 50 mg diclofenac sodium enteric coated tablet (Fig. 6.2).  
Figure 6.2:  The chromatograms of blank plasma (A) and of plasma (spiked with IS) 
obtained from a volunteer 2.5 hr after administration of a 50 mg 
diclofenac sodium tablet (B) 
        
A B
6.4.1.4 Precision 
Precision refers to the variation or the scatter of the measurements around the 
mean value. It is also the measure of reproducibility of the whole analytical method 
including the sample preparation, extraction, reconstitution and sample analysis. 
Bioavailability of diclofenac 
141
The within day (repeatability) and between day (reproducibility) precision was 
calculated as the relative standard deviation (RSD) of the mean peak area 
obtained after repeated injection. 
The repeatability of the analytical method was determined for each concentrations 
of the calibration standards by calculating the variations in the measured peak 
area for the same sample injected at different times during the same day. For 
reproducibility, the samples were injected at different days. The results for 
precision of the method are shown in Table 6.2. 
A relative standard deviation (RSD) between 5.4% and 11.2% and between 3.1% 
and 11.8% was obtained for repeatability and reproducibility, respectively. These 
values were not greater than the acceptance criteria of 15%. 
Table 6.2: Intra- (repeatability) and inter-day (reproducibility) precision for the  
determination of diclofenac sodium in plasma (n = 8) 
Precision (RSD %) 
Concentration (ng/ml) 
Intra-day Inter-day 
20 8.3 11.5 
50 8.0 8.6 
100 9.8 4.1 
500 11.0 3.1 
1000 11.2 10.5 
1500 5.4 11.8 
2000 7.0 7.2 
  
6.4.1.5 Accuracy 
Accuracy describes the closeness of the mean test result (obtained by applying 
the method) to the true concentration of the analyte. Accuracy was determined by 
comparing the measured diclofenac sodium concentrations and the spiked 
concentrations in plasma. The results of the measured diclofenac sodium 
concentrationsfrom the spiked plasma samples and the RSD-value at each 
concentration are summarized in Table 6.3. At all concentrations tested the mean 
value did not deviate by more than 10% from the nominal concentration. The RSD 
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values fall within the acceptance level (FDA guidance: RSD less than 15%, except 
for the LOQ where it should not exceed 20%). 
Table 6.3:  Accuracy (n = 8) for the determination of diclofenac sodium in plasma 
                                   Concentration (ng/ml) 
 20 50 100 500 1000 1500 2000 
Mean 18.3 49.1 93.4 486.4 1029.7 1506.3 2028.2 
RSD (%) 11.5 7.4 8.2 2.5 5.9 6.1 4.5 
% of nominal conc. 91.5 98.2 93.4 97.3 103.0 100.4 101.4 
 
6.4.1.6 Recovery 
Recovery is defined as the concentration of diclofenac sodium found in the spiked 
samples after the extraction procedure. Appropriate concentrations of diclofenac 
sodium methanolic solutions were added to blank plasma to make concentrations 
of 20, 50, 100, 500, 1000, 1500 and 2000 ng/ml. After extraction and 
reconstitution, their peak areas were compared with those obtained by injecting 
the same concentration of diclofenac sodium in mobile phase. Recovery was 
calculated as the ratio of the peak area of the extracted sample versus the 
unextracted sample multiplied by 100. The coefficient of variation of the recovery 
at different concentrations was also determined. 
Table 6.4 shows that values obtained for recovery were above 75% in the 20 to 
2000 ng/ml concentration range and were reproducible (RSD between 3.1 and 
9.7%). These values are within the minimum value required for recovery (75%) 
with a maximum RSD of 15%.  
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Table 6.4:  Recovery of diclofenac sodium and flurbiprofen for the determination of 
diclofenac sodium in plasma (n = 8)  
 Conc. (ng/ml) Recovery (%) RSD (%) 
Diclofenac sodium 20 85.2 9.2 
 50 95.3 9.1 
 100 95.3 9.7 
 500 94.8 6.1 
 1000 90.2 3.1 
 1500 93.0 4.4 
 2000 98.3 4.9 
Flurbiprofen 625 97.2 5.6 
 
6.4.1.7 Stability of diclofenac sodium in plasma 
The stability of the drug in plasma was determined at concentrations of 50, 500 
and 1500 ng/ml in plasma stored at -20°C for 2 months. Analyses were performed 
after 30 and 60 days. The determined concentrations and standard deviation, 
shown in Table 6.5, indicated that the drug was stable in plasma for at least 60 
days. 
Table 6.5:  Stability of diclofenac sodium in plasma after storage at -20°C (n = 8) 
Actual concentration (ng/ml)(± SD) after Theoretical conc. 
(ng/ml) 
30 days 60 days 
50 49.7 ± 3.1 49.2 ± 3.4 
500 494.0 ± 20.7 511.0 ± 22.9 
1000 1063.0 ± 56.7 1002.0 ± 53.6 
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6.4.2  In vitro drug release 
The profiles obtained after dissolution testing (Fig 6.3) show that there was a 
remarkable difference between the stability of the two formulations after 3 months 
storage under simulated tropical conditions. The percent drug release from the 
Novartis formulation remained at 100% after 3 months of storage under simulated 
tropical conditions, while the release of the Camden formulation after 45 min 
decreased from 84% to 11%. The tablets from this formulation failed to 
disintegrate during the entire dissolution test, retaining their original shape and 
forming a plastic mass. 
Figure 6.3:  Dissolution profiles of Voltaren® 50 (a) and Diclo® 50 (b) tablets stored 
for 0 (X) and 3 (Q) months at simulated tropical conditions (75% RH, 
40°C), following dissolution testing in a phosphate buffer medium (pH 
6.8) using the USP 2 apparatus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The dissolution profile of the Camden formulation stored at simulated tropical 
conditions and obtained using the reciprocating cylinder method (USP method 3) 
was similar to the one obtained using the USP 2 method (Fig. 6.4). The percent 
drug release after 45 min in phosphate buffer pH 6.8 was 13%. The tablets failed 
to disintegrate for the entire duration of the test as they retained their original 
a
0
20
40
60
80
100
0 10 20 30 40 50
Time (min)
%
 re
le
as
ed
b
0
20
40
60
80
100
0 10 20 30 40 50
Time (m in)
%
 re
le
as
ed
 
a 
 
b 
Bioavailability of diclofenac 
145
shape and formed a plastic mass. When performing a disintegration test as 
described in the European Pharmacopoeia, all 6 tablets of the Camden 
formulation failed to disintegrate after 2 hr in a 0.1N HCl and 1 hr in a phosphate 
buffer (pH 6.8). 
  
Figure 6.4:  Dissolution profiles of Diclo® 50 tablets stored for 3 months at simulated 
tropical conditions (75% RH, 40°C) following dissolution testing in 
phosphate buffer (pH 6.8) using the USP 3 apparatus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.4.3 In vivo drug availability 
As one subject did not follow the study protocol (the tablet was broken in two and 
not taken as a whole as it was required by the protocol) the plasma concentration 
profiles and pharmacokinetic data of this volunteer (number 8) were not included 
in the data analysis The individual diclofenac plasma concentrations of 11 subjects 
after single administration of a 50 mg enteric-coated diclofenac sodium tablet 
exposed to different storage conditions are shown in Fig. 6.5 and 6.6, and the 
individual pharmacokinetic parameters in Table 6.6 and 6.7. Since in most 
subjects the plasma drug concentration was below the limit of detection at 10 hr, 
the graphs have been truncated at 10 hr. 
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Figure 6.5:  Individual diclofenac plasma concentration/time profiles (n=11) after 
administration of a single dose of 50 mg diclofenac sodium as an enteric 
coated tablet: Diclo ®50 stored at ambient conditions (D1); Diclo® 50 
stored at simulated tropical conditions (D2) 
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Figure 6.6: Individual diclofenac plasma concentration/time profiles (n=11) after 
administration of a single dose of 50 mg diclofenac sodium as an enteric 
coated tablet: Voltaren® 50 stored at ambient conditions (D3); Voltaren® 
50 stored at simulated tropical conditions (D4) 
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Table 6.6:  Individual AUC0-16hr and Cmax values of 11 subjects following 
administration of a single dose of 50 mg diclofenac sodium as an enteric 
coated tablet  
Formulationa 
Subject 
D1a D2a D3a D4a 
AUC0-16hr (ng.hr/ml) 
1 1045 1357 2119 2008 
2 1578 1963 1497 1961 
3 1109 1260 1418 1497 
4 1040 1021 1186 766 
5 1529 1888 2192 1455 
6 1867 1749 1505 1166 
7 1299 1587 1510 1817 
9 2570 2155 1623 2091 
10 1438 1559 1783 2770 
11 2653 1919 2218 1793 
12 1454 1768 2583 1942 
Mean 1598 1656 1785 1751 
SD 559 339 431 526 
Cmax (ng/ml) 
1 1103 777 1576 1905 
2 1406 1006 1159 1674 
3 1457 1010 938 1159 
4 1371 1282 1543 754 
5 1282 1376 1996 1728 
6 2000 1064 1358 1261 
7 1671 877 1374 1375 
9 2000 1004 938 1625 
10 1949 826 1297 1944 
11 1944 1299 1998 1803 
12 1383 954 1523 1665 
Mean 1597 1043 1427 1536 
SD 327 198 356 362 
a(D1: Diclo® 50 stored for 3 months at ambient conditions; D2: Diclo® 
50 stored for 3 months at simulated tropical conditions; D3: 
Voltaren® 50 stored for 3 months at ambient conditions; D4: 
Voltaren® 50 stored for 3 months at simulated tropical conditions). 
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Table 6.7:  Individual tmax values (hr) of 11 subjects following administration of a 
single dose of 50 mg diclofenac sodium as an enteric coated tablet  
tmax (hr) Subject 
D1a D2a D3a D4a 
1 1.0 2.5 1.5 1.0 
2 0.5 1.5 2.0 1.5 
3 1.0 1.0 4.0 2.0 
4 1.0 2.0 2.0 1.0 
5 0.5 1.5 1.5 1.0 
6 0.5 1.0 1.0 1.0 
7 1.0 1.5 2.0 2.0 
9 0.5 1.5 4.0 1.5 
10 1.0 1.5 2.0 1.5 
11 1.5 1.0 1.5 2.0 
12 1.0 2.0 1.5 1.5 
Mean 0.9 1.5 2.0 1.5 
Range 0.5 - 1.5 1.0 - 2.5 1.5 - 4.0 1.0 - 2.0 
a(D1: Diclo® 50 stored for 3 months at ambient conditions; D2: Diclo® 
50 stored for 3 months at simulated tropical conditions; D3: 
Voltaren® 50 stored for 3 months at ambient conditions; D4: 
Voltaren® 50 stored for 3 months at simulated tropical conditions). 
 
 
The arithmetic mean diclofenac plasma concentration/time profiles of both 
formulations are shown in Fig. 6.7, and the mean (arithmetic) pharmacokinetic 
parameters in Table 6.8. 
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Figure 6.7:  Mean (n=11) diclofenac plasma concentration / time profiles following 
administration of a single dose of 50 mg diclofenac sodium: Diclo® 50 (A) 
and Voltaren® 50 (B) stored for 3 months at ambient conditions (♦) and 
at simulated tropical conditions () 
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Table 6.8:  Mean (n=11)(arithmetic) pharmacokinetic parameters (± SD) following 
administration of a single dose of 50mg diclofenac sodium as enteric 
coated tablets  
Formulationa 
Parameter  
D1 D2 D3 D4 
 AUC 0-16hr (ng.hr/ml) 1598 ± 559 1656 ± 339 1785 ± 431 1751 ± 526 
Cmax (ng/ml) 1597 ± 327** 1043 ± 197* 1427 ± 357 1535 ± 361 
Cmax/AUC (hr-1) 1.1 ± 0.2** 0.7 ± 0.2* 0.8 ± 0.2 0.9 ± 0.2 
tmax  (hr) 0.9 ± 0.3* 1.5 ± 0.5 2.0 ± 1.0** 1.5 ± 0.5 
lag time (hr) 0.7 ± 0.3* 1.0 ± 0.3 1.8 ± 1.2** 0.9 ± 0.5  
t 0.5 (hr) 1.4 ± 0.8 1.5 ± 0.5 1.5 ± 0.4 1.5 ± 0.6 
*significantly different from ** (p < 0.05) 
a(D1: Diclo® 50 stored for 3 months at ambient conditions; D2: Diclo® 50 stored for 3 months at 
simulated tropical conditions; D3: Voltaren® 50 stored for 3 months at ambient conditions; D4: 
Voltaren® 50 stored for 3 months at simulated tropical conditions). 
Comparison of the mean AUC values of the two formulations stored at the different 
test conditions showed that they were not significantly different, indicating that 
there was no difference in the extent of drug absorption from the formulations 
stored at the ambient conditions and those stored under simulated tropical 
conditions. The extent of absorption from the Novartis and the Camden 
formulations stored at ambient conditions were also not significantly different.  
The mean Cmax obtained from the Novartis tablets exposed to the different storage 
conditions was not significantly different. The storage conditions did not influence 
the rate of absorption from the Novartis tablets. As observed during the dissolution 
tests, the in vitro drug release from this formulation was also not affected by 
storage at high temperature and high relative humidity.  
The Cmax values obtained for the Camden formulation showed that the samples 
exposed to simulated tropical conditions yielded a significantly lower Cmax 
compared to those exposed to ambient conditions. The Cmax for the Novartis and 
Camden samples that were exposed to ambient conditions were not significantly 
different.  
The parameter Cmax/AUC was proposed by Endrenyi et al. (1991) as a better 
measure for the absorption rate. Dividing Cmax by AUC compensates for the 
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influence of intra-individual variability in clearance on Cmax. Comparison of the Cmax 
/AUC values showed that there were no significant differences between the 
absorption rate from the Novartis formulations exposed to the different storage 
conditions. However, there was a significant difference between the ratios 
obtained from the Camden formulation samples exposed to the different storage 
conditions.  
The time to the onset of absorption (lag time) showed a wide inter-subject variation 
(ranging from 0.5 to 4 hr). Statistical analysis of the log transformed data showed 
no significant differences of this parameter between the Novartis formulation 
exposed to the different storage conditions. Similar observations were made for 
the Camden samples. Comparing the two formulations stored at ambient 
temperatures, the lag time of the Camden formulations was shorter than the one 
observed for the Novartis formulation and the difference was statistically 
significant.  
The tmax values varied between the subjects, but the variances were normally 
distributed. This parameter of the Novartis samples stored at ambient and 
simulated tropical conditions was not significantly different. However, the tmax value 
of the Camden formulation exposed to ambient conditions was significantly shorter 
than that of the Novartis formulation stored under similar conditions. 
6.5 Discussion  
The HPLC method used to determine diclofenac in plasma was sensitive, accurate 
and reproducible. The limits of detection and linearity range achieved were similar 
to the ones reported by Giagoudakis and Markantonis (1998). The 
pharmacokinetic parameters obtained in this experiment were similar to ones 
reported in literature. AUC values of 1262 ng.h/ml after the administration of a 
single dose of 50 mg diclofenac sodium as enteric coated tablet have been 
reported by Terhaag et al. (2000). Cmax values of 1285 ng/ml and 1400 ng/ml were 
also obtained by Walter and von Niecieck (2001) and Hanses et al. (1995), 
respectively. The terminal half-life (1.5 hr) was similar for both formulations and 
was in agreement with the values (2 hr) reported in literature (Davies and 
Anderson, 1997). 
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The in vitro dissolution and bioavailability of the Novartis formulation were not 
influenced by the storage conditions. The evaluation of the main bioavailability 
parameters (AUC and Cmax) obtained for this formulation showed that the 
bioavailability remained unchanged when stored at high humidity and high 
temperature. Thus there is a great degree of assurance that the efficacy of this 
formulation will remain unchanged during distribution and storage in countries with 
Class IV tropical climatic conditions. On the contrary, the in vitro drug release from 
the Camden formulation was reduced dramatically after 3 months of storage under 
simulated tropical conditions. Although the extent of absorption (AUC) of samples 
exposed to the different storage conditions was similar, Cmax after exposure to 
simulated tropical conditions was significantly lower than that from the samples 
stored at ambient conditions. These observations suggest that the formulation has 
not been optimized to withstand the storage and distribution in countries with a 
tropical climate (class IV).  
The dissolution tests carried out using the USP 2 and USP 3 methods for the 
Camden samples stored under simulated tropical conditions gave similar results: 
the drug release was very low and the tablets failed to disintegrate. However, the 
pharmacokinetic parameters obtained for this formulation show that the extent of 
absorption (AUC) was not significantly altered, but the rate of drug absorption 
(Cmax) was only moderately lower. The poor relationship between the in vitro 
dissolution and bioavailability of oral solid dosage forms stored at high 
temperature and high relative humidity has also been reported for nitrofurantoin 
tablets (Gouda et al., 1984) and etodolac capsules (Dey et al., 1993). When 
operated at low agitation rates (5 dips/min), the USP apparatus 3 creates 
hydrodynamic conditions equivalent to those obtained by USP Method 2 at 50 rpm 
and also similar dissolution profiles in case of drugs with high to moderate 
solubility (Yu et al., 2002). In this study the USP Method 3 was operated at higher 
agitation rates yet the dissolution profile was not different from that obtained with 
the USP Method 2 at 50 rpm. This indicates that other factors rather than the 
insufficient hydrodynamic stress created by the dissolution apparatus are 
responsible for the failure of the dissolution process to predict the in vivo 
observations. The in vivo drug release is not only affected by agitation intensity, 
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but also by presence of peristaltic destruction forces (Kamba et al., 2002), 
digestive enzymes and bile salts in the gastrointestinal fluids.  
6.6 Conclusion 
Storage of enteric coated diclofenac sodium tablets under simulated tropical 
conditons has shown that the combination of temperature and high humidity (as is 
found in tropical countries) may cause changes in the formulation, leading to a 
decrease of the in vitro drug release even when the drug content remained stable. 
The observed changes on the in vitro drug release were not reflected to the same 
magnitude in the bioavailability of the formulation. The USP 2 and 3 dissolution 
tests were too conservative and not predictive of the in vivo performance of the 
enteric coated diclofenac tablets stored under simulated tropical conditions. The 
results of in vitro drug release tests have to be interpreted with caution when 
considering changes in dissolution characteristics due to storage conditions (high 
temperature / high humidity). The use of simulated gastric and intestinal fluids as a 
medium and dissolution test parameters simulating the peristaltic destruction 
forces during the dissolution testing of oral solid dosage forms exposed to 
conditions of high temperature and high humidity should be investigated.  
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7. INFLUENCE OF TROPICAL CLIMATIC CONDITIONS ON 
BIOAVAILABILITY OF CIPROFLOXACIN TABLET 
FORMULATIONS  
7.1 Introduction 
Ciprofloxacin, a quinoline carboxylic acid, is a broad spectrum anti-microbial agent 
that is active against both Gram-negative and Gram-positive pathogenic bacteria, 
many of which are resistant to other commonly used antibiotics such as penicillins 
and aminoglycosides. Consequently, in countries where infectious diseases are 
widespread it is considered as an essential life saving drug. In the Tanzanian 
Standard Treatment Guideline (Ministry of Health Tanzania, 1997) it is 
recommended as the drug of choice for the treatment of infections of the 
respiratory tract, middle ear, paranasal sinuses, abdomen, skin, soft tissue, bones 
and joints. It is also indicated for septicaemia and prophylaxis in patients 
undergoing abdominal surgery.  
In the biopharmaceutical drug classification scheme, ciprofloxacin is considered a 
class II drug having a low solubility and high permeability. As observed for other 
drugs in this class, different formulations may present a variable absorption and 
hence a variable bioavailability if their dissolution characteristics are not similar 
(Amidon et al., 1995).   
Presently there are 35 ciprofloxacin formulations registered for the Tanzanian 
market (Pharmacy Board Tanzania, personal communication, 2002). With such a 
large number of formulations on the market, there is a possibility of variations in the 
bioavailability between brands as a result of differences in raw material, formulation 
and/or process technology between the manufacturers. There is no information 
available about the bioavailability of most formulations on market in Tanzania. 
Furthermore, the influence of tropical storage conditions (as is found in most parts 
of the country) on the bioavailability has not been investigated. 
The in vitro dissolution of 9 ciprofloxacin tablet formulations marketed in Tanzania 
has been previously described in Chapter 3. The in vitro drug release and drug 
content from the formulations was determined before and after a stability test for 6 
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months at simulated tropical conditions (75% RH, 40°C). When analysed 
immediately after purchase the in vitro drug release of all formulations was above 
the USP 24 tolerance limits for dissolution. Upon 6 months of storage at simulated 
tropical conditions the drug release of all formulations had not changed, their 
dissolution profiles obtained before and after storage being similar. The in vitro 
dissolution of a solid oral dosage form is not always predictive of its in vivo 
behaviour. Furthermore, there is an extremely large price difference between the 
innovator brand and the other formulations, hence one may expect that the lower 
priced generics may have been produced using inferior excipients and/or process 
technology possibly influencing bioavailability.  
In this chapter, the influence of tropical storage on the quality of ciprofloxacin tablet 
formulations is investigated by conducting a human bioavailability study on tablet 
samples of two ciprofloxacin formulations stored for 3 months at ambient and at 
simulated tropical conditions. The two formulations were chosen on the basis of 
having the best in vitro quality parameters (drug content and drug release) 
amongst the 9 formulations previously evaluated (section 3). 
7.2 In vitro evaluation 
Study plan 
Samples from Bayer (Ciproxin® 500, batch 01D10) and Cadila (Ciprodac® 500, 
batch E9003) were purchased in Belgium and Tanzania, respectively. A part of the 
tablets was stored at ambient conditions for 3 months, whereas the remaining part 
was stored for 3 months at simulated tropical conditions (40°C and 75% RH). After 
3 months the samples were evaluated for their in vitro drug release and in vivo 
drug availability. 
Dissolution tests 
The in vitro drug release of the tablet formulations was determined by performing a 
dissolution test as described by the USP 24 and detailed in Chapter 3.  
Equipment 
A dissolution tester VK 7010 linked to an automatic sampler VK 8000 (VanKel 
Technology, Cary, USA) was used for the dissolution tests. A Lambda 12 UV/VIS 
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spectrophotometer (Perkin Elmer, Norwalk, USA) was used for determining the 
drug concentrations of the samples. 
7.3 In vivo evaluation 
Clinical protocol 
Twelve volunteers (7 females) participated in the study after giving informed 
consent. The age of the volunteers ranged from 19 to 41 years (mean: 26 yrs), 
their weight from 55 to 94 kg (mean: 72 kg) and their body mass index from 20.6 to 
27.2 kg/m2 (mean: 24.0 kg/m2). The volunteers were healthy as proven by medical 
history, physical examination, electrocardiogram, and lab tests (haematological and 
urine). Volunteers with suspected history of alcoholism, barbiturate abuse and 
allergy to ciprofloxacin or fluoroquinolones were excluded from the study. Pregnant 
or lactating females or females with childbearing potential without adequate 
contraception were also excluded from the study. The Ethics Committee of Ghent 
University Hospital approved the clinical protocol.   
Prior and concomitant therapy  
During the entire trial, subjects were required not to use any medication other than 
the trial medication. The exceptions to this rule were paracetamol and oral 
contraceptives. Subjects were allowed to use paracetamol up to 3 days before drug 
administration in each period. The use of paracetamol could be allowed by the 
clinical investigator (no more than 3 x 500 mg per day and no more than 3 g per 
week) for the treatment of headache or other pain. Oral contraceptives (OAC) were 
allowed. In case paracetamol or OAC are used, the dose and dosage regimen was 
recorded on the Concomitant Therapy Form that formed a part of the Case Report 
Form (CRF).  
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Procedure 
The subjects fasted for at least 10 hr before drug administration. Drinking of water 
was allowed up to 2 hr before drug administration. The subjects were required not 
to consume grapefruit, grapefruit juice or beverages containing alcohol or quinine 
between 24 hr before and 32 hr after drug dosing per period. The subjects were 
required to take the whole tablet together with 200 ml of water. From 2 hr after 
dosing, intake of water was allowed. A standard breakfast and lunch were given 3 
and 6 hr post dosing, respectively. The standard breakfast consisted of four slices 
of bread, one slice of ham, one slice of cheese, butter, jelly and two cups of 
decaffeinated coffee or tea with, if desired, milk and/or sugar. The subjects 
remained in the testing facility for 15 hr after receiving the dose.  
Randomisation 
The study was an open randomized 4-period cross-over design. The washout time 
between periods was 5 days. In each period subjects were given a single tablet 
containing 500 mg ciprofloxacin. Subjects entering the study were allocated a 
number from 1 to 12. The randomisation scheme shown in Table 6.1 was used to 
assign the subjects to either of the four treatments: 
9 C1 (Ciprodac® 500 mg stored for 3 months at ambient conditions) 
9 C2 (Ciprodac® 500 stored for 3 months at simulated tropical conditions) 
9 C3 (Ciproxin® 500 stored for 3 months at ambient conditions) 
9 C4 (Ciproxin ® 500 stored for 3 months at simulated tropical conditions). 
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Table 6.1: Randomisation scheme 
Subject Period 1 Period 2 Period 3 Period 4 
1 C1 C2 C3 C4 
2 C2 C3 C4 C1 
3 C3 C4 C1 C2 
4 C4 C1 C2 C3 
5 C2 C3 C4 C1 
6 C3 C4 C1 C2 
7 C4 C1 C2 C3 
8 C1 C2 C3 C4 
9 C3 C4 C1 C2 
10 C4 C1 C2 C3 
11 C1 C2 C3 C4 
12 C2 C3 C4 C1 
 
Blood Sampling 
Venous blood samples of 5 ml were taken from an antecubital vein 45 min before 
and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 15, 24 and 32 hr after the drug 
administration. Blood samples were collected in heparinized tubes and centrifuged 
for 10 min at 1500g within 2 hr after collection. Separated plasma (about 2 ml) was 
aspirated with a disposable pipette and transferred into plastic tubes. The tubes 
were sealed by means of polyethylene stoppers, and labelled with the 
investigator’s name, trial number, CRF identity, subject initials, date and time of 
sampling. Samples were stored at -20°C until assayed. 
7.3.1  Plasma drug analysis 
Plasma ciprofloxacin concentrations were measured by a reversed-phase HPLC-
method with fluorescence detection (Limberg and Buggé, 1994). 
7.3.1.1 Materials  
All solvents were of HPLC grade and all reagents were of analytical grade. 
Ciprofloxacin was purchased from Roig Pharma (Barcelona, Spain), pipemidic acid 
from Sigma Aldrich (Steinheim, Germany) and tetrabutyl ammonium hydroxide 
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from Fluka Chemie (Buchs, Switzerland). Orthophosphoric acid and hydrochloric 
acid were obtained from Vel (Leuven, Belgium), while acetonitrile was obtained 
from Biosolve (Valkenswaard, The Netherlands).  
7.3.1.2 Methods 
Standard solutions 
Stock solutions containing 90 µg/ml ciprofloxacin hydrochloride and 72 µg/ml 
pipemidic acid as an internal standard (Fig 7.1) were prepared in diluent 
(water/phosphoric acid/acetonitrile; 990:1.7:64 v/v). The pH of the diluent was 
adjusted to 3.0 with 0.2N sodium hydroxide. Working solutions of 18, 9, 5.4, 2.7, 
0.9 and 0.45 µg ciprofloxacin hydrochloride per ml were made by appropriate 
dilution in the solvent mixture. The working solution of the internal standard (7.2 
µg/ml) was similarly made. The stock solutions were protected from light, kept at 
4°C and used within 5 days. 
Figure 7.1: The structural formula of ciprofloxacin hydrochloride (A) and the internal 
standard pipemidic acid (B). 
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Sample preparation 
To 200 µl of a plasma sample with unknown drug concentration 50 µl of the internal 
standard solution (pipemidic acid) was added and the mixture was vortexed for 30 
s. Protein precipitation was achieved by the addition of 200 µl of glycine buffer (pH 
2.8) followed by 1 min vortexing. The mixture was centrifuged for 15 min at 4000 
rpm. The upper layer was transferred into a test tube and a 10 µl aliquot was 
injected into the HPLC system. A calibration curve was prepared by spiking 150 µl 
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blank plasma with 50 µl of a ciprofloxacin standard solution and 50 µl of the internal 
standard solution and the same deproteination procedure was followed for this 
mixture. 
Chromatographic conditions 
The HPLC system consisted of a LaChrom L 7100 isocratic pump (Merck, 
Darmstadt, Germany). Separations were performed on a Purosphere RP-C18® (3 
mm internal diameter) column packed with 5 µm particles. A guard column 
Purosphere 100 RP-18® (5 µm) was used to protect the analytical column. The 
column temperature was not standardized, but was maintained at room 
temperature. 
The mobile phase consisted of a mixture of water, orthophosphoric acid (85%), 
acetonitrile and the ion pairing reagent tetrabutyl ammonium hydroxide (0.001M) in 
a ratio of 990: 1.7: 64: 60 (v/v). The pH of the mobile phase was 2.9 and the flow 
rate was set at 0.56 ml/min. Drug concentration was monitored using a LaChrom L 
7480 fluorescence detector at an excitation wavelength (λex) of 278 nm and an 
emission wavelength (λem) of 450 nm. Peak integrations were carried out using a 
LaChrom L7000 integrator. 
7.3.1.3  Validation of the analytical method 
The method used to determine the ciprofloxacin plasma concentration was 
validated as recommended by Shah et al. (1992) and revised in the FDA  Guidance 
for industry (2001). 
7.3.1.4 Pharmacokinetic and statistical analysis 
The peak plasma concentration (Cmax) and the time to reach the peak plasma 
concentration (tmax) were obtained from the plasma concentration / time profiles. 
The area under the plasma concentration-time curve to 32 hr post dosing (AUC0-
32hr) was calculated by linear trapezoidal summation. The terminal elimination rate 
constant (λz) was determined by log-linear regression of the terminal points of the 
plasma concentration-time curve and the half-life time (t0.5) was defined as 
0.693/λz. The MW/Pharm software package (v.3.01, Mediware 1987-1991, Utrecht, 
The Netherlands) was used for the pharmacokinetic analysis. 
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Statistical analysis of the pharmacokinetic data was performed using a two-way 
ANOVA. The data were tested for normal distribution with the Kolmogorov-Smirnov 
test. The homogeneity of variances was tested with the Levene’s test. To further 
compare the effects of the different treatments a multiple comparison among pairs 
of means was performed using the Scheffe test with p < 0.05 as significance level. 
For all statistical analysis the program SPSS version 10.0 was used.  
7.4  Results 
7.4.1 Validation of the bioanalytical method 
7.4.1.1. Linearity 
The lower limit of the calibration range (0.05 µg/ml) was chosen on the basis of the 
reported plasma concentrations after a single oral dose of 500 mg ciprofloxacin 
(Plaisance et al., 1987; Maya et al., 2001). Six calibration standards (0.05, 0.1, 0.3, 
0.6, 1.0, and 2.0 µg/ml) were made by spiking blank plasma with the appropriate 
amounts of ciprofloxacin hydrochloride solution. The concentration of the internal 
standard (pipemidic acid) was 0.8 µg/ml. A blank sample was included in the 
calibration curve to ensure that no interfering components were co-eluted with the 
drug and the internal standard or introduced during preparation of the standards.  
The mean calibration curve (n = 8) of the ciprofloxacin concentration versus the 
ratio of peak areas of ciprofloxacin and the internal standard was calculated.  
The calibration curve showed that the analytical method is linear over the entire 
concentration range (0.05 - 2.0 µg/ml): Y = 5.11618x (± 0.0863) + 0.0193 (± 0. 
03548) with a coefficient of determination (R2) of 0.9996 (± 0.0005). 
7.4.1.2 Limits of detection and quantitation. 
The limit of detection (LOD) was defined as the concentration of the analyte that 
produced a response equivalent to the blank signal plus three times the standard 
deviation of the blank signal (mean of the Y-intercept of the calibration curves). 
From regression analysis of the calibration curve, the limit of detection of this 
method was determined at 0.02 µg/ml. 
The limit of quantitation (LOQ) was defined as the lowest concentration in the 
calibration curve. For this analytical method the limit of quantitation (LOQ) was 
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determined at 0.05 µg/ml, at this concentration the accuracy being 96.0% and the 
relative standard deviation (RSD) 7.1% (FDA guidance: RSD of the LOQ must be 
less than 20% and the accuracy between 80 and 120%). 
7.4.1.3 Selectivity 
The chromatographic procedures were capable of separating the plasma 
constituents from the drug and the internal standard. The retention times were 
about 2.5 and 7.5 min for pipemidic acid and ciprofloxacin, respectively. There 
were no interfering peaks at these retention times as evidenced by the 
representative chromatograms of blank plasma and of plasma (spiked with the 
internal standard) obtained from a volunteer 3.0 hr after administration of a 500 mg 
ciprofloxacin tablet (Fig. 7.2).  
Figure 7.2:  The chromatograms of blank plasma (I) and of plasma (spiked with IS) obtained 
from a volunteer 3.0 hr after administration of a 500 mg ciprofloxacin tablet (II) 
with A and B being the peaks for pipemidic acid and ciprofloxacin, respectively 
 
 
 
 
 
 
 
 
 
 
I
II
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7.4.1.4 Precision 
The precision of the analytical method was determined at concentrations of 0.05, 
0.6 and 2.0 µg ciprofloxacin per ml plasma by calculating the variations of the peak 
areas for the same sample injected at different times during the same day 
(repeatability). For reproducibility, the samples were injected at different days. The 
results for precision of the method are shown in Table 7.2. The relative standard 
deviations (RSD) obtained for the within and between day analysis were both less 
than the acceptance criteria of 15%. 
Table 7.2:  Intra- (repeatability) and inter-day (reproducibility) precision for the 
determination of ciprofloxacin in plasma (n = 8) 
Precision (RSD %) 
Conc. (µg /ml) 
Intra-day Inter-day 
0.05 6.6 7.9 
0.60 3.6 5.3 
2.00 2.6 3.4 
  
7.4.1.5 Accuracy 
The accuracy was determined by comparing the measured ciprofloxacin 
concentrations and the spiked concentrations in plasma. The mean results and the 
RSD at each concentration level are summarized in Table 7.3. The mean value did 
not deviate by more than 10% from the true value and the RSD values are within 
the acceptance level (FDA guidance: RSD less than 15%, except for the LOQ 
where it should not exceed 20%). 
Table 7.3:  Accuracy (n = 8) for the determination of ciprofloxacin in plasma 
Concentration (µg/ml) Accuracy(%) RSD 
0.05 96.0 7.1 
0.60 103.3 3.7 
2.00 100.5 2.0 
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7.4.1.6 Recovery 
50 µl of the appropriate ciprofloxacin standard solution was added to blank plasma 
to make concentrations of 0.05, 0.6 and 2.0 µg/ml. After protein precipitation, their 
peak areas were compared with those obtained by injecting the same 
concentration of ciprofloxacin in mobile phase. Recovery was calculated as the 
ratio of the peak area of the plasma samples divided by the peak areas of the 
mobile phase samples, multiplied by 100. The relative standard deviation of the 
recovery at different concentrations was also determined. The recovery of 
pipemidic acid at 0.8 µg/ml was similarly determined. Table 7.4 shows that the 
values obtained for recovery were above 90% and reproducible (RSD between 3.1 
and 7.1%). These values are above the minimum value required for recovery (i.e. 
75%) with a maximum RSD of 15%.  
Table 7.4:  Recovery of ciprofloxacin and pipemidic acid for the determination of 
ciprofloxacin in plasma (n = 8)  
 Conc. (µg/ml) Recovery (%) RSD (%) 
Ciprofloxacin 0.05 94.5 7.0 
 0.60 95.3 3.1 
 2.00 98.3 2.0 
Pipemidic acid 0.80 95.8 7.1 
 
7.4.1.7 Stability of ciprofloxacin in plasma 
The stability of the drug in plasma was determined at concentrations of 0.05, 0.60 
and 2.00 µg/ml in plasma stored at -20°C. Analyses were performed after 15 and 
30 days. The determined concentrations and standard deviation, shown in Table 
7.5, indicated that the drug was stable in plasma for at least 30 days. 
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Table 7.5:  Stability of ciprofloxacin in plasma stored at -20°C for 30 days (n=8) 
% of the theoretical concentration 
found (± SD) after Theoretical conc. 
(µg/ml) 
15 days 30 days 
0.05 94.0 ± 8.0 94.0 ± 8.0 
0.60 96.7 ± 5.0 102.0 ± 5.0 
2.00 101.1 ± 4.2 99.2 ± 3.8 
 
7.4.2  In vitro drug release  
The in vitro drug release of the two formulations is shown in Fig. 7.3. For the Bayer 
formulation stored at ambient conditions, the drug release after 30 min of 
dissolution testing was 100%, releasing more than 90% of drug within the first 5 
min. The drug release was not influenced by storage at simulated tropical 
conditions. The drug release from the Cadila formulation after 30 min was 100%. 
However, the initial drug release was slower (55% in the first 5 min) than that of the 
Bayer formulation. Similar to the Bayer formulation, storage for 3 months at 
simulated tropical conditions did not influence the drug release. These results are 
consistent with the ones previously obtained after performing dissolution tests on 
different batches of the same formulations from the same manufacturers (Chapter 
3). 
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Figure 7.3:  Dissolution profiles of the Bayer and Cadila formulations obtained after 
30 min dissolution testing on tablets stored for 3 months at ambient 
conditions (X) and at simulated tropical conditions (Q) 
 
 
7.4.3 In vivo drug availability 
The four ‘treatments’ were well tolerated and no drug related adverse effects were 
reported by the volunteers during the study. The individual ciprofloxacin plasma 
concentrations after single administration of a 500 mg ciprofloxacin tablet exposed 
to different storage conditions are shown in Fig. 7.4 and 7.5, and the individual 
pharmacokinetic parameters in Table 7.6 and 7.7. 
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Figure 7.4:  Individual ciprofloxacin plasma concentration/time profiles (n=12) after 
administration of a single dose of 500 mg ciprofloxacin as a Ciprodac® 
500 tablet stored at ambient conditions (C1) and at simulated tropical 
conditions (C2) 
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Figure 7.5:  Individual ciprofloxacin plasma concentration/time profiles (n=12) after 
administration of single dose of 500 mg ciprofloxacin as a Ciproxin® 500 
tablet stored at ambient conditions (C3) and at simulated tropical 
conditions (C4) 
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Table 7.6:  Individual AUC0-32hr and Cmax values of 12 subjects following 
administration of a single dose of 500 mg ciprofloxacin  
Formulationa 
Subject 
C1 C2 C3 C4 
AUC0-32hr (µg.hr/ml.) 
1 10.12 9.18 9.32 9.00 
2 8.14 5.54 10.74 6.27 
3 6.45 5.89 8.32 8.27 
4 6.37 7.01 9.16 8.05 
5 8.70 8.31 6.28 4.15 
6 10.34 10.98 10.31 9.34 
7 8.60 9.46 6.93 9.94 
8 10.70 9.31 8.76 9.02 
9 11.03 10.70 10.05 7.76 
10 8.97 8.55 6.83 7.94 
11 10.69 7.86 9.07 7.31 
12 8.51 9.62 8.16 9.84 
Mean 9.05 8.53 8.66 8.07 
SD 1.58 1.72 1.42 1.63 
Cmax (µg/ml) 
1 1.82 1.93 1.90 1.94 
2 1.68 1.34 1.98 1.70 
3 1.87 1.59 1.96 1.85 
4 1.92 1.84 1.87 1.92 
5 1.95 1.98 1.98 1.09 
6 1.92 1.96 1.97 1.95 
7 1.96 1.95 1.66 1.82 
8 1.50 1.89 1.76 1.97 
9 1.63 1.99 1.96 1.51 
10 1.80 1.98 1.45 1.98 
11 1.97 1.95 1.86 1.71 
12 1.67 1.86 1.85 1.93 
Mean 1.81 1.85 1.85 1.78 
SD 0.16 0.19 0.16 0.26 
a(C1: Ciprodac® 500 stored for 3 months at ambient conditions; C2: 
Ciprodac ® 500 stored for 3 months at simulated tropical conditions, 
C3: Ciproxin® 500 stored for 3 months at ambient conditions C4: 
Ciproxin® 500 stored for 3 months at simulated tropical conditions).  
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Table 7.7:  Individual tmax values (hr) of 12 subjects following administration of a 
single dose of 500 mg ciprofloxacin tablet  
tmax Subject 
C1a C2a C3a C4a 
1 1.0 1.5 1.5 1.5 
2 1.0 2.0 1.5 0.5 
3 2.0 1.5 1.5 1.0 
4 1.0 1.5 1.0 1.0 
5 1.0 2.5 0.5 2.0 
6 2.0 2.0 2.5 1.5 
7 2.0 2.0 2.0 2.0 
8 3.0 1.0 1.5 1.0 
9 2.0 1.0 1.5 1.0 
10 1.5 1.5 1.0 2.0 
11 1.5 2.0 2.5 1.5 
12 1.0 1.0 1.5 1.5 
Mean 1.75 1.63 1.54 1.42 
Range 1.0 - 3.0 1.0 – 2.5 0.5 – 2.5 0.5 – 2.5 
a(C1: Ciprodac® 500 stored for 3 months at ambient conditions; C2: 
Ciprodac ® 500 stored for 3 months at simulated tropical conditions, 
C3: Ciproxin® 500 stored for 3 months at ambient conditions C4: 
Ciproxin® 500 stored for 3 months at simulated tropical conditions) 
The arithmetic mean ciprofloxacin plasma concentration/time profiles of both 
formulations are shown in Fig. 7.6, and the mean (arithmetic) pharmacokinetic 
parameters in Table 7.8. 
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Figure 7.6:  Mean (n=12) ciprofloxacin plasma concentration/time profiles following 
administration of a single dose of 500 mg ciprofloxacin as Ciprodac® 500 
(A) and Ciproxin® 500 (B) tablets stored for 3 months at ambient 
conditions () and at simulated tropical conditions () 
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Table 7.8:  Mean (n=12)(arithmetic) pharmacokinetic parameters (± SD) following 
administration of a single dose of 500 mg ciprofloxacin tablet  
Formulationa  
Parameter  
C1 C2 C3 C4 
 AUC 0-32hr (µghr/ml) 9.05 ± 1.58 8.53 ± 1.72 8.66 ± 1.42 8.07 ± 1.63 
Cmax (µg/ml) 1.81 ± 0.16 1.85 ± 0.19 1.85 ± 0.16 1.78 ± 0.26 
Cmax/AUC (hr-1) 0.21 ± 0.05 0.22 ± 0.03 0.22 ± 0.04 0.22 ± 0.03 
tmax (hr) 1.75 ± 0.72 1.63 ± 0.48 1.54 ± 0.58 1.42 ± 0.51 
t 0.5 (hr) 4.00 ± 1.15 3.97 ± 1.09 3.95 ± 1.02 3.93 ± 0.99 
a(C1: Ciprodac® 500 stored for 3 months at ambient conditions; C2: Ciprodac ® 500 
stored for 3 months at simulated tropical conditions, C3: Ciproxin® 500 stored for 3 
months at ambient conditions C4: Ciproxin® 500 stored for 3 months at simulated 
tropical conditions).  
The Kolmogorov-Smirnov analysis showed that the individual AUC0-32hr, Cmax and 
tmax values were normally distributed. Moreover, the Levene’s test showed a 
homogeneous distribution of the variances for these parameters with no significant 
subject influence.  
The mean AUC0-32hr, Cmax and tmax values obtained from the two formulations were 
similar and independent of storage conditions. The values did not change 
significantly after storage at simulated tropical conditions for 3 months. This shows 
that the extent of drug absorption, the maximum plasma concentration and the time 
to achieve this concentration in plasma from the two formulations were not 
significantly different (p > 0.05) and not influenced by the high humidity / high 
temperature storage conditions.  
The parameter Cmax/AUC has been recommended to compare the absorption rate 
between formulations (Endrenyi et al., 1991; Tothfalus and Endrenyi, 1995) as 
dividing Cmax by AUC compensates for the influence of intra-individual variability in 
clearance on Cmax. As observed for Cmax and tmax, (parameters that indicates the 
absorption rate) there was no significant difference on the Cmax/AUC0-32hr values 
obtained for the two formulations, even after storage at simulated tropical 
conditions. This shows that the formulations had a similar absorption rate that was 
not influenced by storage at high temperature and high humidity. Since 
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ciprofloxacin is a drug with a high permeability, this observation indicates that the 
dissolution characteristics of the two formulations in the gastrointestinal tract were 
similar and in vitro dissolution is a good indicator for the bioavailability for such 
drugs. 
7.5 Discussion  
The pharmacokinetic parameters obtained in this study were similar to the ones 
reported in literature. In a review on the pharmacokinetics of ciprofloxacin, 
Vancebryan et al. (1990) has reported AUC-values ranging from 6.78 to 13.5 
µg.hr/ml and Cmax-values from 1.51 to 3.23 µg/ml after oral administration of a 
single 500 mg tablet. The terminal half-life (t0.5) and tmax of both formulations were 
similar and in agreement with the values (3.3-5.04 hr and 1.0-1.45 hr, respectively) 
reported by these authors. 
The in vivo drug availability from the two formulations mirrored the in vitro drug 
dissolution characteristics as was expected: ciprofloxacin has a high permeability, 
therefore dissolution is the rate limiting step in its absorption. Since the 9 
formulations from the Tanzanian market had similar dissolution characteristics it 
can be assumed that they would have similar bioavailability profiles. 
This observation illustrates an example where the Essential Drugs Concept (EDC) 
can be of immense benefit to a poor nation if it is judiciously implemented. The 
market price of the innovator brand was at least 20 times higher compared with 
that of the other formulations (Table 3.7), yet it had a similar bioavailability profile 
compared with the generic brand. When the necessary mechanisms for monitoring 
the quality of drugs on market have been put in place by the regulatory authorities, 
encouraging the use of generics could save a lot of resources. On the contrary 
when the quality of drugs on market cannot be ensured, the presence of cheap 
generics may lead to loss of confidence by both prescribers and users who may 
prefer the expensive brands on the assumption that the higher the price the better 
the quality.  
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7.6 Conclusion 
The pharmacokinetic parameters obtained from the two formulations show that all 
drugs had satisfactory and comparable in vivo release profiles, even after exposure 
to tropical storage conditions. Clinically the formulations are expected to be 
similarly effective. The encouragement to use cheaper generic brand as stipulated 
in the Essential Drugs Concept should be complemented by the establishment of a 
functioning quality assurance mechanism that continuously monitors the quality 
and efficacy of drugs on market. 
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8. GENERAL CONCLUSIONS AND RECOMMENDATIONS 
Increasing access to effective and affordable essential drugs is one of the 
objectives of any rational national drug policy. The WHO recommends the essential 
drugs concept as the best strategy for such an endeavour, especially to developing 
countries where meagre resources are available. Reports about the presence of 
substandard drugs on the market even when anecdotal, risks promoting irrational 
drug use, hence denting the benefits achievable by adoption of such a strategy. 
This study aimed at providing information on the quality of drugs on market in 
Tanzania. 
The in vitro tests revealed that although all formulations contained the labelled drug 
in sufficient quantities, some formulations had not been optimised for stability in 
tropical climatic conditions. Essential drug formulations with a fixed dose 
combination showed a poor dissolution of one component (the lesser soluble 
component of the combination). This raises a concern, as the effectiveness of such 
drugs depends on the synergistic action exerted by both components. It is 
recommended that similar studies be done on more of such drug formulations as 
they are increasingly being recommended for infectious diseases since their use 
could delay the emergence of resistant microorganisms. 
The bioavailability determination of acetylsalicylic acid and enteric coated 
diclofenac sodium tablets showed a poor in vitro / in vivo correlation. Since in vivo 
tests cannot be routinely used as quality control tests, efforts should be made to 
optimize the current in vitro dissolution test parameters to make the dissolution test 
predictive of bioavailability.  
In general this study has shown that the prevalence of substandard drugs in 
Tanzanian is not as widely spread as was expected from literature reviews. 
Institution of a functioning quality assurance system is the most reliable deterrent 
against substandard drugs. In addition, such a system would provide to the general 
public information on the quality of drugs on market thus promote public confidence 
on the drug supply system and hence stimulate rational drug use.  
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9. SUMMARY 
The quality and affordability of drugs is one of the major public health concerns in 
many developing countries. To address the problem of affordability in these 
countries, the WHO initiated the Essential Drugs Concept (EDC) and encouraged 
its member states to adopt this concept as a strategic policy to ensure that effective 
drugs to treat the majority of diseases in a community are constantly made 
available at affordable prices. Tanzania adopted the concept into its national drug 
policy, but it has since then lacked facilities to control and monitor the quality of 
drugs on market (an essential component of the EDC). As a result, there has been 
little information on the quality of drugs marketed in the country. In addition to 
safeguarding the general public against the hazards of substandard drugs, such 
information is necessary to build up public confidence in the health system and 
promoting rational drug use. 
This thesis is aimed at evaluating the quality of the most commonly used essential 
drugs and at investigating the influence of tropical storage conditions on the in vitro 
and in vivo drug availability from different formulations of these drugs marketed in 
Tanzania. In Chapter 1 a literature review is presented about the health policy and 
the current situation of pharmaceutical market in Tanzania and also about the 
global concerns on the prevalence of substandard/counterfeit drugs in developing 
countries. The objectives of the study are outlined in Chapter 2. 
57 formulations of 9 essential drugs were sampled from major importers and 
distributors of pharmaceuticals for the Tanzanian market. During collection of the 
samples it was noted that there existed a large price difference between innovator 
and generic brands. In chapter 3, the in vitro quality parameters (drug content, 
dissolution and the influence of tropical climatic conditions (Class IV: 75% relative 
humidity / 40°C) on the in vitro dissolution) were determined. The results showed 
that there were no fake drugs and that drug content in all formulations was within 
pharmacopoeia specifications. Only few formulations had an in vitro drug release 
that was below the USP 24 dissolution tolerance limits. Furthermore, the 
dissolution rate of some formulations that previously met the USP 24 requirements, 
failed after 6 months storage at simulated tropical conditions.  
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Inter-laboratory differences between sets of dissolution data of the same batch of a 
formulation are explored in chapter 4. Dissolution tests were performed in Tanzania 
and Belgium on cipofloxacin and metronidazole formulations. For each formulation 
the sets of data are compared using the FDA’s similarity factor f2 and Principal 
Component Analysis (a technique that enables visualisation of similarities or 
differences between sets of multivariate data). The evaluation showed only minor 
differences between the data obtained at both laboratories. The similarity of the 
between laboratory dissolution data could be explained by the fact that validated 
equipment was used and that the tests were performed by the same analyst, 
hence highlighting the importance of training the personnel working in a quality 
control laboratory. 
The bioavailability of two acetylsalicylic acid (ASA) formulations(Dispril® and a 
formulation manufactured by Shelys is presented in Chapter 5. The latter 
formulation had a 100% in vitro drug release within 5 min, while the former 
released only 27% of the labelled drug after 30 min of dissolution test. Evaluation 
of the primary pharmacokinetic parameters obtained in the study showed that the 
extent of drug absorsption (for both ASA and its main metabolite salicylic acid) from 
the Shelys formulation was similar to that of Dispril®. However the Shelys 
formulation yielded a significantly lower Cmax and had a longer tmax  indicating that 
the rate of absorption from this formulation was lower. The effect of a lower 
absorption rate from this formulation on the efficacy (other than delayed onset of 
pain relief) will probably be insignificant as the Cmax obtained for SA was above the 
minimal concentration required for analgesia.    
In Chapter 6 the influence of tropical storage conditions on the bioavailability of 
diclofenac sodium tablets was investigated by performing a 4-period cross-over 
study involving tablets of the innovator brand (Novartis) and a generic brand 
(Camden). The bioavailability profiles of the Novartis and Camden tablets stored at 
ambient conditions were similar, as were their dissolution profiles. The 
bioavailability of the Novartis tablets was not influenced by storage at high 
temperature and high relative humidity. Although the Camden formulation had its in 
vitro dissolution significantly reduced after exposure to Class IV conditions, its 
bioavailability showed only a moderate reduction in the rate of drug absorption, 
while the extent of drug absorption was not significantly altered. These 
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observations indicated that some formulations available on the Tanzanian market 
were not optimized for stability in tropical climates and highlighted the possibility of 
a poor in vitro / in vivo correlation. 
In Chapter 7 the influence of tropical climatic conditions on bioavailability of two 
ciprofloxacin formulations was investigated by performing a 4-period crossover 
study on 12 subjects. In vitro, all ciprofloxacin formulations had similar potencies, in 
vitro dissolution and stability profiles. The pharmacokinetic parameters obtained 
showed that the two formulations had similar bioavailability profiles that were not 
influenced by storage at tropical climatic conditions. Since ciprofloxacin is a low 
solubility and high permeability drug, it can be presumed that all 9 formulations 
would have similar bioavailability profiles as their dissolution and stability profiles 
were similar (despite a very large price difference between the innovator and 
generic brands). The results show the importance of encouraging the use of 
generic versions (especially in developing countries) when the necessary quality 
control measures have been instituted. 
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10. SAMENVATTING 
In veel ontwikkelingslanden is de kwaliteit en de kostprijs van geneesmiddelen één 
van de voornaamste zorgen binnen de gezondheidssector. Om het probleem van 
de kostprijs in deze landen aan te pakken, heeft de WHO het Essential Drugs 
Concept (EDC) opgesteld en zijn leden aangemoedigd om dit concept op te nemen 
in hun nationaal gezondheidsbeleid. Deze strategie verzekert dat er continu 
geneesmiddelen beschikbaar zijn die doeltreffend zijn tegen het merendeel van de 
ziektes welke de bevolking treffen en dit tegen een aanvaardbare kostprijs. 
Tanzania heeft dit concept opgenomen in zijn nationaal geneesmiddelenbeleid, 
maar er is een tekort aan faciliteiten om de kwaliteit van de geneesmiddelen 
beschikbaar op de markt daadwerkelijk te controleren (een essentieel onderdeel 
van het EDC). Hierdoor is er zeer weinig informatie beschikbaar is over de kwaliteit 
van de geneesmiddelen beschikbaar op de Tanzaniaanse markt. Deze informatie is 
niet alleen noodzakelijk om de bevolking te vrijwaren van de gevaren van 
verbonden aan geneesmiddelen van mindere kwaliteit, maar ook om het 
vertrouwen in het gezondsheidssysteem op te bouwen bij de bevolking en om een 
rationeel geneesmiddelen gebruik aan te moedigen.  
Deze thesis heeft als doel de kwaliteit te evalueren van een aantal frequent 
gebruikte essentiële geneesmiddelen en te onderzoeken wat de invloed is van 
tropische bewaaromstandigheden op de in vitro en in vivo beschikbaarheid van 
deze geneesmiddelen uit de verschillende formulaties die op de Tanzaniaanse 
markt verkocht worden. In Hoofdstuk 1 werd een literatuuroverzicht gegeven van 
het gezondheidsbeleid en de huidige situatie op de farmaceutische markt in 
Tanzania en ook van de mondiale bezorgheid die er is omwille van de 
aanwezigheid van vervalse geneesmiddelen in ontwikkelingslanden. De 
doelstellingen van dit onderzoek zijn geschetst in Hoofstuk 2. 
Bij belangrijkste invoeders en groothandelaars van farmaceutische producten voor 
de Tanzaniaanse markt werden stalen genomen van 57 formulaties van 9 
essentiële geneesmiddelen. Tijdens het verzamelen van de stalen werd opgemerkt 
dat er grote prijsverschillen bestaan tussen het originele gepatenteerde product en 
het generisch equivalent. In Hoofdstuk 3 werden de volgende in vitro 
kwaliteitsparameters bepaald: geneesmiddelengehalte, geneesmiddelvrijstelling en 
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de invloed van een tropisch klimaat (75% relatieve vochtigheid/ 40°C) op de in vitro 
dissolutie. De resultaten toonden aan dat er tussen de geanalyseerde producten 
geen vervalste geneesmiddelen waren en dat het geneesmiddelengehalte in alle 
formulaties binnen de specificaties van de United States Farmacoppee (USP 24) 
viel. Enkele fomulaties hadden een in vitro geneesmiddelenvrijstelling lager dan de 
limieten gesteld in de USP 24.  Bovendien voldeed de geneesmiddelvrijstelling van 
sommige formulaties niet meer aan de gestelde USP 24 eisen na 6 maanden 
bewaring onder gesimuleerde tropische condities.  
In Hoofstuk 4 werden de dissolutiedata geëvalueerd van hetzelfde lot van een 
formulatie geanalyseerd in verschillende laboratoria. Dissolutietesten werden 
uitgevoerd in Tanzania en België op ciprofloxacine- en metronidazoletabletten. 
Voor elke formulatie werden de data vergeleken door middel van de FDA’s 
similarity factor f2 and Principal Component Analysis (een techniek die toelaat om 
de verschillen tussen sets van multivariabele data weer te geven). Uit de evaluatie 
bleken er slechts kleine verschillen tussen de data bekomen in beide laboratoria te 
bestaan. De gelijkaardige resultaten kunnen verklaard worden door het feit dat 
gevalideerde toestellen werden gebruikt en dat de testen werden uitgevoerd door 
dezelfde operator. Dit benadrukt het belang van training van het personeel dat 
tewerkgesteld wordt in een laboratorium voor kwaliteitscontrole.  
De biologische beschikbaarheid van twee acetylsalicylzuur (ASA) formulaties 
(Dispril® en een formulatie geproduceerd door de firma Shelys) is voorgesteld in 
Hoofdstuk 5. De eerstgenoemde formulatie stelde in vitro zijn volledige 
geneesmiddelendosis binnen de 5 minuten, terwijl de laatste formulatie slechts 2% 
van het geneesmiddel vrijstelde binnen hetzelfde tijdsinterval  en slechts 27% na 
30 min. De farmacokinetische parameters toonden dat de hoeveelheid 
geabsorbeerd geneesmiddel (AUC)(voor zowel ASA als zijn voornaaste metaboliet 
salicylzuur) na toediening van de Shelys formulatie analoog is aan de AUC-
waarden bekomen na inname van een Dispril®-tablet. De Shelys formulatie had 
echter een significant lagere Cmax en een hogere tmax. Dit wijst op een lagere 
absorptiesnelheid uit deze formulatie, waarvan het effect op de efficiëntie van het 
preparaat waarschijnlijk niet significant zal zijn, aangezien de Cmax-waarden 
bekomen voor salicylzuur hoger zijn dan de minimale concentratie vereist voor het 
analgetisch effect.   
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In Hoofdstuk 6 werd de invloed van tropische bewaaromstandigheden op de 
biologische beschikbaarheid van natriumdiclofenac onderzocht,  dit zowel voor het 
originele gepatenteerde product van Novartis als voor een generische vorm van de 
firma Camden. De biologische beschikbaarheid van Novartis- en Camden-tabletten 
bewaard bij kameromstandigheden waren gelijkaardig, net zoals hun 
dissolutieprofielen. De biologische beschikbaarheid van de Novartis-formulatie 
werd niet beïnvloed door bewaring bij hoge temperatuur en hoge relatieve 
vochtigheid. Dit in tegenstelling met de Camden formulatie blootgesteld aan 
gesimuleerde tropische condities waar de in vitro dissolutie significant daalde. In 
vivo vertoonde deze formulatie echter slechts een geringe daling van de 
geneesmiddelen absorptiesnelheid, terwijl de mate waarin het geneesmiddel 
geabsorbeerd werd (AUC) niet significant wijzigde. Deze observaties wijzen op het 
feit dat sommige formulaties welke beschikbaar op de Tanzaniaanse markt, niet 
geoptimaliseerd zijn naar stabiliteit toe in een tropische klimaat en benadrukken het 
belang van een goede in vitro/ in vivo correlatie. 
In Hoofdstuk 7 werd de invloed van tropische bewaaromstandigheden op de 
biologische beschikbaarheid van twee ciprofloxacine formulaties onderzocht. In 
vitro hadden alle ciprofloxacine formulaties gelijkaardige in vitro dissolutie– en 
stabiliteitsprofielen. De farmacokinetische parameters toonden dat de twee 
formulaties dezelfde biologische beschikbaarheidsprofielen hadden en dat deze 
niet beïnvloed werden door bewaring bij gesimuleerde tropische condities. 
Aangezien ciproflaxacine een slecht oplosbaar geneesmiddel is met een hoge 
permeabiliteit en hun dissolutie- en stabiliteitsprofielen hetzelfde waren, kan 
verondersteld worden dat alle formulaties een analoge biologische 
beschikbaarheid zullen hebben (ondanks de grote prijsverschillen tussen het 
originele product en de generische equivalenten). Deze resultaten wijzen op het 
belang van het aanmoedigen van het gebruik van generische producten 
(voornamelijk in ontwikkelingslanden) wanneer de noodzakelijke kwaliteitscontroles 
zijn ingesteld. 
